case_id,final_status,schema_valid,prompt_hash,model_requested,model_actual,response_id,response_created,usage_input_tokens,usage_output_tokens,response_sha256,parsed_present,parse_path,parse_error,ai_recommended_regimen_text,ai_abx_code_1,ai_abx_code_2,ai_abx_code_3,rebuilt_utc
1,OK,1,862157fea0a11bc2d8e724c76ad6a738655fc881e61aca42c8614da5455f9292,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_060d46de3976dbeb0169877f1171a88196b87a031e30749e67,1770487569,1990,238,3e0ef73739fc26e29c0b1ee2fa0e9eea81218d4917bcb2fde2493ac1cbfe0c0d,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q6h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Severe community-onset pneumonia with septic shock/MV/vasopressors → broad IV beta-lactam for typical pathogens including Pseudomonas risk in ICU-level CAP.
- Add azithromycin for atypical coverage and potential benefit in severe CAP; no MRSA history/risk provided so avoid routine MRSA agent.
- eGFR 63 mL/min/1.73m2 → no renal dose adjustment needed in first 24h.",TZP_IV,AZM_IV,NA,2026-02-08T05:01:07Z
2,OK,1,7ef645a0122e89baeb1a5b01c70b0d561eec931ba2ecd890941f18c1e7d8e977,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_072c5dfc871659180169877f1171cc81959a87b2245dcf7291,1770487569,2011,251,dbd4e1a3bb00105fae473c098e8ea11a29d181a506937d48b6e21901325726df,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 3.375 g
DRUG_1_INTERVAL: q8h (renal-adjusted for eGFR 33)
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset pyelonephritis with sepsis and high severity (MV/NIV, ICU transfer) warrants broad IV Gram-negative coverage including Pseudomonas.
- No major MDR/MRSA history; piperacillin-tazobactam provides single-agent coverage for likely Enterobacterales and some Enterococcus without routine MRSA therapy.
- CKD (eGFR 33) supports renal-adjusted dosing and avoidance of empiric aminoglycoside add-on toxicity in first 24h.",TZP_IV,NA,NA,2026-02-08T05:01:07Z
3,OK,1,a4cdd231a34e184bac935d8eb76a1afba5631c59a53c756f221bc86adddf0182,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_04d017833541a52c0169877f116db88191ae421c19c679f110,1770487569,1980,231,50cd9b58ac850b958241e1aa9c6ff4ba37f7d886925f7499bc944c398bbcd921,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Low-severity healthcare-associated UTI without sepsis/shock; ceftriaxone provides empiric coverage for common Enterobacterales (E. coli/Klebsiella/Proteus) and is appropriate as monotherapy.
- No MRSA/ESBL/CRE history and no recent antibiotics; avoid broader agents (e.g., carbapenem/TZP) and unnecessary combination therapy.
- Renal function preserved (eGFR 82); no renal dose adjustment needed.",CRO_IV,NA,NA,2026-02-08T05:01:07Z
4,OK,1,ba8362bac22c1407dde90dffa9b13477be96accdcdc61bfe876885999bdda1c4,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_06f9052cbe3a639b0169877f15472881948ab17bb09ca078af,1770487573,1984,238,82687dacbf6f779a75b1b85d23931e7b4c15501e50cabf1ae3df1124859adfe1,1,output[0].content[0].text,,"DRUG_1_NAME: MEM_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q8h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Septic shock with MV/vasopressors and healthcare-associated pneumonia risk (recent hospitalization) warrants broad IV antipseudomonal Gram-negative coverage for first 24h.
- Meropenem provides single-agent coverage for Enterobacterales and non-fermenters (incl. Pseudomonas/Acinetobacter) suggested by local ward epidemiology; no structured MRSA risk/history to justify empiric anti-MRSA agent.
- Renal function preserved (eGFR 106), so standard dosing used.",MEM_IV,NA,NA,2026-02-08T05:01:07Z
5,OK,1,780f085c99417b91153667455ecff9e4fde99767f7b4b5656ff77d0b61f96f93,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0dbbcf88879497c00169877f15589081a08d5145b80ef4f722,1770487573,1964,225,50aa1afe3077dcadb9893de3e26f0a684c62ac4f4b4353cf911d884f95ab41b3,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with leukocytosis; ceftriaxone + azithromycin provides standard empiric coverage for typical + atypical pathogens.
- Low severity and no MRSA/ESBL history; avoid routine MRSA or antipseudomonal therapy despite recent hospitalization.
- eGFR 133: no renal dose adjustment needed for ceftriaxone or azithromycin in first 24h.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
6,OK,1,1096c1606a3b9257a6cb9b2b19c8a836a234c0c51dab5d6e1a697347eedb6445,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0a22ed39b39710ad0169877f156910819da5fac15993f39087,1770487573,1985,230,85199f755a50322de5823f85fa050022b616d25d54b213aababca54f8a30de97,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q8h (renal-adjusted for eGFR 42)
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Septic shock/vasopressors with healthcare-associated UTI: needs immediate broad IV Gram-negative (incl. Pseudomonas) coverage.
- No major MDR/MRSA history; single-agent TZP provides Enterobacterales + some Enterococcus coverage while avoiding unnecessary combination therapy.
- Dose interval adjusted for CKD (eGFR 42) to balance efficacy and toxicity risk in an elderly patient.",TZP_IV,NA,NA,2026-02-08T05:01:07Z
7,OK,1,7eda55cb97aa563801cdf8efd736e5e7f757e757e7716dfc27eb08528eea9eb2,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0f40432c5424a03a0169877f18be7c819e814d062783e4f6c1,1770487576,1993,228,4dc345f82f8ca6fa34b9e2c81f623f1fec13d35bd485574bdf1bc5c61677ca7f,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset pneumonia with respiratory failure (moderate severity): empiric CAP coverage with beta-lactam + macrolide.
- No MDR/MRSA risk factors documented; avoid broader anti-pseudomonal or MRSA agents.
- eGFR 47: ceftriaxone and azithromycin do not require renal dose adjustment at this level; viral screen positive but severity supports short empiric antibacterial coverage pending cultures.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
8,OK,1,2f939f257950e49cf5e36c3668becce142c5e34fee42c6486a8cd03e6d8718fe,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0ef820b6535e2af60169877f19530c819db31cb57e1f2b4309,1770487577,1957,226,ce1f462f63f10d3b2346bea51bfc87d2be806340e8b490a875560daf5cc871cf,1,output[0].content[0].text,,"DRUG_1_NAME: FEP_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h (renal-adjusted for eGFR ~15)
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- High-severity healthcare-associated pneumonia with MV/NIV → IV broad Gram-negative (incl. Pseudomonas) coverage appropriate; cefepime supported by local respiratory epidemiology.
- No structured MRSA risk/history provided → avoid empiric anti-MRSA agent.
- Severe renal impairment (eGFR 15) → use renal-adjusted cefepime dosing for first 24h.",FEP_IV,NA,NA,2026-02-08T05:01:07Z
9,OK,1,bb4583ae5a75a9ec4d1088e2d17a5d6abe9930e788a5fbec47cf77f8b7797463,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0d31225dc26b19ed0169877f195d608194ad95cdea3002f22e,1770487577,1968,246,f7e67956e5a36bdeb07c30acafa715bcea7381b320b2eaba14fd49002ecedf85,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with respiratory failure and marked inflammation (WBC 14.7, CRP 237) warrants empiric IV CAP coverage for typical + atypical pathogens.
- No MDR/MRSA risk factors (no prior MRSA/ESBL, no recent hospitalization/antibiotics, no LTC), so avoid routine anti-MRSA or antipseudomonal therapy.
- eGFR 81: no renal dose adjustment needed for ceftriaxone/azithromycin in first 24h.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
10,OK,1,f64be9962ffff7af935d02edc7fa1ec20c1ecbeea243881f91fc9f14df34eef2,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_00dd95705a149b660169877f1c367481a192c9b9a5042d97f9,1770487580,2008,245,f3b3fa9e22e883304f5ccbfe19297ecf75a6749268b860e389083f94d8c3b2c8,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset pyelonephritis with sepsis and no MDR risk/history: ceftriaxone provides appropriate empiric Gram-negative coverage (E. coli/Klebsiella/Proteus) without unnecessary broadening.
- Avoid aminoglycosides given severe renal failure (eGFR 5) and avoid routine anti-MRSA/anti-pseudomonal therapy absent risk factors.
- Renal dosing: ceftriaxone typically does not require adjustment in severe renal impairment; use standard q24h dosing for first 24h.",CRO_IV,NA,NA,2026-02-08T05:01:07Z
11,OK,1,54cdc9601a14a5c58047033eb6348d9f226fd382f19cfb5761227f14a18dd071,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_05eb0bf7ae57c3bf0169877f1cc8148197b076551c68b3ed15,1770487580,2075,237,47654f958b4c0c4bce3b6d35a6fa2b5cc70277f03dc6cf1c93dd2019ff9f74ef,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with respiratory failure and high CRP; give inpatient IV CAP regimen despite pre-admission AZM_PO exposure.
- Ceftriaxone for typical CAP pathogens; azithromycin for atypicals/adjunct coverage; no MRSA/MDR risk factors to justify VAN/anti-pseudomonal therapy.
- eGFR 31: ceftriaxone and azithromycin do not require renal dose adjustment at these doses for first 24h.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
12,OK,1,ccb408b8af34cc609be180027ac62581edcb09ef1d93f5998b26511d955831cf,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_06d27bba540157180169877f1d274c8193868f9ca7be05fcfd,1770487581,1947,249,6df94cdf2ac4326aee5cbded8158c7a56576c944c813d75ae053f7f65893e56a,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Severe community-onset CAP with respiratory failure requiring MV/NIV and elevated lactate → IV beta-lactam + macrolide empiric coverage for typical and atypical pathogens.
- No MDR/MRSA risk factors (no recent antibiotics/hospitalization/LTC; no prior MRSA/ESBL) → avoid routine anti-MRSA or anti-pseudomonal escalation in first 24h.
- Renal function unknown (creatinine/eGFR not available) → standard adult dosing used for first 24h.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
13,OK,1,7a321034a15d0caaff884ee1dd29e9dea59f228902bd3fed8bbcb05231a67854,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0d60b11ee795d9930169877f20284881a0bf7f66eec3666e4d,1770487584,1980,225,2354c5e295ac37fb949a9d3afbe21b40add121ba11194da42eeb13c2765ef6d9,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Low-severity healthcare-associated UTI without sepsis/shock or MDR risk/history: ceftriaxone provides appropriate empiric Gram-negative coverage for common pathogens (E. coli, Klebsiella, Proteus).
- Avoids unnecessary broad antipseudomonal or MRSA/Enterococcus coverage given no supporting risk factors.
- Renal function normal (eGFR 113); no renal dose adjustment needed for ceftriaxone.",CRO_IV,NA,NA,2026-02-08T05:01:07Z
14,OK,1,b8ccecbdcecc60fb00038e48661e753663317418950adc9c9ec12c2b2f6410d8,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0c008ae338e860880169877f20743081a1bebd0c28af928b74,1770487584,2025,242,fc11cbbd7fd775de5806c2b1e270567b7e17d307e48b7e5f43ae4cd8f810f6a9,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset pneumonia with respiratory failure and immunosuppression: start inpatient IV CAP regimen covering typical + atypical pathogens.
- Recent home azithromycin (pre-treatment) supports adding a beta-lactam backbone; no structured MRSA/ESBL history to justify VAN/linezolid or carbapenem in first 24h.
- eGFR 134 mL/min/1.73m2: no renal dose adjustment needed for ceftriaxone/azithromycin.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
15,OK,1,0b0ed110e4775203741b5d9052765a0591d143992403cbbaf19a3e7bd562ce13,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_08bedc6ce988b9a30169877f20e2a8819494b0817a3ff11e0c,1770487584,1496,234,ad07b9e3e5595a555fa8a1d4a2ef1619d84b9d71fe1bb3e2403bec5c9c9aa0b1,1,output[0].content[0].text,,"DRUG_1_NAME: NO_ANTIBIOTIC
DRUG_1_DOSE: NA
DRUG_1_INTERVAL: NA
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset acute diarrheal disease with low severity (no sepsis/shock/ICU needs) and only mild inflammatory markers; empiric systemic antibiotics not indicated in first 24h.
- Recent amoxicillin/clavulanate exposure increases likelihood of antibiotic-associated diarrhea (including C. difficile); prioritize diagnostic evaluation/supportive care rather than additional empiric antibacterial therapy.
- Significant renal impairment (eGFR 27) increases risk of harm from unnecessary antibiotics.",NO_ANTIBIOTIC,NA,NA,2026-02-08T05:01:07Z
16,OK,1,7f59d09324011c51958d14ea67c7fbb53945f863b9c317e65293904f0c54410a,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0e73320ddd3c44b30169877f23a2bc819fbf34275fa53115cb,1770487587,1976,212,056280ada70c9a238f5615c9ab18451a40939f2e49b2611a7dd42cf008ef5068,1,output[0].content[0].text,,"DRUG_1_NAME: NO_ANTIBIOTIC
DRUG_1_DOSE: NA
DRUG_1_INTERVAL: NA
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Low-severity community-onset pneumonia with viral screening POSITIVE and minimal inflammatory response (WBC 4.9, CRP 10) supports viral etiology over bacterial coinfection in first 24h.
- No sepsis/respiratory failure/ICU needs and no MDR/MRSA risk factors; withholding empiric antibacterials avoids unnecessary exposure.",NO_ANTIBIOTIC,NA,NA,2026-02-08T05:01:07Z
17,OK,1,ceb6ab79eceb8e0adfba0ed79bf8aca04e19e6947ee338351244a04741c20345,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_08f9e1de3def753d0169877f245764819e87286c8906d98f64,1770487588,1969,221,774a3fa24af9721adb459de8ad933dea104d147cdb6df4186bd0f7b9d53dab25,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with respiratory failure (moderate severity): ceftriaxone + azithromycin provides empiric coverage for typical and atypical CAP pathogens.
- No MDR/MRSA history or recent healthcare/antibiotic exposure: avoid routine MRSA or antipseudomonal therapy.
- Normal renal function (eGFR 113): standard dosing appropriate for first 24h.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
18,OK,1,0a09e00a893a0a45e001f52abf4b150aaa090818970de1f63bc35faf61c598ae,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0b29478121e14f320169877f24a2e881968a8ea39d3afa246f,1770487588,1972,251,2a400c51937915762e9e5d6c79b896871bff486d9ab3872ffb32a3e660fd604d,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q12h (renal-adjusted for eGFR ~15)
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Septic shock with respiratory failure (MV/vasopressors/ICU): needs immediate broad IV empiric coverage for community-onset sepsis.
- TZP provides broad Gram-negative (incl. Pseudomonas) and anaerobic coverage appropriate for undifferentiated bloodstream infection/sepsis; no structured MRSA/ESBL risk to justify routine VAN/carbapenem.
- Severe renal impairment (eGFR 15) supports renal-adjusted interval to reduce toxicity in first 24h.",TZP_IV,NA,NA,2026-02-08T05:01:07Z
19,OK,1,438decbf740c373025fd3fb53144cfc7c428eae2e20900433ce544807547deab,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_07bbe1d4149444ca0169877f267724819c947fc640e419a57f,1770487590,1978,238,60782d92f801996ca04a47295bfcb3b657b6f1bd342a9f2552facdadf0da0578,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with respiratory failure (moderate severity): empiric beta-lactam + macrolide for typical + atypical bacterial coverage in first 24h.
- No MDR/MRSA risk factors and no shock/ICU needs: avoid broader anti-pseudomonal or MRSA agents.
- Viral screen positive lowers bacterial probability but does not exclude coinfection; low WBC supports avoiding escalation beyond standard CAP coverage (renal function normal; no adjustment needed).",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
20,OK,1,52c7fa05ba2d82b7991c722f82ad238034855c1b7a3d1028510be5578df8a4fe,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_00f024ee41d562250169877f279570819c9f618884a71d5ca6,1770487591,1972,212,1829eeab831f475e599afc13dc6f6aa54e89f3d19c6105c265b4f9c3e3dbacd5,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q6h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset pneumonia with septic shock/MV/vasopressors → IV broad-spectrum beta-lactam appropriate for first 24h.
- No MRSA history or recent healthcare/antibiotic exposure → avoid empiric MRSA agent.
- eGFR 85 mL/min/1.73m2 → no renal dose adjustment needed for initial dosing.",TZP_IV,NA,NA,2026-02-08T05:01:07Z
21,OK,1,92c00237d5ba1e96b547a6fd94802cb5f43ee0eb40bf6843f7ee7be7cb232b5e,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_07ba2ca3cecb3f2a0169877f2893dc819691d21e67be9aaaeb,1770487592,1973,241,293bd82779483e316e89de61cbff33f702e566b07860e1d98ae5ef800fe69c7a,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q8h (extended infusion preferred); renal-adjusted for eGFR 36: 3.375 g q8h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Healthcare-associated pneumonia with respiratory failure and LTC residence → need broad IV coverage including Pseudomonas/Enterobacterales.
- No prior MRSA history and no shock/ICU → avoid routine MRSA add-on; single-agent antipseudomonal BL/BLI adequate for first 24h.
- Dose adjusted for CKD (eGFR 36) to reduce toxicity while maintaining exposure.",TZP_IV,NA,NA,2026-02-08T05:01:07Z
22,OK,1,f5485d29f3a0e75de8f613b028d478b96f0d21fabc395ac5705753cfeb0ade71,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_08175edce6e39ac30169877f2a6ba88197b27c4466200fa6c2,1770487594,1975,230,391f3336ecd62b178535d4e961231e5c0d01c99b087abea3e3337bcc6ad89665,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q6h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- High-severity community-onset sepsis with MV/NIV and ICU transfer: start broad IV empiric coverage for Gram-negatives (incl. Pseudomonas) and anaerobes.
- No MRSA/MDR history or recent healthcare/antibiotic exposure: avoid routine MRSA add-on in first 24h.
- eGFR ~61 mL/min/1.73m2: no renal dose adjustment needed for initial dosing.",TZP_IV,NA,NA,2026-02-08T05:01:07Z
23,OK,1,bbabf2852ec9d848ccd9966c8477a31239ae712f55ffadc0456bd1b4628af815,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0e0da744b73fc4b60169877f2b1e7081a293530e76920db87e,1770487595,1980,238,25116e86219f54447ca36a8394d56d1dd05a92741eb39a8ad63949e5752bf165,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with respiratory failure (moderate severity) warrants empiric bacterial coverage despite positive viral screen.
- CRO_IV + AZM_IV provides standard CAP coverage including typical pathogens and atypicals; no MRSA/MDR risk factors to justify VAN/LZD or antipseudomonal therapy.
- eGFR 88 mL/min/1.73m2: no renal dose adjustment needed for ceftriaxone/azithromycin in first 24h.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
24,OK,1,49bbcbf65f85f45035ca31979fcc8c0a9a3f39609483eb689dd25b98f71565d5,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_031dedee3b57408b0169877f2c86588196996a36049257f966,1770487596,1979,237,1da14cc0c18360e666f9871dcd46c757e581a3e818c01ba0c865baf3e3a2c375,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with respiratory failure (moderate severity): ceftriaxone + azithromycin provides standard empiric coverage for typical and atypical CAP pathogens.
- No MDR/MRSA risk factors and viral screen positive with low inflammatory markers (WBC 6.2, CRP 14.1): avoid broader anti-pseudomonal or MRSA therapy.
- eGFR 84: no renal dose adjustment needed for this first-24h regimen.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
25,OK,1,957fda44d42404ec026f52b88edcbb1b6635cbaa33b01a01cec0df55e7bb6773,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_059682cbc6a497060169877f2dd1a8819c9ece78fa13884002,1770487597,1990,242,8f673c63457b15d2f0ec0f8ff70c16fdb376655382b5df238d86418838a9c92a,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q6h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Severe community-onset pneumonia with septic shock/MV/vasopressors → broad IV empiric coverage; TZP provides streptococci and Gram-negative (incl. Pseudomonas) coverage.
- Add azithromycin for atypical coverage and potential benefit in severe CAP; no MRSA history/risk so avoid VAN/LZD.
- eGFR 71 mL/min/1.73m2 → no renal dose adjustment needed in first 24h.",TZP_IV,AZM_IV,NA,2026-02-08T05:01:07Z
26,OK,1,fcbcf62a4ed86721d2c4f4f2649666cdc25d24d79aad4c2b10d1250bb91b67cd,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0e85255734185fa50169877f2e479881a3b1cba1f01625eb97,1770487598,1984,246,c6a1633dab8dc7a4eea2820bf45c8bb9ef8523c582957f759e451f7f082c9d03,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q6h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Septic shock with MV/vasopressors/ICU transfer: needs immediate broad IV empiric coverage for community-onset sepsis including Gram-negatives (incl. Pseudomonas) and anaerobes.
- No documented MRSA/ESBL/CRE/VRE history or recent healthcare/antibiotic exposure, so avoid routine MRSA or carbapenem escalation in first 24h.
- eGFR 80 mL/min/1.73m2: no renal dose adjustment needed for initial dosing.",TZP_IV,NA,NA,2026-02-08T05:01:07Z
27,OK,1,c9b9351f4d50fb161e6496df95aedc8bef1daf327ca22fe9b4b5ea6a3ed58f05,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_01ae42daf381212b0169877f3018fc8195b3e1985eeaf5f4f5,1770487600,1980,246,daa061bea82c7d9351c9a9b7c06e172903702253d13403d80103a8cc92782eb0,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Moderate community-onset CAP with respiratory failure: ceftriaxone + azithromycin provides standard empiric coverage for typical and atypical bacterial pathogens.
- No MRSA/ESBL/CRE risk factors and no septic shock/ICU/vasopressors, so avoid routine MRSA or broad antipseudomonal therapy.
- eGFR 74 mL/min/1.73m2: no renal dose adjustment needed for ceftriaxone or azithromycin in first 24h.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
28,OK,1,c0f7ecc7acffd0fcc89826e887999d7e78b2f38886223ed67b0fe7d48737bb94,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_014f423bdb489bb50169877f31749081a0a2ee8ebc933d4577,1770487601,1972,237,a199663b9cf7887fdafa051cc4e21e49b7f66314c977eaca0d0bcf1391887ea4,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q12h (renal-adjusted for eGFR ~19)
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Healthcare-associated pneumonia with sepsis/respiratory failure and LTC residence → need broad IV Gram-negative (incl. Pseudomonas) and anaerobe coverage.
- No prior MRSA history and no shock/ICU/vasopressors → avoid routine MRSA add-on in first 24h.
- CKD (eGFR 19) → choose single-agent TZP with renal-adjusted interval to limit toxicity.",TZP_IV,NA,NA,2026-02-08T05:01:07Z
29,OK,1,d39b2fb09abb9fd911518d74f056543acebbc2bf113574ac84373880b2ce1d6a,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0d32f3f79098d24c0169877f3217d48193bb624a5fa3fc30a7,1770487602,1974,228,9c1eca3bc84954037b720eac2d87fbce9a0944b2cfac968be38a170f21841670,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with respiratory failure and leukocytosis: ceftriaxone + azithromycin provides standard empiric coverage for typical + atypical pathogens.
- No MDR/MRSA risk factors and no shock/ICU/vasopressors: avoid broader antipseudomonal or anti-MRSA therapy.
- eGFR 89: no renal dose adjustment needed for this regimen in the first 24h.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
30,OK,1,a98a59f8588adb082e38a8ec980beeed8fa8c5aeb5c4db0a37ac530ebc6b852d,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0663c0bb8a92b69a0169877f33f8a88195bcc4e45578db1cee,1770487603,1964,268,70cb90825db2062a45f352d1641b1c5bcb137020bb8f4ac12b57bd990bcd54a7,1,output[0].content[0].text,,"DRUG_1_NAME: MEM_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h (renal-adjusted for eGFR ~15)
DRUG_2_NAME: VAN_IV
DRUG_2_DOSE: 15 mg/kg
DRUG_2_INTERVAL: once, then dose by levels (renal-adjusted for eGFR ~15)
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Septic shock with healthcare-associated bloodstream infection/sepsis: broad IV empiric coverage needed including Gram-negatives (incl. Pseudomonas) and anaerobes (MEM_IV).
- Add MRSA-active agent (VAN_IV) given high severity/ICU-level illness and substantial Gram-positive bloodstream pathogen probability in this ward context (CoNS/S. aureus).
- Avoid aminoglycosides due to severe CKD (eGFR 15) and nephrotoxicity risk in shock.",MEM_IV,VAN_IV,NA,2026-02-08T05:01:07Z
31,OK,1,817b7301252cb3528a31a472304a60e8ee6e15a3c5ea74a9a1b0bd957b35ad12,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_00f5b73650e9993a0169877f3545b081979d4d800a4b49823c,1770487605,1957,217,1085fb7f91c84c9827d678c16dcb7bf4a77c7527b7ce7a33dd7d02942bd6e9d8,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h (renal-adjusted for eGFR 33)
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset sepsis/bloodstream infection without shock or MDR risk factors: ceftriaxone provides broad empiric coverage for common Gram-negative and streptococcal causes.
- Avoids routine MRSA coverage given no prior MRSA/MDR history and low derived severity; single-agent therapy limits toxicity in a 92-year-old with reduced renal function.",CRO_IV,NA,NA,2026-02-08T05:01:07Z
32,OK,1,adf89a7aedfb50deb53d86c3de5a015a25bbe36cc3f6d41d0527e7814d4ccb26,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_04c4b262a23f91230169877f35e26881979a027ffbce674079,1770487605,1988,261,3f60521570dc21c756b1704e1a41282dfded8587b562558566d98005c614dd94,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q12h (renal-adjusted for eGFR 5 mL/min/1.73m2)
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset pneumonia with septic shock/MV/vasopressors → IV broad-spectrum empiric therapy for first 24h.
- TZP provides coverage for common severe CAP pathogens including gram-negatives (incl. Pseudomonas) and anaerobes; no structured MRSA risk/history to justify routine MRSA agent.
- Severe renal failure (eGFR 5) → extended-interval renal-adjusted dosing; avoid aminoglycosides given nephrotoxicity risk in advanced CKD.",TZP_IV,NA,NA,2026-02-08T05:01:07Z
33,OK,1,6ffc95b14c047aa91f79051267f9fd57dc29b4cc01bbcd79a331e010b309e927,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0f764cfc3e647b910169877f38c0b08190a18de7161e372d66,1770487608,1979,238,5ed79243d9deead370cce0620c97952fd0e5e93b2a67902b9b5c2284f1d4dd11,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with respiratory failure (moderate severity): ceftriaxone + azithromycin provides standard empiric coverage for typical and atypical bacterial pathogens.
- No MDR/MRSA risk factors and no septic shock/ICU needs, so avoid broader anti-pseudomonal or MRSA agents.
- eGFR 106: no renal dose adjustment needed for this 24h empiric regimen; elevated transaminases noted—avoid unnecessary additional hepatotoxic agents.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
34,OK,1,3f8668ecbcb53f23e588b94672558c97d4aa2acbf03ce970414d4bf952f14bef,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0f2017d6c09cb2210169877f399d3881948b996845bf062749,1770487609,1999,229,1b0ec1e892363ab9a37499250363a69dc72494591cc9401468af9002d4963390,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Severe community-onset pneumonia with MV/NIV and ICU transfer → IV CAP regimen covering typical bacteria plus atypicals.
- No MDR/MRSA risk factors and low inflammatory markers with positive viral screen → avoid routine MRSA/antipseudomonal escalation in first 24h.
- eGFR 84 mL/min/1.73m2 → no renal dose adjustment needed for ceftriaxone/azithromycin.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
35,OK,1,95700152ea579b31e616033626dfb9d9a39d36730702de108d7ad682ca3fd5ea,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_05cdc4543759593b0169877f3a2d1481a0a447a9af07291476,1770487610,1972,232,a6a0c878a2e1c10031466d68952eb545de31f514a3f0007e1f33908ae63edbc8,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with respiratory failure and immunosuppression: ceftriaxone + azithromycin provides empiric typical + atypical coverage for first 24h.
- No MDR/MRSA history or recent healthcare/antibiotic exposure to justify broader anti-pseudomonal or MRSA therapy.
- eGFR 57: no renal dose adjustment needed for ceftriaxone or azithromycin in the first 24h.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
36,OK,1,49751962c655c64215af1d0e363090a87e3701d52ccd494fa9c5d2685c61ad1f,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0599de7c43408c230169877f3c4bcc8190b8ee877bb68ec3fd,1770487612,2105,242,3d5621ccea908755ec72ce274570cca78f37cd44f7f21948e324ba4c9b923038,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset pneumonia with high severity (respiratory failure, ICU transfer) warrants empiric IV therapy despite positive viral screen; ceftriaxone provides core CAP bacterial coverage.
- Recent home azithromycin for this episode reduces incremental benefit of repeating macrolide in first 24h; no structured MRSA/MDR risk factors to justify broader/MRSA coverage.
- Renal dosing: eGFR 27 mL/min/1.73m2—ceftriaxone typically does not require adjustment at this level.",CRO_IV,NA,NA,2026-02-08T05:01:07Z
37,OK,1,ff0d3fff6908579b620bf14d9aa5c414ae997c97179fbd34def18d56a2e0949d,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0e13e5e90bcf6dc50169877f3cfeb88194b7e7f26eb70ab320,1770487613,1988,227,33fdff346816ef79f5c2c8478642998f516582fb276c76a8af023da884bea109,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q6h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Severe community-onset pneumonia with septic shock/MV/vasopressors → broad IV empiric coverage for typical CAP pathogens plus Gram-negatives including Pseudomonas.
- Add azithromycin for atypical coverage in severe CAP; no MRSA history or MDR risk factors to justify routine MRSA agent.
- Renal function normal (eGFR 96) → no renal dose adjustment needed.",TZP_IV,AZM_IV,NA,2026-02-08T05:01:07Z
38,OK,1,445b9a014c383f78ef405c883b5a81ccdc7074fbdcc59557beeba206cd11ef18,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0eb3e2cd0c95d05d0169877f3da4cc8192a600b4b7abd1ddf3,1770487613,1514,228,045e80987646beda7a0dc2ee082c2875b6f5a5cf765b15c5668772d8ab6efb29,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset “other infection” with moderate severity and elevated CRP; ceftriaxone provides broad empiric coverage for common community Gram-negative and streptococcal pathogens.
- No MDR risk factors and no prior MRSA/ESBL history, so no empiric MRSA or anti-pseudomonal therapy.
- eGFR 78 mL/min/1.73m2: no renal dose adjustment needed for ceftriaxone.",CRO_IV,NA,NA,2026-02-08T05:01:07Z
39,OK,1,254b5a6bbfbec25d0bed734bc584c3bcfb8b5e9fe1eda08bc22610e757dec4bf,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_00475957098bb84d0169877f4030ac81918b460b22cf5de6e8,1770487616,2057,233,08d929ae2e2ce62eb174886204ab476d7394c3b0af549c702e95d15a8a56c9c5,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q6h
DRUG_2_NAME: VAN_IV
DRUG_2_DOSE: 15 mg/kg
DRUG_2_INTERVAL: q12h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset pneumonia with respiratory failure plus recent hospitalization/antibiotics → broaden to cover gram-negatives including Pseudomonas (TZP_IV).
- Prior MRSA history/colonization → add MRSA coverage (VAN_IV).
- eGFR 89 mL/min/1.73m2: standard dosing; avoid additional agents given prior outpatient levofloxacin exposure and low inflammatory markers/viral positive test.",TZP_IV,VAN_IV,NA,2026-02-08T05:01:07Z
40,OK,1,badd3d836de2399327caa18aad2b0a043cde4f6b1a8e20d22455cd876af586bd,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0c0192ad381001880169877f4060f081939be93278158a25a8,1770487616,1975,210,ab09b5e2d4886dc256500c82ce9788e442346ee62c68a60ea4f4c22ebc954b57,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Moderate community-onset CAP with respiratory failure: empiric IV beta-lactam + macrolide for typical + atypical coverage.
- No MRSA or MDR risk factors; avoid VAN/anti-pseudomonal agents.
- eGFR 106: no renal dose adjustment needed for ceftriaxone/azithromycin.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
41,OK,1,98f8f95de7941c7a96537b28a0b9539e569aafffc1c60df602d0a4635cbcb0cf,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_01e094f2e37b45c90169877f425ae48197afa74a0a82023768,1770487618,1979,230,2256b0fd28e9d3a2507dceff84e55fde28773120ddccafde15be0b3d9aca2408,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Moderate community-onset CAP with respiratory failure and high CRP: empiric beta-lactam + macrolide for typical + atypical coverage.
- No MDR/MRSA risk factors and no shock/ICU/vasopressors: avoid broader anti-pseudomonal or MRSA agents.
- eGFR 97: no renal dose adjustment needed for ceftriaxone/azithromycin in first 24h.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
42,OK,1,d7fd2980494e7781cda659f3365f49bfcf5d793db25465ca1649e66cff0d703f,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0e5b3a180904767e0169877f4377248190bec638f88dc3e31b,1770487619,2077,226,826f1f6ba5eaaccf625c29899ad25e44488199fadec08bddd0a649a8b1dd2c0f,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with elevated CRP; despite positive viral screen, short empiric antibacterial coverage is reasonable.
- Prior home AZM_PO already provided atypical coverage; ceftriaxone adds core pneumococcal/H. influenzae coverage without unnecessary combination therapy.
- No MRSA/MDR risk factors and low severity, so no MRSA or antipseudomonal escalation; renal function normal (eGFR 92), no adjustment needed.",CRO_IV,NA,NA,2026-02-08T05:01:07Z
43,OK,1,c605d9eb1eff07f00d18aa22b2537d657caa44bfb57397cc48d84cda0f4ec6fd,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0fd0faa44fa079ec0169877f4398a08192a0d007e82634cae4,1770487619,1974,257,2efa94be94e46156fc05f206ccbedc951b0921ff2ee16365f1a1e73e032ec72c,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h (renal function eGFR 47: no adjustment)
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with documented respiratory failure (moderate severity): empiric IV beta-lactam + macrolide for typical + atypical bacterial coverage.
- No MRSA or MDR risk factors (no prior MRSA/ESBL, no recent hospitalization/LTC/antibiotics), so no empiric MRSA/anti-pseudomonal escalation.
- Viral screen positive lowers bacterial probability but does not exclude coinfection in a hypoxemic presentation; short-course empiric coverage pending cultures is reasonable.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
44,OK,1,993b24d84353c297aadc0baa2f5b423e4eea23847edae68bd34eb3e3d82349d3,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0ae8c91e26df45e20169877f45a2b881a1b4ac515dac4ca96f,1770487621,1974,232,11f50c0eca8a9c89b83ffc2936b86bb3deecb152dc08044641b55657f80b5ea5,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Moderate community-onset CAP with respiratory failure: empiric beta-lactam + macrolide for typical + atypical bacterial coverage while cultures pending.
- No MRSA/ESBL/CRE risk factors and no septic shock/ICU needs: avoid routine MRSA or antipseudomonal therapy.
- eGFR 66: no renal dose adjustment needed for ceftriaxone/azithromycin in first 24h.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
45,OK,1,2fbb46a1734b80ac5f38d9cfc1fb5eaa35772afe2bbda52f0e73948dd55f1601,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0977ae4a237d0ffa0169877f471ad88193b92524d4b9770029,1770487623,1986,236,3bef8fcd770bc2999ad6786330a1be6b64aa39c3521dd094852103406c20ddc6,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q8h (renal-adjusted for eGFR 33)
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset pneumonia with septic shock/MV/vasopressors → broad IV empiric coverage appropriate in first 24h.
- TZP provides coverage for typical CAP pathogens plus gram-negative/anaerobic coverage; no structured MRSA or ESBL risk to justify VAN/linezolid or carbapenem.
- Avoids additional agents given renal impairment (eGFR 33) and markedly elevated transaminases.",TZP_IV,NA,NA,2026-02-08T05:01:07Z
46,OK,1,fc4e2effab30d2fb24ccf7b1d0627cab4ec9ed3cc14e359b850115a2f8c90d5c,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0f1a6b30c515e6000169877f481404819d9833068b13771575,1770487624,1968,238,6a0efceb9796b5cc218fcb060aeee289f53421d7500cda0855fdf8589eb71ef3,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with respiratory failure and leukocytosis: empiric beta-lactam + macrolide for typical + atypical coverage.
- No MDR/MRSA risk factors and no shock/ICU/vasopressors: avoid broader antipseudomonal or MRSA agents.
- eGFR 82 mL/min/1.73m2: no renal dose adjustment needed for ceftriaxone/azithromycin in first 24h.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
47,OK,1,4efcbbcf682061cad27a108bb9788aededb1022d6c689804f386df26da132dac,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_060362eb3e53b5210169877f4a73b88191b27d2b34c47395f4,1770487626,1989,241,fcfd53d43fbd4b15194e6cc59e7b1034134e216b4afd2cfcc94cde6607b140bf,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with respiratory failure (moderate severity): IV beta-lactam + macrolide for typical + atypical bacterial coverage while cultures pending.
- No MDR/MRSA risk factors and viral screen positive with low-moderate inflammatory markers: avoid broader anti-pseudomonal and MRSA agents in first 24h.
- eGFR 77 mL/min/1.73m2: no renal dose adjustment needed for ceftriaxone/azithromycin.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
48,OK,1,a4a515355b03b276b7eb0603af148db80b5bbba6cde86f340883151f0ceea6a8,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0a69bd9a9c39c1e80169877f4afc64819e9e09df7c4fef22a2,1770487627,2043,230,8e71c8ab3b4d4eea17f402e15acc7eea173e04f2a4328d327b69719dc10448a9,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset UTI with leukocytosis; ceftriaxone provides broad Enterobacterales coverage appropriate for low-severity presentation.
- Prior outpatient antibiotic exposure (agent unknown) increases risk of resistance; ceftriaxone is a reasonable empiric step-up without unnecessary antipseudomonal/MRSA coverage.
- eGFR 70 mL/min/1.73m2: no renal dose adjustment needed for ceftriaxone in first 24h.",CRO_IV,NA,NA,2026-02-08T05:01:07Z
49,OK,1,be1ccecb52544b1b566ec5223247fdb95a07e380d7c2cc5a34fcde18e816f8b5,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_08ba228311bd4c4e0169877f4b5618819f8b40b1beab0966a1,1770487627,1975,238,6dfa215f0c2d4b3b9bac72d58331e0f3582bf0c8de4ece67bb0e9f0c47a31e40,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h (no renal adjustment for eGFR 9)
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Severe community-onset CAP with respiratory failure/MV and marked leukocytosis: IV beta-lactam + macrolide for typical + atypical coverage in first 24h.
- No documented MRSA/ESBL/CRE risk factors, so avoid routine MRSA or carbapenem therapy.
- Avoid aminoglycosides given advanced CKD (eGFR 9) and nephrotoxicity risk.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
50,OK,1,c2868ea55eaf2f5f8093045411148e930985624269fddd8d869eb98832ca4d7e,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0b45bea244cc5a350169877f4ddc848192881848cd023b9db8,1770487629,2004,228,b2a644ef5ac18014b307c6b5bb0ac4a011f7604ba3e4afae8f6856c320bf9503,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Severe community-onset pneumonia with MV/NIV and ICU transfer: empiric IV beta-lactam + macrolide for typical + atypical CAP coverage.
- No MDR risk factors and no prior MRSA/ESBL history: avoid routine MRSA or antipseudomonal therapy in first 24h.
- eGFR 91: no renal dose adjustment needed for ceftriaxone/azithromycin.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
51,OK,1,eddac1fa077ef4c4cda0cbf550559887041186718fc0094d072060ecfcae1b25,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0526415535c95a820169877f4e8170819da50b3e27c1ddcb17,1770487630,1975,219,bc13ab134af82920cecb7481a78983790cc40231f946e99c54ad629b330918a7,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Moderate community-onset pneumonia with respiratory failure: empiric CAP coverage with IV beta-lactam + macrolide for typical and atypical pathogens.
- No MDR/MRSA risk factors and no shock/ICU needs: avoid broader anti-pseudomonal or MRSA agents.
- eGFR 104: no renal dose adjustment needed for this first-24h regimen.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
52,OK,1,0a9926946d7b1d5e5122b9fd15fb9944d0766cb167e728844589251289881535,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_063c86fa694ac0be0169877f4ec628819f83968d648298b6c6,1770487630,1986,239,f9df4942c36ae6d693f18c1fe1a37ff615b1ac1f65de497c193f06720b2200a9,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h (no renal adjustment needed at eGFR 40)
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset UTI with elevated CRP but low severity and no MDR risk/history: ceftriaxone provides appropriate empiric Gram-negative coverage (E. coli/Klebsiella predominant locally).
- Avoids unnecessary broad antipseudomonal or MRSA therapy given no supporting risk factors.
- Renal function eGFR 40: ceftriaxone generally does not require dose adjustment; avoids aminoglycoside nephrotoxicity risk.",CRO_IV,NA,NA,2026-02-08T05:01:07Z
53,OK,1,de340372fe5ae565d6749168bfe2e0734f061714fd87f42a205f0c5073a45e80,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0bd29f6e47e8b6070169877f5166f4819fa90799a52fda3e19,1770487633,1996,232,2cf523fe1407b85d43e2d09b8e76452e1315cac49a96c3c6ade8586eeab2e276,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Severe community-onset pneumonia with respiratory failure/MV and ICU transfer → empiric IV CAP regimen covering typical pathogens plus atypicals.
- No MDR/MRSA history or recent healthcare/antibiotic exposure → avoid routine anti-MRSA or antipseudomonal therapy in first 24h.
- eGFR 92 mL/min/1.73m2 → no renal dose adjustment needed for ceftriaxone/azithromycin.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
54,OK,1,29f72023c08a5072fa1aad1a446fd2a4ec90e910576d0caa1c6b212c41a03800,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_00dbdd6eb7d1c6200169877f52c2e88196bc16e1d29a982efd,1770487634,1975,238,3441cb4af248c8714dbde2efcdbf80d8050f76d3233d82c1c544f7dd19405816,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with respiratory failure (moderate severity): empiric IV beta-lactam + macrolide for typical + atypical bacterial coverage in first 24h.
- No MDR/MRSA risk factors and no shock/ICU/vasopressors: avoid broader anti-pseudomonal or MRSA agents.
- Normal renal function (eGFR 119): standard dosing; viral screen positive does not exclude bacterial coinfection given severity/WBC elevation.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
55,OK,1,c6e80364f8f55859910832b905ef1e8ee1a99843b10aae78fcb9003160f422c6,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_08cef4fa4da4156b0169877f52c01481929d8e932b47031913,1770487634,1993,209,5767344f0437a7629e065f4d48a1b5299c4e8c2a405f4269009bddde95a93671,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q6h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- High-severity pneumonia with ICU transfer and healthcare-associated acquisition → broad IV empiric coverage including Pseudomonas and other Gram-negatives.
- No MRSA history/risk factors provided → avoid routine MRSA agent.
- eGFR 89 mL/min/1.73m2 → no renal dose adjustment needed in first 24h.",TZP_IV,NA,NA,2026-02-08T05:01:07Z
56,OK,1,28f5343156753e9a90d245724071e111c8a209b8dd63b202af1d32cd5299f01d,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_03a25813441b84800169877f54d980819fbf768cb8b35b16fc,1770487636,1982,234,9e92f70d088e489cdef9622e25586e21a0ea0ae1475e89419b96a7382018e35a,1,output[0].content[0].text,,"DRUG_1_NAME: MEM_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h (renal-adjusted for eGFR 19)
DRUG_2_NAME: VAN_IV
DRUG_2_DOSE: 15 mg/kg
DRUG_2_INTERVAL: q24–48h (renal-adjusted; dose by levels)
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Septic shock with community-onset sepsis: broad IV empiric coverage needed in first 24h.
- Prior ESBL history supports carbapenem (meropenem) for resistant Gram-negative coverage.
- Prior MRSA colonization supports adding vancomycin for MRSA coverage; both agents renal-adjusted for eGFR 19.",MEM_IV,VAN_IV,NA,2026-02-08T05:01:07Z
57,OK,1,cf4b401710ed47a5d5171494043fd582e3213d20963c07a600bd100137cfe1fb,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_040a4e2dfac3f34e0169877f55da58819e9dfb363baac5a59d,1770487637,1989,226,8dc7d5afa99388d777a3ba27cbec26ab53d9250cec931d9a094da20517735197,1,output[0].content[0].text,,"DRUG_1_NAME: MEM_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q8h
DRUG_2_NAME: VAN_IV
DRUG_2_DOSE: 15 mg/kg
DRUG_2_INTERVAL: q12h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Septic shock with MV/vasopressors/ICU transfer → IV broad empiric therapy for first 24h.
- Prior ESBL history + healthcare-associated sepsis → meropenem for ESBL-risk Gram-negative coverage.
- High likelihood of catheter/skin-source Gram-positive bacteremia in ward ecology (CoNS/S. aureus) → add vancomycin for MRSA/CoNS coverage.",MEM_IV,VAN_IV,NA,2026-02-08T05:01:07Z
58,OK,1,50c190dc52fa4f00decf247199b90e5b00da7b64eaa989ba1ffd4f1bec9671fc,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0ffeb7568d47c3f30169877f567a308196899c906b3953bb60,1770487638,1982,236,e50d1a6d5ea52bd5ab1fe6a1af90bd17081c3ca9a689e3e7be0d74401fbe6416,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with respiratory failure and elevated CRP: empiric inpatient CAP coverage with beta-lactam + macrolide.
- No MDR/MRSA risk factors and no shock/ICU/vasopressors: avoid broader anti-pseudomonal or MRSA agents.
- eGFR 82 mL/min/1.73m2: no renal dose adjustment needed for ceftriaxone or azithromycin in first 24h.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
59,OK,1,6347bc2cb5c06488224902ad7d9c7eee50a41c0bcf2656e4ff157d395d3d2bf7,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_03e6b0fef4c387ab0169877f58fb588190be52fcc15c894757,1770487641,2045,228,d0ebdf86d17556290132a7acd01ec64309cb390404e0705a5fbf44022fd060a2,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with documented respiratory failure (moderate severity) warrants inpatient IV CAP coverage despite positive viral screen.
- CRO_IV + AZM_IV provides typical + atypical CAP coverage; no MRSA/MDR risk factors to justify VAN/LZD or antipseudomonal therapy.
- Home AMC1G_PO suggests pre-treatment; escalation to IV regimen appropriate for admission severity; renal function unknown (standard dosing used).",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
60,OK,1,2bbdaa19ba78c2cf9c3f658ea917a656b7042147884a0a45170d0934b4d4e54b,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_03333308169cfc650169877f592c108194999750097bef8ba0,1770487641,1990,238,5d9a69e3778f05bc8258ba8d8d75ac8d3ced216c65a7c682123b8bcb75856e2c,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h (renal function unknown adjustment not required; eGFR 18)
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset pneumonia with respiratory failure: empiric CAP coverage with ceftriaxone + azithromycin for typical + atypical bacteria.
- No MDR/MRSA history or recent healthcare exposure, so no empiric anti-MRSA or antipseudomonal therapy.
- eGFR 18: ceftriaxone and azithromycin generally do not require renal dose adjustment for first 24h.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
61,OK,1,06099a781b3c2f87653838255a7df9332e01746e6392021a35700a4c320c2917,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_01ccd51e5c9eee590169877f59e7d881a0a92ecb8e6d06f1bf,1770487641,1992,238,d48cc66ad817f38a92d237e854122ca992c9dbd7f5f952e1e9b5e39225de50a6,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Severe community-onset pneumonia with respiratory failure/ICU transfer and leukocytosis: empiric CAP coverage with ceftriaxone + azithromycin for typical + atypical pathogens.
- No MRSA or MDR/Pseudomonas risk factors in structured history, so avoid routine VAN/anti-pseudomonal beta-lactam.
- eGFR 66: no renal dose adjustment needed for ceftriaxone or azithromycin in first 24h.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
62,OK,1,b074c02b153ca4fdf44d7d9d4c9541965c6040ab3aa21542d5b49a66dda8f832,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0b3accf7591d01ba0169877f5c4300819081e519e91f799beb,1770487644,2011,218,02f94c60a7e01b83856c98f26cb42861facda70f48180051e21d96ed54420b0d,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with respiratory failure and leukocytosis; give empiric IV beta-lactam coverage for typical bacterial pathogens while cultures pending.
- Viral screen positive and already pre-treated with azithromycin at home; avoid additional macrolide and avoid routine MRSA/Pseudomonas coverage without specific risk/history.
- Renal function unknown; ceftriaxone generally does not require renal adjustment in typical dosing.",CRO_IV,NA,NA,2026-02-08T05:01:07Z
63,OK,1,85f57bea3ea640b7e7fc12782a24d3c0e8e22e46229d9d81a2ad9be61768d592,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_028a0bf9cb0406eb0169877f5d1fa08194b8b023fc02b636b0,1770487645,1985,255,aa4edc579d61fe24adbcecf52421eb98c6d6610397b48c5e39f5e357f761c8c2,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h (eGFR 52 mL/min; no renal adjustment needed)
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with respiratory failure (moderate severity): empiric beta-lactam + macrolide for typical + atypical bacterial coverage despite positive viral screen.
- No MRSA/ESBL/CRE risk factors and no septic shock/ICU needs: avoid routine MRSA or antipseudomonal therapy.
- Ceftriaxone provides core pneumococcal/Enterobacterales coverage; azithromycin adds atypical coverage and potential anti-inflammatory benefit in CAP.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
64,OK,1,4b3cf9bee8c4e787f44241e5149e0249f532ee32021b037a8ebc5261f8e2d5c0,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0366ce021496a16f0169877f5d6f188195b83453990f745565,1770487645,2048,231,583c1f45f5c14960af756c067521efcba7c7950a15a304fdf97a3a16cc3a21a8,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset UTI with low severity and minimal inflammatory response; ceftriaxone provides broad empiric Gram-negative coverage appropriate for typical uropathogens.
- Avoids repeating recent home fluoroquinolone exposure (LEV_PO) and limits unnecessary combination therapy.
- Severe renal impairment (eGFR 5): ceftriaxone generally does not require renal dose adjustment; chosen to avoid nephrotoxic agents (e.g., aminoglycosides) in CKD.",CRO_IV,NA,NA,2026-02-08T05:01:07Z
65,OK,1,829c23d268cedc5bdcef5a2162e98e7443a6ae790644b3f25454cc71380f4897,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_09e4f1a2d5f822430169877f5fdc6c819595a1c44819c0aef9,1770487647,1969,227,722698996575daab8c6de649353fb251366c9cd28687d672e96baf6f2e6bdd17,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with respiratory failure and immunosuppression: empiric beta-lactam + macrolide for typical + atypical pathogens.
- No MDR/MRSA history or recent healthcare/antibiotic exposure: avoid routine anti-MRSA or antipseudomonal therapy.
- eGFR 97: no renal dose adjustment needed for ceftriaxone/azithromycin in first 24h.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
66,OK,1,7a901b7b8ed2b26c98854119dde0d6f8ac62d9246500cb7151bdd0510c51a69a,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0ff8f584fa57de6a0169877f60feb88190a3a8a3380faeed41,1770487649,1994,232,1a95c507a7f95b27291b9b3669f5b2832245550015a765548a98e54bd871a5dd,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset pneumonia with respiratory failure and immunosuppression: empiric CAP coverage with ceftriaxone + azithromycin for typical and atypical bacteria.
- No MDR risk factors or prior MRSA/ESBL history: avoid routine anti-MRSA or antipseudomonal therapy.
- eGFR 48: ceftriaxone and azithromycin do not require renal dose adjustment at these doses for first 24h.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
67,OK,1,989404387c7c6469e74e1b1fe168d255e8f2b5b80f700c40d3a9d9d74defbab7,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0062d6ccd5036a400169877f61246c819482eee1b51b9474d2,1770487649,1976,218,c53f5376daaed2a053787e9b68c4161c3b9fd2e0ff58cd54903ec1d7709353fe,1,output[0].content[0].text,,"DRUG_1_NAME: FEP_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q8h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- High-severity pneumonia with MV/NIV and ICU transfer plus recent hospitalization → empiric broad IV antipseudomonal beta-lactam coverage appropriate.
- No MRSA history/risk provided and no septic shock → avoid routine MRSA agent in first 24h.
- eGFR 85 mL/min/1.73m2 → standard cefepime dosing (no renal adjustment needed).",FEP_IV,NA,NA,2026-02-08T05:01:07Z
68,OK,1,36bc2c7a1561be8cd1aef4c01d21e69481bdb5e7bea514fe171e5f0108cd56da,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0b14e1dd298d9e080169877f634eb081a39037383ab6c44643,1770487651,1970,201,a594acb494926f4655c1f97a828e4d4a81555463aee2e40dc4b3ec73653928e7,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with low severity and no MDR/MRSA risk factors: ceftriaxone + azithromycin provides standard empiric coverage for typical and atypical pathogens.
- Normal renal function (eGFR 84): no renal dose adjustment needed for this 24h empiric regimen.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
69,OK,1,2ca5f8525af38de49f66b92d7e3e0c2d1a515f7397dcddba9a8034cabd30a509,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0a8f37c59c4dfce10169877f646aac819384ba2cb2cf2485db,1770487652,2006,234,d3594f824395ac830a97e26de10c730237d9f5598bd915c6e8363bf91ce9785f,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h (no renal adjustment needed at eGFR 34)
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Severe community-onset pneumonia with ICU transfer/respiratory failure → empiric IV CAP regimen covering typical pathogens plus atypicals.
- No MDR/MRSA history or recent healthcare/antibiotic exposure → avoid routine MRSA or broad antipseudomonal therapy.
- Viral screen positive and very low CRP/WBC not elevated, but severity supports short empiric antibacterial coverage while cultures pending.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
70,OK,1,5bada8777fd6318e48852a526f166908185e3eab8af89bed825ff979ba54d8df,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_011118c3ef0f29c80169877f646dc081a381b85d212ba78ea3,1770487652,1968,233,16fa0c01a5f2e04a6bcb35dae02ca39df7b91c78de12cab7b75749ffaa0460ec,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h (renal adjustment not required at eGFR 20)
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset sepsis/bloodstream infection without MDR risk factors: ceftriaxone provides broad empiric coverage for common Gram-negative and streptococcal pathogens.
- Avoids unnecessary MRSA/enterococcal coverage given no prior MRSA/ESBL/VRE history and low inflammatory markers.
- Single-agent regimen limits toxicity in advanced CKD (eGFR 20) and severe transaminitis.",CRO_IV,NA,NA,2026-02-08T05:01:07Z
71,OK,1,86b95a67d017d5d37262851e0b1efedb805392643b83f37aa285e87d3a42e8e0,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0029b11b7f16b6dd0169877f6619d081909eecc6b3f1b58958,1770487654,1980,234,27e7eb0c8432167dde8f9695ee097cfb9318389a90c29382c6165cdace339272,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset pneumonia with respiratory failure (moderate severity) warrants empiric IV CAP coverage despite positive viral screen (possible bacterial coinfection).
- Ceftriaxone + azithromycin provides typical + atypical CAP coverage; no MRSA/ESBL history and no LTC, so no empiric MRSA or broad anti-pseudomonal therapy.
- eGFR 92: no renal dose adjustment needed for either agent in first 24h.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
72,OK,1,23f351f671c367f44ca9d019ccc05faac5ade5ed9ce09034ba6a7db2a028486d,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0e159339b45ce7db0169877f68eb00819eb576f00e56c82766,1770487656,1959,224,e350334412d408d31466a2e8325a40d457401e37e074739858924cdae7b88a4d,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset moderate CAP with respiratory failure: ceftriaxone + azithromycin provides empiric typical + atypical coverage.
- No MDR/MRSA risk factors and no shock/ICU/vasopressors: avoid broader antipseudomonal or anti-MRSA therapy.
- Renal function normal (eGFR 105): standard dosing; monitor given elevated transaminases.
",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
73,OK,1,27cca2e19b695d8fbbcd3f7643223858bd47d62a3fd0952664b749db570c4050,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_005d573993a293150169877f67ff9481a2ab6ec8a98617df98,1770487656,2083,244,a72f41b0c318784881576cc59fef0659140fcb9b0d32969ff2b7b03e4953adf7,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- High-severity community-onset pneumonia with ICU transfer/respiratory failure: use IV CAP regimen covering typical bacteria plus atypicals.
- No MRSA or MDR risk factors; avoid empiric VAN/LZD and antipseudomonal therapy.
- Prior home AZM_PO suggests possible partial pretreatment; continue macrolide (IV) for atypical coverage while adding ceftriaxone for pneumococcus/Enterobacterales (renal function adequate; no adjustment needed at eGFR 79).",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
74,OK,1,d4f1590b40818ca9b97d1fe9d225cd185f0efea8cdd7c4cf0ad65101d15b87b8,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_02a8723c5f9a85d60169877f69c218819cb7ec4eb4cf63aab5,1770487657,1994,248,b1e72a3e9a9262c2aa070e178604b6d16ad9cfb8963258f143ae7c988936b235,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h (renal function unknown adjustment not required; eGFR 17)
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with low severity but bacterial possibility (WBC 11.2, CRP 35) despite positive viral screen; ceftriaxone provides standard CAP bacterial coverage.
- No septic shock/ICU/MV and no MRSA/MDR risk factors, so avoid broader anti-pseudomonal or MRSA combination therapy.
- Severe renal impairment (eGFR 17): ceftriaxone generally does not require renal dose adjustment for short-course empiric use.",CRO_IV,NA,NA,2026-02-08T05:01:07Z
75,OK,1,8fa07dea6d984d1040cfa5074065fd63d7019d92fe29fd646c4c24c2e620296d,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_01904cff696789a40169877f6bd8c881a08ea4265dfcf34839,1770487659,1995,237,fd526402335a5ff8bdabbffc9dbe7f266a2e00d540f9c584b3228ad263321b15,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q8h (extended infusion; renal-adjusted for eGFR 39)
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Severe community-onset pneumonia with respiratory failure on MV and vasopressors/ICU: start broad IV beta-lactam with antipseudomonal activity.
- No documented MRSA history or recent healthcare/antibiotic exposure to justify empiric MRSA agent.
- Single-agent TZP provides coverage for typical CAP pathogens plus gram-negative rods (including Pseudomonas) suggested by local ward epidemiology.",TZP_IV,NA,NA,2026-02-08T05:01:07Z
76,OK,1,9cb3c104489c757f40126318018a51c98759e7fd50beb6ee9e10a6942a59f2de,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0cdafc44866c35ae0169877f6c481c81a1bf6067d00673f6e4,1770487660,1987,263,e75248f3d3e84b312b109308fa6ea722a94033c1a9b7510cb66558e13e01fc4d,1,output[0].content[0].text,,"DRUG_1_NAME: MEM_IV
DRUG_1_DOSE: 500 mg
DRUG_1_INTERVAL: q24h (renal-adjusted for eGFR ~5)
DRUG_2_NAME: VAN_IV
DRUG_2_DOSE: 15 mg/kg
DRUG_2_INTERVAL: once, then dose by levels (severe renal failure)
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Septic shock with MV/vasopressors/ICU: broad IV empiric coverage for community-onset sepsis including Gram-negatives (incl. Pseudomonas) and anaerobes (MEM_IV).
- Add MRSA-active agent (VAN_IV) given high-severity bloodstream infection/sepsis where early adequate coverage is critical despite no prior MRSA history.
- Doses adjusted for profound renal dysfunction (eGFR 5 mL/min/1.73m2).",MEM_IV,VAN_IV,NA,2026-02-08T05:01:07Z
77,OK,1,a2a23a0d04c8d429f02f432870c65a7e355674f0a5be9afb54339efc8f98c3b2,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_053d58f7c81790290169877f6d8a3c8195b5c1cabe0d808746,1770487661,1981,236,5620f55f745c8f8601e47c06f2e22a9b9e2a4cd645d7a2dfd88e151aa3d0fa43,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q6h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Severe community-onset pneumonia with septic shock/MV/vasopressors → IV broad empiric coverage; TZP provides streptococci, H. influenzae, and antipseudomonal Gram-negative coverage.
- Add azithromycin for atypical CAP pathogens and potential immunomodulatory benefit in severe CAP.
- No MRSA history or recent healthcare/MDR exposure in structured data → avoid routine MRSA agent in first 24h.",TZP_IV,AZM_IV,NA,2026-02-08T05:01:07Z
78,OK,1,0de61c9756710c113fa94aa78e60d1207dbf5bfe76e52352f326060acc251df4,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_02cc4a383421f55d0169877f6fc31881a1980dc01fa1b255fa,1770487663,1979,238,ae7bf8f5fec7570a60fc2f6114734ff9a78254010877d5d909ab0e450a2427af,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset pneumonia with respiratory failure (moderate severity): IV beta-lactam + macrolide for typical + atypical bacterial coverage in first 24h.
- No MRSA history and no ESBL/CRE/VRE history; recent hospitalization alone does not mandate empiric MRSA or carbapenem therapy.
- eGFR 85 mL/min/1.73m2: no renal dose adjustment needed for ceftriaxone/azithromycin.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
79,OK,1,a33b8fca90baaca170b5dd50ce4f7fa4b8b78f422a96e52ca2bac67736437ceb,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_022c434ebcb46e950169877f70727c81908eb9f3617554e045,1770487664,1977,210,137576288a15d7f6be7c6a19cea3316fad679a8e72d8e5871cc42ffc15138faa,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with low severity and no MDR/MRSA risk: ceftriaxone provides core pneumococcal/H. influenzae coverage.
- Add azithromycin for atypical coverage; viral test positive does not exclude early bacterial coinfection.
- Normal renal function (eGFR 111): no renal dose adjustment needed.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
80,OK,1,4f76a5ba50c011734daaa4e0958e246d7fb386427dcb381224dbd102e101c412,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_053d35f258f758f80169877f726f6081a096440a7591882404,1770487666,1980,218,c2cab46aa79ac904ee758b7355c0abefb998839a96d40db95bb1962ab5853217,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q6h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- High-severity community-onset COPD infectious exacerbation with ICU transfer and recent hospitalization: broad IV coverage for Gram-negatives including Pseudomonas and typical respiratory pathogens.
- No MRSA history/risk flags provided, so avoid empiric anti-MRSA agent.
- eGFR 68 mL/min/1.73m2: no renal dose adjustment needed for first 24h.",TZP_IV,NA,NA,2026-02-08T05:01:07Z
81,OK,1,ee9db6eceff5be8502d1103882bdcd7ef81c290d3a8d316d44723aa6ed9c4e7b,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0eb13e6d5b3021800169877f7348208194bf154ede54d45a15,1770487667,1984,238,c961638798265c3d14043971cfa120d2862b7c1a831510bc84a27728451e86c7,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset COPD infectious exacerbation with respiratory failure requiring MV/NIV → IV therapy; cover typical respiratory bacteria and possible atypicals.
- No MDR/MRSA history or recent healthcare/antibiotic exposure → avoid routine anti-MRSA or antipseudomonal broadening in first 24h.
- eGFR 51 mL/min/1.73m2: ceftriaxone and azithromycin do not require renal dose adjustment at this level.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
82,OK,1,da6dc4a6c6cc4c4b6bf0dfc3a533cdbbcd2bd5abaaad600a67801861f634f746,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0e7e8711ecb5acab0169877f7358b481a1a9a755e76af5eb65,1770487667,2006,227,96814eb94d8233db35ca615d1d991f5d7b714b586bee5fae9ad3126c1bc14ebd,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q6h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset pneumonia with septic shock/MV/vasopressors → IV broad-spectrum beta-lactam for early coverage of severe bacterial CAP, including Gram-negatives and Pseudomonas.
- No structured MDR history or MRSA risk factors provided → avoid routine MRSA add-on in first 24h.
- eGFR 70 mL/min/1.73m2 → no renal dose adjustment needed for initial dosing.",TZP_IV,NA,NA,2026-02-08T05:01:07Z
83,OK,1,8032b71b887a8aba7140e4d9aafe46491a242d2b9ec498529d5d9ee6002e07a8,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0b617f239cceff150169877f75c95881a0a6df50a3ac04109d,1770487669,1976,213,efb94fb81f828176ca42d0b61742e690db76d11dfbbda76c542bed9ed7419180,1,output[0].content[0].text,,"DRUG_1_NAME: MEM_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h (renal-adjusted for eGFR ~16)
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- High-severity community-onset sepsis with prior ESBL history/colonization → empiric carbapenem to cover ESBL Enterobacterales and other severe Gram-negative causes.
- Avoid added nephrotoxic combination therapy (eGFR 16) and no structured MRSA risk/history to justify routine glycopeptide in this case.",MEM_IV,NA,NA,2026-02-08T05:01:07Z
84,OK,1,d2ed87243f9b82a82b9db3559d69290a7b326dd6114345daa9ae24d6b3252670,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_044c902d50f7c68d0169877f76f2408193ba74771749f2eefa,1770487670,1962,233,d1f3632fbf729a5a974fc12743e1aea33938f37c14f9b892a42c21ac5c441fe0,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with respiratory failure and leukocytosis: empiric beta-lactam + macrolide for typical and atypical respiratory pathogens.
- Immunosuppressed/malignancy increases risk of bacterial pneumonia; no structured MDR/MRSA history to justify broader anti-MRSA or anti-pseudomonal therapy in first 24h.
- eGFR 133: no renal dose adjustment needed for ceftriaxone or azithromycin.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
85,OK,1,cdf1eb6e088c5da65c04174cbe4a6393965127f41add80c4dd681e781d8b9190,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0709ccbf3a83a6e30169877f77282c81a2bb0526c8eefa690f,1770487671,2021,238,d992b7608d26743444c203497703bea73237c260ec9f71becc708e9994787d6d,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q8h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset COPD infectious exacerbation with respiratory failure and leukocytosis; empiric broad IV beta-lactam/beta-lactamase inhibitor provides coverage for common Gram-negatives including Pseudomonas suggested by local prior.
- Recent antibiotic exposure (unknown agent) increases risk of resistant Gram-negative pathogens; TZP provides broader empiric coverage without routine MRSA therapy (no MRSA history/risk provided).
- Renal function preserved (eGFR 79), so standard dosing used.",TZP_IV,NA,NA,2026-02-08T05:01:07Z
86,OK,1,500a84a05222de6fb533dde0001bcf0129b0fa6bd19a8170869a017436e950d7,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0f5278c361a6d7c90169877f794b3c819598fd865d549f853d,1770487673,1980,237,53e5ca08b6b45d0366327e86181750fa5362b892a3c6a853e6045d4aa954bc38,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Severe community-onset CAP with respiratory failure requiring MV/NIV → IV beta-lactam + macrolide for typical + atypical coverage in first 24h.
- No MDR risk factors and no prior MRSA/ESBL history → avoid routine anti-MRSA or antipseudomonal therapy.
- eGFR 56: no renal dose adjustment needed for ceftriaxone/azithromycin in this range; monitor given markedly elevated transaminases.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
87,OK,1,e9a121d06447b1d494978c9d769be612cce731d2099d0202d9fcf718965ed9d9,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_01ab17769ab1846d0169877f7a7614819495ff1f8bf9c35c00,1770487674,1981,233,000b723d2c949d0375b76cd6de548be85610dada618b18c6c077e7b6045ea153,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with high severity (respiratory failure, ICU transfer): empiric IV beta-lactam + macrolide for typical + atypical coverage.
- No MDR/MRSA risk factors and no septic shock/vasopressors: avoid routine anti-MRSA or antipseudomonal therapy.
- eGFR 84: no renal dose adjustment needed for ceftriaxone/azithromycin in first 24h.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
88,OK,1,c86e62edcdad1f690385d56dcb0f9feb12c784289b2d0cfeb01c3cab514375bd,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0e335619476d2c570169877f7ac68c81a3b44e09688b3b22eb,1770487674,1980,262,07b25d6fbe36f8c5f4e13005ed0a7f4eaec8fc74d0ea8a006e5c700a17537c03,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- High-severity community-onset pneumonia with respiratory failure/ICU transfer: empiric CAP coverage with IV beta-lactam + macrolide for typical + atypical bacteria.
- No MDR/MRSA risk factors and no septic shock/vasopressors: avoid routine anti-MRSA or antipseudomonal therapy.
- eGFR 121 mL/min/1.73m2: no renal dose adjustment needed for ceftriaxone/azithromycin in first 24h; viral screen positive does not exclude bacterial coinfection given CRP 175 mg/L.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
89,OK,1,c7b95e8f24d62ab1af1ce03e2baeb55d7d25729b7cd0e8cfccd6310a4e6d3c4e,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_014b18e81df1a0b00169877f7cf988819d882c7068ca5418b9,1770487676,1985,243,6387aa254eb1d4f545c4138a022efd8c317417fd245799a9879bbe75f42d6bf7,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q12h (extended infusion preferred), renal-adjusted for eGFR 19
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset pneumonia with septic shock/MV/vasopressors → IV broad-spectrum empiric coverage appropriate for first 24h.
- TZP provides coverage for typical CAP pathogens plus Gram-negative/aspiration risk and Pseudomonas, without adding MRSA coverage (no MRSA history/risk factors provided).
- Renal dysfunction (eGFR 19) → dose/interval adjusted to reduce toxicity while maintaining exposure (extended infusion).",TZP_IV,NA,NA,2026-02-08T05:01:07Z
90,OK,1,ed96de98a3df2eb13a81e8ab416275e867a16c33e7088c09e918327a8fe20348,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0992495217dff3720169877f7e80fc819e852a56b934352a48,1770487678,1998,227,f93898c657db87fc58701f5ce292e1f5b78ed53dd3b4f5e9f24a90b95cfda651,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q12h (renal-adjusted for eGFR 17)
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Severe community-onset pneumonia with septic shock/MV/vasopressors → broad IV empiric coverage including Pseudomonas and other Gram-negatives.
- No MRSA history or recent healthcare/antibiotic exposure → avoid routine MRSA agent.
- Viral screen positive but shock and leukocytosis support possible bacterial coinfection; TZP provides single-agent broad coverage while awaiting cultures.",TZP_IV,NA,NA,2026-02-08T05:01:07Z
91,OK,1,cbdd5b6b45ea2f2efe39d00e4dbd03cbf4913280db40b3c5eedfdd87c08fbcf3,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0a0be006331eca1c0169877f7eb7908190a98017d5903dc2ee,1770487678,1981,245,ddbbcaf521dc086d96b4ff1431bc9aaecfd36ec60285577453ca3101ddc53467,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h (renal function eGFR 46: no adjustment)
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with respiratory failure and elevated WBC/CRP: ceftriaxone + azithromycin provides standard empiric coverage for typical + atypical pathogens.
- No MDR/MRSA risk factors documented, so avoid broader antipseudomonal or MRSA agents in first 24h.
- IV route appropriate given respiratory failure (moderate severity) and need for reliable early therapy; dosing compatible with eGFR 46.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
92,OK,1,7ff64be5366c9a7be0ef5db642330d9789cc2b2af9e7f92e178675d8b05a7ed3,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0379acde5e0d6e430169877f8131788196bb6c47a4cdfaf179,1770487681,1988,230,e97cd0d40840f24a1261cb2431edc75a0db56f053cfee2b70e6326fcd8911b5a,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with respiratory failure (moderate severity): empiric beta-lactam + macrolide for typical + atypical bacterial coverage.
- No MDR/MRSA risk factors and viral screen positive with low-moderate inflammatory markers: avoid broader anti-pseudomonal and MRSA agents.
- eGFR 72: no renal dose adjustment needed for ceftriaxone/azithromycin in first 24h.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
93,OK,1,f648037c21a7a3da346e6d717f72ee5345c9009b5492919ed437e63af6fd8d88,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_085d50ff5e44f02a0169877f826a1081939a2191ea118e7be8,1770487682,1995,249,2a645a184dc9c7131cafe6d61e92183436bc5edcb923ee737b4063948832a705,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q6h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Severe community-onset pneumonia with septic shock/MV/vasopressors → IV broad empiric coverage; TZP provides streptococci and broad Gram-negative (incl. Pseudomonas) coverage.
- Add azithromycin for atypical coverage in severe CAP; viral test positive does not exclude bacterial coinfection given shock and very high CRP.
- No MRSA risk factors (no prior MRSA, no recent healthcare/LTC exposure) → avoid routine MRSA agent in first 24h.",TZP_IV,AZM_IV,NA,2026-02-08T05:01:07Z
94,OK,1,c62988c75fe495567b48cd5fb58b51137f6b19190ace77225335fb2477f612b2,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0aee813331fd32a90169877f8284108193b62ad67058150e48,1770487682,1972,225,be28ea96f02e5649a3444f5e62e81859c507028bc38ca74f0b62738363a16357,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with respiratory failure (moderate severity): IV beta-lactam + macrolide for typical + atypical coverage in first 24h.
- No MDR/MRSA risk factors and no septic shock/ICU needs: avoid broader anti-pseudomonal or MRSA agents.
- eGFR 85: no renal dose adjustment needed for ceftriaxone/azithromycin.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
95,OK,1,ab734dbdbfc41c6ff4909513aa89ee178155f1277c30b29ff4b077d280de2737,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0f63ec1f316c2a700169877f847fbc819d8da40f00d45bf8be,1770487684,1981,236,13eaaaae2019b0ddfc630b9cd37cf3ce369c618d5b4bb01547de2d71933f2b52,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset sepsis/bloodstream infection with no MDR risk factors: ceftriaxone provides broad empiric coverage for common Gram-negative and streptococcal causes while avoiding unnecessary combination therapy.
- No MRSA history or healthcare exposure; despite local staphylococcal prevalence, routine empiric glycopeptide is not supported by the structured risk profile.
- eGFR 114 mL/min/1.73m2: no renal dose adjustment needed for ceftriaxone.",CRO_IV,NA,NA,2026-02-08T05:01:07Z
96,OK,1,ca1e30f7da37e915d39ec4d2aab0d9ba25d7a63ada8b2de3ccef55f719c98402,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0d48675268a6d1fd0169877f85c3dc81a08f4083a80e90ff14,1770487685,1997,249,cbf23271bebc57a0d8dcce19fef0046e2a6b5543f0ff6e1f15c0e999d85b2b0b,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q8h (extended infusion; renal-adjusted for eGFR 45)
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Severe community-onset pneumonia with septic shock/MV/vasopressors → broad IV empiric coverage including Pseudomonas and other Gram-negatives with TZP.
- Add azithromycin for atypical CAP coverage in severe pneumonia; no structured MRSA risk/history to justify routine MRSA agent.
- Viral screen positive lowers bacterial probability but does not exclude bacterial coinfection given shock-level severity; treat empirically for first 24h.",TZP_IV,AZM_IV,NA,2026-02-08T05:01:07Z
97,OK,1,80229f7c6b93c5d360cae79dc63f65e1f337c60d983f517cb3e86f5a4c5b6f0e,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_03d17fd8ef95f04b0169877f86f97881a0985f42ed558cbc1c,1770487687,2023,269,33f46a8f4585f0926670774381792bf597b050563c99e94ebebeb421c1fd3151,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q6h
DRUG_2_NAME: VAN_IV
DRUG_2_DOSE: 25 mg/kg loading dose, then 15 mg/kg
DRUG_2_INTERVAL: load once, then q12h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Septic shock with MV/vasopressors: immediate broad IV empiric coverage for community-onset sepsis, including Gram-negatives and anaerobes (TZP).
- High likelihood of staphylococcal bloodstream infection in local prior plus immunosuppression and recent healthcare/antibiotic exposure: add MRSA-active agent (VAN).
- eGFR 94 mL/min/1.73m2: no renal dose reduction needed in first 24h; use weight-based vancomycin with loading for shock.",TZP_IV,VAN_IV,NA,2026-02-08T05:01:07Z
98,OK,1,3407842634108976532af92b7d0691068edc1ec24f01936fe9d1a3ec652a70a0,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0d2f40208955081e0169877f88b1508196b3e64675545dff1e,1770487688,1982,203,325a8c59fd21c8c202762bd3f8a20dab64931061a1b5940f92d7f7d0a796a2b7,1,output[0].content[0].text,,"DRUG_1_NAME: NO_ANTIBIOTIC
DRUG_1_DOSE: NA
DRUG_1_INTERVAL: NA
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Low-severity community-onset pneumonia with normal WBC and no sepsis/respiratory failure; admission viral screening POSITIVE increases likelihood of viral etiology.
- No MRSA history and no recent antibiotics; recent hospitalization alone without severe illness does not mandate empiric broad-spectrum antibacterial therapy in first 24h.",NO_ANTIBIOTIC,NA,NA,2026-02-08T05:01:07Z
99,OK,1,7c3510c1eb664193f68576dfaab1616f8e6effe806b714300b5e1984bc511701,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0931a35f89d134900169877f89d4708195b0c4c66772880a3c,1770487689,1957,247,c3423927ce877dc0146a8f4cda4cae9d249fc967c01804ef36e4a63015f7dde0,1,output[0].content[0].text,,"DRUG_1_NAME: VAN_IV
DRUG_1_DOSE: 15 mg/kg
DRUG_1_INTERVAL: q12h
DRUG_2_NAME: CRO_IV
DRUG_2_DOSE: 2 g
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Healthcare-associated sepsis/BSI with LTC + recent hospitalization/antibiotics: cover likely Gram-positives (incl. staphylococci) with vancomycin.
- Add ceftriaxone for empiric Gram-negative coverage in BSI while avoiding broader anti-pseudomonal therapy given low severity and no ESBL/CRE history.
- eGFR 87: no renal dose reduction needed for ceftriaxone; vancomycin initial dosing per weight with early level-guided adjustment.",VAN_IV,CRO_IV,NA,2026-02-08T05:01:07Z
100,OK,1,f002ada2a5f274fd7a5600f1353c4d770fbe631f9fe76f5d8ece33be23e0d96d,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0f32be3454ccbbd30169877f8bb7c881a3934027f3d91d9d98,1770487691,1977,224,9e1762f9afe96f49fe99014dfbb7486b8867492698d57d4812898c18fcb6b1f3,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Severe community-onset pneumonia with respiratory failure requiring MV/NIV → IV CAP regimen covering typical bacteria plus atypicals.
- No MDR/MRSA risk factors and normal WBC; viral screen positive but severity supports empiric bacterial coverage for first 24h.
- eGFR 95 mL/min/1.73m2 → no renal dose adjustment needed for ceftriaxone/azithromycin.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
101,OK,1,2d8db2a8a4d282be4ada34be9ce8de77c5e6e2da33cbe25fcf6222f76f0ca426,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0afb9be7f05f56ed0169877f8bdf6081a2bb6b0f0483cefe9c,1770487691,1982,226,6e5c9aa168e546fdec637ca563f2383ac6516575e06c25541c72e26bb2e226ec,1,output[0].content[0].text,,"DRUG_1_NAME: FEP_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q8h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- High-severity community-onset pneumonia with respiratory failure/ICU transfer: broad IV beta-lactam plus atypical coverage for first 24h while cultures pending.
- No MRSA history or major MDR risk factors: avoid empiric anti-MRSA therapy.
- eGFR 74 mL/min/1.73m2: no renal dose adjustment needed for cefepime/azithromycin.",FEP_IV,AZM_IV,NA,2026-02-08T05:01:07Z
102,OK,1,157f2319ee5ad9d32aa23a039c6c18ffa64a459838f857d161995ce2ab96deb4,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_04436a97fae5107a0169877f8d83e48197b9367fb0c23363e0,1770487693,1973,236,2a6c95b82b6e0cf8b21dfd1f87b57bf28a2da2eb2aca5d6cfa7a7c9afc89b9d7,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset pneumonia with respiratory failure (moderate severity) warrants empiric IV CAP coverage despite positive viral screen (possible bacterial coinfection).
- Ceftriaxone + azithromycin provides typical + atypical CAP coverage; no MRSA/MDR risk factors to justify VAN/linezolid or antipseudomonal therapy.
- eGFR 54: no renal dose adjustment needed for ceftriaxone or azithromycin in first 24h.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
103,OK,1,aa2eae993cfbc56399116cecd76d160ad8b58e20294bcda649aaa8d30ec89197,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_051a5a394eac0ef70169877f8f22b08197a2d1d17173815708,1770487695,1977,220,61fbd681bf84264af1cd585ad2f7e79eb119cc55b5ea3836ecd57629f5ff4b80,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q8h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- High-severity community-onset pneumonia with respiratory failure/ICU transfer: start broad IV beta-lactam with antipseudomonal activity for first 24h while cultures pending.
- No MRSA history or MDR risk factors provided, so avoid empiric MRSA agent.
- eGFR 61 mL/min/1.73m2: no renal dose adjustment needed for initial dosing.",TZP_IV,NA,NA,2026-02-08T05:01:07Z
104,OK,1,c33d12c2e639a89885220ae835204228cc3256f5bcc1bd4ea0db7fb59db2ae8e,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_009370fb6f718e6d0169877f8f841881928b946a179f8b97a4,1770487695,2071,267,2986b048bfa174e1ba7b3fce1cc4f0bd74b5372d300cf2c87d8c56e6408a106f,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- High-severity community-onset CAP with ICU transfer/respiratory failure → IV beta-lactam + macrolide empiric coverage for typical + atypical pathogens.
- No MRSA or MDR risk factors and no septic shock/vasopressors → avoid routine MRSA/antipseudomonal escalation despite local Gram-negative signal.
- eGFR 78 mL/min/1.73m2 → no renal dose adjustment needed for ceftriaxone/azithromycin in first 24h; prior home cefixime suggests possible partial pretreatment, so use parenteral therapy.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
105,OK,1,afa9abc178f14772807603d5d473afac5725006758a5834dc58c9ddba1eef8f1,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_066813277a07fd970169877f914c308190add7e2e06da2ee15,1770487697,2033,244,cbaccc24ac5ec7432b9138dc4662e310c1b112f71ee6e29622a315daede21ebe,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with respiratory failure and elevated CRP/PCT → empiric inpatient CAP coverage with beta-lactam + macrolide.
- No MRSA history and no recent hospitalization/LTC → avoid routine VAN/linezolid.
- Recent oral cefixime exposure → use IV ceftriaxone (different 3rd-gen cephalosporin with reliable CAP activity) plus azithromycin for atypicals; renal function normal (eGFR 82), no adjustment needed.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
106,OK,1,329843d53686f2fc119a11ec4faf4dc102b3f0e5e479fabb6cb729eed7c4ce77,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0d01558c45cbb2880169877f92e97481a1974ec38ab9cc3f9d,1770487698,1985,233,5e87b70df1edd9497dc2788b96afc747655890b74a244fcc610228c4ba3e3bcd,1,output[0].content[0].text,,"DRUG_1_NAME: FEP_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q8h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Healthcare-associated pneumonia with respiratory failure and local ward ecology showing notable Gram-negative/Pseudomonas signal → empiric antipseudomonal beta-lactam (cefepime).
- Add azithromycin for atypical coverage in pneumonia; no MRSA history/risk factors provided, so avoid routine MRSA coverage.
- eGFR 89 mL/min/1.73m2 → standard adult dosing (no renal adjustment needed).",FEP_IV,AZM_IV,NA,2026-02-08T05:01:07Z
107,OK,1,1a2b98a241302d9935062040dbaf4aa8255984b82194adc71e4ea635c08875de,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_08bed3f40a957f1c0169877f93e6788194865aa4968e00e5aa,1770487699,1976,253,131a1dea37cc0c4d693f7129c17038f7e7b6dc47c0f9375311b4adf0dee50c4c,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with moderate severity/respiratory failure and leukocytosis: empiric beta-lactam + macrolide for typical + atypical coverage.
- No MDR/MRSA risk factors (no prior MRSA/ESBL, no recent hospitalization/antibiotics, no LTC), so avoid broader anti-pseudomonal or MRSA agents.
- eGFR 89 mL/min/1.73m2: no renal dose adjustment needed for ceftriaxone/azithromycin in first 24h.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
108,OK,1,935c123654b1ff23decd286412d9fddf7972db36ceb339189d96d3f80d1eeef4,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0aac4940b187f5960169877f95f98c8193820d850d88218789,1770487702,1964,243,892855a5c422ceb47df9c1130165c52713521832c6bc488fc34f4a25e6c07635,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h (renal adjustment not required at eGFR 23)
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset moderate CAP with respiratory failure and very high CRP: empiric beta-lactam + macrolide for typical + atypical coverage.
- No MRSA or ESBL/CRE risk factors provided; avoid routine VAN/linezolid and avoid unnecessary antipseudomonal therapy despite COPD.
- Renal dysfunction (eGFR 23): chosen agents are appropriate without renal dose reduction in the first 24h.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
109,OK,1,e75b8e8c084e9f4f3c52fc5b9b2dc7fd3b7d2d5f3b1a779902654892891a5253,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0314d0840ed8da3e0169877f9698d4819482080302b3e96ae8,1770487702,1995,224,374728faff85d11ce0221a655e0e54815b5a45e650f8fdfb480aee7d9abd6d8a,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q6h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Septic shock with MV/vasopressors/ICU transfer → require IV broad empiric coverage for severe community-onset pneumonia.
- No MRSA or ESBL/CRE/VRE history and no recent healthcare/antibiotic exposure → avoid routine MRSA/add-on combination therapy.
- eGFR 89 mL/min/1.73m2 → no renal dose adjustment needed for first 24h.",TZP_IV,NA,NA,2026-02-08T05:01:07Z
110,OK,1,2b0086e55266b963f98408b9a34f97f47a67edb616e6ba3f6bd9f17defe81b88,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_005e94d40375460d0169877f989e3481a0a057f6f02ffb7718,1770487704,2079,228,a220c9b117f4ca5c8bbe9daf0454b715fdf7f1a11b97e98e57adfd65f85a5377,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Moderate community-onset pneumonia with respiratory failure: empiric CAP coverage with IV beta-lactam + macrolide for typical and atypical pathogens.
- No MRSA/MDR risk factors and already pre-treated with AMC1G_PO for this episode, so avoid broader anti-pseudomonal/MRSA agents in first 24h.
- Renal function normal (eGFR 122); no renal dose adjustment needed.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
111,OK,1,2d695828491706edb88e5c323e2df87da57a98bc5ba9db6c9a30c00aa0a0f035,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_026e312b77d8048b0169877f99d7fc819fa338fdc708f034b5,1770487705,1987,239,f98c2b3a2acccddc36a689208673fea01a5fd8fecbc95f3f98774672d893fd03,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q12h (renal-adjusted for eGFR 18)
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- High-severity community-onset pneumonia with septic shock/MV/vasopressors → IV broad empiric coverage appropriate in first 24h.
- TZP provides coverage for typical CAP pathogens plus Gram-negative rods including Pseudomonas (supported by local respiratory epidemiology) while avoiding unnecessary MRSA therapy given no MRSA history/risk.
- Dose interval adjusted for severe CKD (eGFR 18) to reduce toxicity risk.",TZP_IV,NA,NA,2026-02-08T05:01:07Z
112,OK,1,9d77a6f8aff3cf6f5b92cd1f6dc19ac5511c4f0126833655c171928d01ee5008,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_02e2c65c9d8238240169877f9a56d8819d9bef1ebfbd284263,1770487706,1984,242,e402c87349882163cf91ac0f6ff7d0aeae391a5ebfb09c01b1db8b183702c897,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q8h (renal-adjusted for eGFR ~30)
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Severe community-onset pneumonia with septic shock/MV/vasopressors → broad IV beta-lactam coverage including Pseudomonas plus atypical coverage.
- No prior MRSA history or major MDR risk factors provided → avoid routine MRSA agent in first 24h.
- CKD (eGFR 30) → renal-adjust TZP; avoid adding nephrotoxic aminoglycoside empirically.",TZP_IV,AZM_IV,NA,2026-02-08T05:01:07Z
113,OK,1,73ca5e0e3dfc7dfa5308a5ae17317a4d5d8b525f26cb54bad60f4db4e7436d57,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_00becd4f79d303270169877f9c4d4881929f9dd0cfceed9302,1770487708,2045,245,21328e26edb5521cf026d5033125f9e9b91b53725c68d6e8241a5ce9c44aff8f,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset sepsis/bacteremia with high CRP and elevated lactate; needs empiric IV broad coverage while cultures pending.
- Ceftriaxone provides single-agent coverage for common community bloodstream pathogens (e.g., Enterobacterales, streptococci) with low complexity; no structured MRSA/ESBL risk to justify routine vancomycin/carbapenem.
- eGFR 54 mL/min/1.73m2: no renal dose adjustment needed for ceftriaxone in first 24h.",CRO_IV,NA,NA,2026-02-08T05:01:07Z
114,OK,1,2b7617042294163f46cc82c5a485323682dc7fc516546038de46b56fd0d14e9a,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0d94a0df2a6ba2660169877f9e189881a0a2f5c839fc8c2814,1770487710,1978,222,dea43fa0c6100c4d7240bc8eb70eaf4fe34762dd97d496d4d655dec0aa154f78,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q6h (renal-adjusted for eGFR 55)
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- High-severity pneumonia with septic shock/MV/vasopressors and recent hospitalization → broad IV antipseudomonal beta-lactam empiric coverage.
- No structured MRSA history/risk provided → avoid routine MRSA agent in first 24h.
- Viral screen positive but shock/respiratory failure supports empiric antibacterial coverage pending cultures.",TZP_IV,NA,NA,2026-02-08T05:01:07Z
115,OK,1,79012fec2aae74b40ac3ce1a6cedb7b40f5fa03f528ed95fd9fe5d26c21938ac,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_06701008dc01d3c50169877f9fb4e4819fbe9adfbbade43bac,1770487711,1975,221,ce7baa174af871794201e03f0f3629d4895069df17b822c308087ebef8b9a814,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q6h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Severe community-onset pneumonia with septic shock/MV/vasopressors → broad IV empiric coverage including Pseudomonas/Gram-negatives (TZP_IV).
- Add atypical coverage for CAP (AZM_IV).
- No structured MRSA risk factors (no prior MRSA, no recent abx/hospital/LTC) → avoid routine MRSA agent.",TZP_IV,AZM_IV,NA,2026-02-08T05:01:07Z
116,OK,1,91eb99f6d442953084fc8b9b2d32901610ccfbae83e5a4abf53a4a2ef5a0ae77,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0f4551748b9ccd1e0169877fa07cd8819ebc02f3d2525f3d82,1770487712,1995,241,f53ade30667b799377ee9f61b10bf7049eaf83641607bc2ecd11dd96b741f0e1,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q8h (extended infusion; renal-adjusted for eGFR 36)
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- High-severity community-onset pneumonia with septic shock/MV/vasopressors → broad IV empiric coverage appropriate for first 24h.
- No MRSA history or major MDR risk factors → avoid routine MRSA agent; TZP provides broad Gram-negative (incl. Pseudomonas) and anaerobe coverage.
- Viral screen positive but shock and elevated CRP/lactate support possible bacterial coinfection warranting empiric therapy.",TZP_IV,NA,NA,2026-02-08T05:01:07Z
117,OK,1,a0ae36d3f21f8d154181cdd697f655d09a578e319e38b36c3f46c0da0ab6d2b8,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_06c51d9440fba5340169877fa2149c8197a544f5d431cd739a,1770487714,1976,260,f30f11911645fd950d59a643bd97cef9a9de529ca7e26343beaa3a82dfd5aa0b,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Moderate community-onset CAP with respiratory failure: empiric beta-lactam + macrolide to cover typical pathogens and atypicals.
- No MRSA or MDR risk factors (no prior MRSA/ESBL, no recent antibiotics/hospitalization/LTC), so avoid VAN/linezolid and antipseudomonal agents.
- eGFR 84 mL/min/1.73m2: no renal dose adjustment needed for ceftriaxone/azithromycin in first 24h; viral screen positive lowers bacterial probability but severity supports initial empiric coverage.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
118,OK,1,8ca2bd2860e00da58da5855478acfa9c8edbf9f23fa0d7e03b8e1c8b3aaa5c5c,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0729eb21aa06e0490169877fa3119081978130bea45e701a62,1770487715,1982,238,f24a08b798efc7afa64f472fa2d6588b2d71eca301cee40bec17db791ef759e0,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h (renal function eGFR 27)
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with respiratory failure (moderate severity): IV beta-lactam + macrolide for typical + atypical coverage in first 24h.
- No MRSA/MDR risk factors and no septic shock/ICU transfer: avoid routine VAN/anti-pseudomonal escalation.
- Viral screen positive lowers bacterial probability but does not exclude coinfection; modest CRP supports limited empiric coverage rather than none.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
119,OK,1,fae7e00f6b1e14fdb13f34df902c2017db01dd0492ce4fb677c3a10d1188d752,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0d31e0f3552e16e00169877fa44e9481919b99fb9d017965e8,1770487716,1972,254,4b211b78c6ea61b7912f72adb4b5d9f3d9592840c43bc36588bc3e090c678503,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q8h (renal-adjusted for eGFR 31)
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset septic shock with MV/vasopressors: needs immediate broad IV bactericidal coverage; TZP provides Gram-negative (incl. Pseudomonas) and anaerobe coverage for undifferentiated sepsis.
- No structured MDR/MRSA history or recent healthcare/antibiotic exposure to justify empiric MRSA or CRE-directed combination therapy in first 24h.
- Renal dysfunction (eGFR 31) supports dose-interval adjustment to reduce toxicity while maintaining early sepsis exposure.",TZP_IV,NA,NA,2026-02-08T05:01:07Z
120,OK,1,53ace9809c65912019ac5be116e39664593a66f82be87dbaed3646c578417276,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_062515b23c0f84330169877fa623f8819e8f109850b05961f1,1770487718,1974,265,ca3dbd4d4e8bde75774384f26ad6ca4f4757c5f397f9fc052a6743e743706529,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with respiratory failure and marked inflammation (WBC 18.8, CRP 151): ceftriaxone + azithromycin provides standard empiric coverage for typical and atypical CAP pathogens.
- No MDR/MRSA risk factors (no prior MRSA/ESBL, no recent hospitalization/antibiotics, no LTC), so no empiric anti-MRSA or antipseudomonal escalation.
- eGFR 66 mL/min/1.73m2: no renal dose adjustment needed for ceftriaxone or azithromycin in first 24h.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
121,OK,1,c5fda7a289f80015c1a74af57a0a7f2e964a9ab0fecb4e7b15af8cf6b35f4fcd,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_044a1622953c1ed60169877fa7506081a0970b3edcf79af2db,1770487719,1972,243,c65d0935702fe57defbf416bb42a73f4291ffc4357c8a9fbb6d8913ac8c86f07,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with respiratory failure (moderate severity): ceftriaxone + azithromycin provides standard empiric coverage for typical + atypical pathogens.
- No MDR/MRSA risk factors (no recent abx/hospitalization/LTC; no prior MRSA/ESBL): avoid broader antipseudomonal or MRSA agents.
- eGFR 45: ceftriaxone and azithromycin do not require renal dose adjustment at these doses for the first 24h.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
122,OK,1,2159e3b5cd209dc981dfebe3e54f64eb07b174d24c413f452a595942d1be547f,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_02ef690ab7913bd90169877fa874cc819397b87c698f04e3c9,1770487720,1969,222,f5eca3ab04ed0f7d5e7c5ffb18ed577884f637c3d0d67554565a342239005663,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q6h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Healthcare-associated pneumonia with sepsis/respiratory failure and high PCT/CRP: start broad IV antipseudomonal beta-lactam for early adequate coverage.
- No MRSA history/exposure and no major MDR risk factors provided, so avoid routine MRSA/dual Gram-negative therapy in first 24h.
- Renal function normal (eGFR 124), so standard dosing appropriate.",TZP_IV,NA,NA,2026-02-08T05:01:07Z
123,OK,1,3867bdadc132a8bece6d96c2fe86f120404acc4528b091d2703be54410c6b051,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_031c3ae97c5dad130169877faa33708196a1790893bbfd99a0,1770487722,1970,225,a2b64cc5178890a756c376c3772f062022650de2966f4b0b6a82ec05a8302633,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q6h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset COPD infectious exacerbation with septic shock/MV/vasopressors → broad IV empiric coverage needed for likely Gram-negatives including Pseudomonas (notable local prior).
- No MRSA history or MDR risk factors provided → avoid routine MRSA add-on in first 24h.
- eGFR 76 mL/min/1.73m2 → no renal dose reduction required for initial dosing.",TZP_IV,NA,NA,2026-02-08T05:01:07Z
124,OK,1,405ccec34ea9e546f409d608c589c25708ed4d494c52229ba9d8d37277c98ef8,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0887a8e2d479a8920169877faadcfc8194a8603e0e371969ad,1770487722,1993,241,fe98108123d9908ac6a350369266b2241beba2e86e0793e6d880e219dbf91e10,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q8h (renal-adjusted for eGFR ~52)
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Severe community-onset pneumonia with septic shock/MV/vasopressors → broad IV empiric coverage including Pseudomonas and other Gram-negatives with TZP.
- Add azithromycin for atypical coverage in severe CAP; viral test positive does not exclude bacterial coinfection in shock.
- No MRSA history or recent healthcare/antibiotic exposure → avoid routine MRSA agent in first 24h.",TZP_IV,AZM_IV,NA,2026-02-08T05:01:07Z
125,OK,1,b232dc23c879ada85039db3d5f55a04e45622e5075338cab5073d0c3e2f08698,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_00cad730f02f54570169877fac326881a18216e909ce19a0ce,1770487724,1974,215,b7f28aa49efe3da364e9ec579f5fd4a6dcc8cccad64524f5b6c72e9dd971c749,1,output[0].content[0].text,,"DRUG_1_NAME: NO_ANTIBIOTIC
DRUG_1_DOSE: NA
DRUG_1_INTERVAL: NA
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Low-severity community-onset pneumonia with viral screening POSITIVE and only mild inflammatory markers (CRP 32, WBC 3.8) without sepsis/respiratory failure supports viral etiology and observation without empiric antibacterials in first 24h.
- No MDR risk factors or prior MRSA/ESBL history to justify broad empiric coverage.",NO_ANTIBIOTIC,NA,NA,2026-02-08T05:01:07Z
126,OK,1,062549e88c890a8cc96d6819feba9a33d9a34683ef0147ff9d1d2e738c86693d,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_04165f0c2aedd3790169877fadcce081908cde9bc46c9fc61e,1770487725,2051,249,ea238ffa8e4c5ba82791abab1014f13ae94b7371d81cfdd69e716a8488e58918,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q8h (renal-adjusted for eGFR 42)
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset pyelonephritis with marked inflammation (WBC 21.9, CRP 411) and recent beta-lactam exposure (AMC1G_PO) → broaden empiric Gram-negative coverage.
- TZP provides coverage for Enterobacterales and Pseudomonas (present in local epi) without adding routine MRSA therapy (no MRSA history/risk).
- Renal dosing applied for eGFR 42 mL/min/1.73m2.",TZP_IV,NA,NA,2026-02-08T05:01:07Z
127,OK,1,4c68dec8122a9c1d51cbf61424a4b4f2244a47144d2653c939365ee7c52ad880,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_074cf9a60aac3db10169877faed97081938c5205301267edb0,1770487726,2005,230,9cef81b9cd2beb5b0d76ec0b4878c86ea80682d4d3822a429e8f0594197dab73,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Severe community-onset pneumonia with respiratory failure/MV and ICU transfer: empiric IV beta-lactam + macrolide for typical + atypical CAP coverage.
- No MDR/MRSA history or recent healthcare/antibiotic exposure to justify routine anti-MRSA or anti-pseudomonal therapy in first 24h.
- eGFR 90: no renal dose adjustment needed for ceftriaxone or azithromycin.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
128,OK,1,f04f46380d228149c442427b76703a50473f9cfb8b5559ae56268c652269bba9,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0fffe40101c974f80169877faf56f0819dab0e92ad419e7560,1770487727,2074,229,b5d2f8e900169850c9811e844c4fde59ee62ea31d51f516288f3189193c7f5dc,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with respiratory failure and very high CRP despite pre-treatment with AMC1G_PO → escalate to inpatient IV CAP regimen.
- Ceftriaxone + azithromycin provides typical + atypical coverage; no MRSA/MDR risk factors to justify VAN/linezolid or antipseudomonal therapy.
- eGFR 97: no renal dose adjustment needed for either agent in first 24h.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
129,OK,1,7fa0c7e1e5329715f0715f78316c6e9f73d5d9a0ee02cbd590bb33b2e524a487,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0ba7df60ced4a4050169877fb23a408196ab67d2ca121a3cab,1770487730,1978,222,752b2c3117c2e81494ae06bfdb80c4a37d313c59273ca8139f821129d119c576,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Moderate community-onset CAP with respiratory failure and elevated inflammatory markers: empiric beta-lactam + macrolide for typical + atypical bacterial coverage.
- No MDR/MRSA risk factors documented; avoid broader antipseudomonal or anti-MRSA therapy in first 24h.
- eGFR 86: no renal dose adjustment needed for ceftriaxone/azithromycin.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
130,OK,1,bc2fc726f9607b918ddd5b3084db2e6955e43d7514b1be9367148797f34648ce,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_04c617548cd6ac1e0169877fb2d1b4819fb17146f4f65dd2c0,1770487730,1993,244,f623cadfe7b44826a1d6b2f208e536f25ddeedc1293be5f4256026c6240237cd,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h (renal function unknown adjustment not required at eGFR 32)
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Severe community-onset pneumonia with respiratory failure/MV and ICU transfer: empiric IV beta-lactam + macrolide for typical + atypical CAP coverage.
- No MDR/MRSA history or recent healthcare/antibiotic exposure to justify broader anti-MRSA or anti-pseudomonal therapy in first 24h.
- Viral screen positive but markedly elevated CRP/WBC and high severity support treating possible bacterial coinfection initially.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
131,OK,1,024946c33dcf98379fe467dc931283a12d2f00b397909216e2a43f6b943e3537,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0bbf2d3644f1e0100169877fb34ea881949a63ac99ddfae6d4,1770487731,2004,224,59e8f1017cff24bf3e067e2fdb904a5bc476649c2e10811c2a1ba5956fd1d0f8,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset pyelonephritis without MDR risk factors; ceftriaxone provides appropriate empiric Gram-negative coverage (E. coli/Klebsiella/Proteus) for first 24h.
- Avoids unnecessary broad antipseudomonal and MRSA therapy given no prior ESBL/CRE/MRSA and no recent healthcare exposure.
- Renal function preserved (eGFR 104); no renal dose adjustment needed.",CRO_IV,NA,NA,2026-02-08T05:01:07Z
132,OK,1,49a9fe8f4adcae0f61d694f695bb59e0f108fe3129e531fdad1d0fd58d7a6ff7,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0ce2babf5407f2ea0169877fb56d20819195b13d42fc4593a0,1770487733,1976,219,7ba48aecb5901d8806f977baeda5f22f5d0924fb0808b035006c5359dde148fb,1,output[0].content[0].text,,"DRUG_1_NAME: FEP_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q8h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Healthcare-associated pneumonia with respiratory failure and recent hospitalization → broaden initial Gram-negative (incl. Pseudomonas) coverage; cefepime aligns with local respiratory epidemiology.
- No MRSA history/risk provided and inflammatory markers modest → avoid routine MRSA/add-on combination therapy in first 24h.
- eGFR 92 mL/min/1.73m2 → no renal dose adjustment needed.",FEP_IV,NA,NA,2026-02-08T05:01:07Z
133,OK,1,f84648dc40457dd69f5165aae33a41d50652064ada84080cb3a726a037cf466b,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0ca56bf8ae437f690169877fb76754819284628de17c8d6747,1770487735,2001,233,9a6ef886428f55e27beee9cae828924ddc3e8a1ef16fdd55e74529b2b40e8991,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Severe community-onset pneumonia with respiratory failure/MV and ICU transfer → empiric IV CAP regimen covering typical pathogens plus atypicals.
- No MDR/MRSA history or recent healthcare/antibiotic exposure → avoid routine anti-MRSA or broad antipseudomonal therapy in first 24h.
- eGFR 70 mL/min/1.73m2 → no renal dose adjustment needed for ceftriaxone/azithromycin.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
134,OK,1,edd66c8d31e37618064857eef114088c3992556dfcb9d0e66d3e8a9eeab211e1,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_00ffce2061d3a1cf0169877fb76bac81a3abb3432e8b5f55be,1770487735,1973,245,875a7b12d57251c819688e7df7ec7d4d475f3333d14a58a6bd5c2d38ed9b97d4,1,output[0].content[0].text,,"DRUG_1_NAME: AMC_IV
DRUG_1_DOSE: 2 g (amoxicillin component)
DRUG_1_INTERVAL: q8h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset SSTI with marked inflammation (WBC 25.3, CRP 276) warrants empiric IV therapy; amoxicillin-clavulanate provides broad streptococcal/MSSA and anaerobe coverage typical for non-purulent/complicated SSTI.
- No sepsis/shock and no MRSA/MDR risk factors documented, so avoid routine MRSA or antipseudomonal combination therapy.
- Renal function normal (eGFR 96), so standard dosing used.",AMC_IV,NA,NA,2026-02-08T05:01:07Z
135,OK,1,63a240ae6dff98314af4380979206972a9ddcaac59d4ed243a50a42984b088f5,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0e19bfc3043486d60169877fb92fa8819c9364d2aa89764feb,1770487737,1988,238,1a88a73c55274734ca95ff10a8b02491f33db7f5dbdbdf38d16ad87849f705e7,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset pyelonephritis with low severity and no MDR history/exposure: ceftriaxone provides appropriate empiric Gram-negative coverage (E. coli/Klebsiella predominant locally).
- Avoid aminoglycosides given profound renal failure (eGFR 2 mL/min/1.73m2) and toxicity risk; no MRSA/Enterococcus-specific indication from structured data.
- Ceftriaxone requires no renal dose adjustment, suitable for first 24h while cultures pending.",CRO_IV,NA,NA,2026-02-08T05:01:07Z
136,OK,1,6025475d10e55fabcc8860907ef955ce502ee34e67be060d3ed4e251806a9132,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_06f41ff204431b870169877fbb0aac81a1a34ffce49ea587cf,1770487739,1977,249,940bccdabdfde7745b36b7500ec2b5d2138954bbe42eb3ca7cebb4fbf3234d47,1,output[0].content[0].text,,"DRUG_1_NAME: MEM_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q8h
DRUG_2_NAME: VAN_IV
DRUG_2_DOSE: 15 mg/kg
DRUG_2_INTERVAL: q12h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Septic shock with MV/vasopressors (high severity HCA sepsis) warrants broad IV empiric coverage including antipseudomonal Gram-negative and anaerobes: meropenem.
- LTC resident with high local Staphylococcus spp prevalence in bloodstream infections supports empiric Gram-positive/MRSA coverage: vancomycin.
- eGFR 72 mL/min/1.73m2: no renal dose reduction needed for initial 24h; use vancomycin with level-guided adjustment thereafter.",MEM_IV,VAN_IV,NA,2026-02-08T05:01:07Z
137,OK,1,0fe57d8b4c713791ee1e06a0cbc286325bd8679a0290bbbb38bf9f479d1fa851,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_038daeff877ceedb0169877fbb1044819eb0e179c3dcffcf8f,1770487739,1963,218,7c1bf64513da6bc8c5b069cbe8a33c47cb32c9f8381453093a07e74def633f09,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset moderate CAP with respiratory failure and marked leukocytosis: empiric beta-lactam + macrolide for typical + atypical coverage.
- No MDR/MRSA history or recent healthcare/antibiotic exposure: avoid routine anti-MRSA or antipseudomonal therapy.
- Normal renal function (eGFR 109): standard dosing appropriate.
",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
138,OK,1,2bb0376ec26fa7e6af36cc1e01883a69c44ddad8359a0301371f3e9a6a8c63c4,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0c28bb760cb624f60169877fbcddec819fa7ff0f3345f80286,1770487740,1523,222,587ebd49427d72353ccbc049cdfa1f7d32019456300a47a1afe557b6444bb250,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 3.375 g
DRUG_1_INTERVAL: q8h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset intra-abdominal infection with marked leukocytosis/CRP: broad empiric gram-negative + anaerobe coverage with a single agent.
- No MRSA/ESBL risk factors and low severity: avoid routine MRSA or double gram-negative coverage.
- Renal adjustment for eGFR ~20 mL/min/1.73m2: reduced TZP dosing interval for first 24h.",TZP_IV,NA,NA,2026-02-08T05:01:07Z
139,OK,1,7b10d29546c36bf2cd792cf296da56be81f40fd7bee5dae994e4e4afc1f510e0,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_05272b0d8a6c08100169877fbe6f408193b7635d18c6f7e82d,1770487742,1984,224,56dddb1a59acceee19650dffd7834b2818b3189b13ea962c698954e8220e538a,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with respiratory failure and marked leukocytosis: empiric beta-lactam + macrolide for typical + atypical coverage.
- No MDR/MRSA risk factors documented; avoid routine anti-MRSA/anti-pseudomonal escalation.
- eGFR 5: ceftriaxone and azithromycin do not require renal dose adjustment at these doses for first 24h.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
140,OK,1,07abc9d1da510b9e5bff4256c3425ebe99acefc187f283b447300121d18dc21a,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_05beeae5617fea370169877fbf8654819d844918ddc03c8147,1770487743,2004,223,631a973d19996c9ac079b90e8b4da98133306c0ef4b084a991b73cbf5839878d,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q6h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset pneumonia with septic shock/MV/vasopressors (high severity) warrants broad IV empiric coverage including Pseudomonas and other severe CAP pathogens.
- No MRSA history or major MDR risk factors provided, so avoid routine MRSA add-on in first 24h.
- eGFR 113 mL/min/1.73m2: no renal dose adjustment needed for initial dosing.",TZP_IV,NA,NA,2026-02-08T05:01:07Z
141,OK,1,28b75744bf7200bded304dbd365b4503e53a5be08ba5d63c8956ca5c45c5e9fd,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_03d82d4dc6c7d9a90169877fc04b9481a298ced076137a8954,1770487744,1968,245,62c9444912ba3cd5cf914ed4d9f78dcad913e82a8b3154927345112782a4b095,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h (eGFR 51)
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with respiratory failure and elevated CRP: empiric beta-lactam + macrolide for typical + atypical coverage.
- No MDR/MRSA risk factors (no prior MRSA/ESBL, no recent hospitalization/antibiotics, no LTC), so avoid broader anti-pseudomonal or MRSA agents.
- Ceftriaxone dosing appropriate without adjustment at eGFR ~51; azithromycin adds atypical coverage without renal adjustment.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
142,OK,1,50eebd7da920fdbc67a7acd8e7b3b0809d466ed495fa4a0e5e66800b2e42334b,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_021f8850ca3e9ef10169877fc1d99c81a1adf61c0e2296d9fa,1770487745,1978,240,26aeb1b09fc530bc0b593fec1896836ca71757ddb6a67456a9a2d34bc29aff66,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Moderate community-onset CAP with respiratory failure and elevated WBC/CRP: empiric beta-lactam + macrolide for typical + atypical bacterial coverage.
- No MDR/MRSA risk factors (no prior MRSA/ESBL, no recent hospitalization/LTC), so no vancomycin/anti-pseudomonal escalation.
- eGFR 62: no renal dose adjustment needed for ceftriaxone/azithromycin in first 24h.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
143,OK,1,8deb4321749b739324196018e7dc48dc570456fd40743e7f8068a73112cef610,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_01d01acb5109787b0169877fc31cfc819daf0eaa6e234eb669,1770487747,1996,220,57c2fa226dc2dff1e163ddefc33d559194aa6667d23d0f2f5f6cfa630d44a897,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset pyelonephritis with sepsis: ceftriaxone provides appropriate empiric Gram-negative coverage (E. coli/Klebsiella) without unnecessary anti-MRSA or carbapenem use given no MDR risk factors.
- Severe renal impairment (eGFR 2): avoids aminoglycosides; ceftriaxone does not require renal dose adjustment for this degree of renal failure in typical adult dosing.",CRO_IV,NA,NA,2026-02-08T05:01:07Z
144,OK,1,ece5f222447baca54f50fc6dbbb692e33ab0f25e19622150f70d57995e3a1adb,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0dcccc46ce5274b30169877fc421008195a93493664092a69c,1770487748,1979,222,9f165673535ddcdaddf7d64a597140f99cb10152dccb4c7846145a5b6459ffc3,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Moderate community-onset pneumonia with respiratory failure → inpatient IV CAP regimen covering typical + atypical pathogens.
- No MDR/MRSA history or recent healthcare/antibiotic exposure → avoid empiric anti-MRSA/anti-pseudomonal escalation.
- eGFR 128 mL/min/1.73m2 → no renal dose adjustment needed for ceftriaxone/azithromycin.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
145,OK,1,28d6241496c8f8e7dd6ab948cef91fac13931634750bac4151d7c911416b0656,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_039bdb85e1a4ab990169877fc5937481958c57cb8b55cb7172,1770487749,1999,227,9a788ccd7e37f341017f82de818b250238d2cf08c9d811f8fd091a70ac9ff95e,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h (no renal adjustment)
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset pyelonephritis with sepsis and marked inflammation; ceftriaxone provides broad empiric Gram-negative coverage typical for Enterobacterales.
- No major MDR risk factors and no shock/ICU needs, so avoid broader antipseudomonal or combination therapy.
- Severe renal impairment (eGFR 16) favors avoiding aminoglycosides; ceftriaxone does not require renal dose adjustment.",CRO_IV,NA,NA,2026-02-08T05:01:07Z
146,OK,1,2ebff98b76470b1c78f41c95c32db434cae6361e7e2355d447341607715dc210,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_062d13007c860ac00169877fc71ce081a09870c080fbe4c64c,1770487751,1982,257,0fae8c3c08e4692b96ada6ecd2fefad8e9ced3a1eed14f85f9b3cc93d698283e,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h (renal function unknown adjustment not needed; eGFR 13)
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset pyelonephritis without shock/ICU needs: ceftriaxone provides appropriate empiric Gram-negative coverage (E. coli/Klebsiella predominant) while avoiding unnecessary broad antipseudomonal therapy.
- Severe renal impairment (eGFR 13): avoids aminoglycosides due to nephrotoxicity risk; ceftriaxone generally does not require renal dose adjustment.
- No MDR/MRSA history or recent healthcare exposure to justify MRSA or carbapenem coverage in first 24h.",CRO_IV,NA,NA,2026-02-08T05:01:07Z
147,OK,1,f6153aa28ade45efc2444cabb1a33809b23bb40aae670633d88d85b21e01b257,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_074256129c64baa90169877fc76778819497396377e326ab71,1770487751,1987,212,98393cd8261078f58a1e228109466e424d7aba710dccfe5ccb69c8e6f048e540,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h (no renal adjustment)
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset sepsis/bloodstream infection with no MDR risk factors: ceftriaxone provides broad empiric Gram-negative and streptococcal coverage appropriate for many community sources.
- Avoids nephrotoxic agents (eGFR 13) and avoids routine MRSA coverage given no prior MRSA and low severity without shock/ICU needs.",CRO_IV,NA,NA,2026-02-08T05:01:07Z
148,OK,1,c9ec0ddc20c2cd74ef1d9ee7814246c47d85b710c857beb35e1ee6ca0a497c6a,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0cae7ef79f41e4be0169877fc958148195a79ea8967affd366,1770487753,1997,233,5c2b47677d547c2a1585ee61a194281988e6e01bb95e543460a9f78e3b7f670c,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q6h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Septic shock with MV/vasopressors/ICU: needs immediate broad IV bactericidal coverage for community-onset sepsis.
- TZP provides broad Gram-negative (incl. Pseudomonas) and anaerobic coverage plus many streptococci/enterococci; no structured MRSA risk/history to justify empiric anti-MRSA agent.
- Renal function preserved (eGFR 90): standard dosing used for first 24h.",TZP_IV,NA,NA,2026-02-08T05:01:07Z
149,OK,1,ed738fd15f879e913fa5887f40e9c38598bef032586ee9399a61337fa5a94d72,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0fc2fd5f5a46da630169877fcb419481958bd23c7dbf3f5804,1770487755,1981,232,36f9c13f352453d2ed2ce49f31d5dcf45a1db49f27c2d9ffd86d065327cbd780,1,output[0].content[0].text,,"DRUG_1_NAME: VAN_IV
DRUG_1_DOSE: 15 mg/kg
DRUG_1_INTERVAL: q24h (renal-adjust; target AUC monitoring per protocol)
DRUG_2_NAME: FEP_IV
DRUG_2_DOSE: 2 g
DRUG_2_INTERVAL: q12h (eGFR 57)
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Healthcare-associated sepsis with LTC residence: cover MRSA/coagulase-negative staphylococci (common in local BSI prior) with VAN_IV.
- Add broad Gram-negative (including Pseudomonas) coverage for HCA bloodstream infection with FEP_IV; avoid extra agents to limit toxicity (not in shock, no vasopressors).",VAN_IV,FEP_IV,NA,2026-02-08T05:01:07Z
150,OK,1,4aaa61407e7fd16463706b2c36dbfb33e9bb10a17696fa0f162c3914e6626e6d,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0b57842856f72b200169877fcb827c819db807d9a869ec1319,1770487755,1960,209,12203411b71089113343e657cefe2c38fcca5fe562b543dfc1fd7643d5552db7,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset UTI with low severity and no MDR risk factors: ceftriaxone provides appropriate empiric Gram-negative coverage (e.g., E. coli/Klebsiella) without unnecessary broad antipseudomonal/MRSA therapy.
- Renal adjustment not required for ceftriaxone at eGFR 44 mL/min/1.73m2.",CRO_IV,NA,NA,2026-02-08T05:01:07Z
151,OK,1,bc6684d984db6077cd1335858b1afcc63aa6fbe54b49b014730ec3605a5aebed,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_06907d4431e3daac0169877fcd34f081a19907adbf5cc8d359,1770487757,1971,221,87c8d1bfcf319de2c52f464dee61baebe28fc632e8434a955c3dadf20c797edc,1,output[0].content[0].text,,"DRUG_1_NAME: FEP_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q12h (renal-adjusted for eGFR 36)
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset pneumonia with respiratory failure and leukocytosis; recent hospitalization/antibiotics increases risk for resistant Gram-negatives including Pseudomonas → cefepime.
- Add azithromycin for atypical coverage as part of empiric CAP therapy.
- No MRSA history/risk provided → avoid routine MRSA coverage.",FEP_IV,AZM_IV,NA,2026-02-08T05:01:07Z
152,OK,1,9d5fdf1537df45913e9dd835a57132bc38aed608b63e4611bd34caa198244d1a,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0dd95188b0e9096d0169877fcef9a4819cb4778353fad38e64,1770487758,1983,238,a4f12284848379dbd30835ba2c1d737f4912596c75d279fc079421d5d0d6ce64,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Severe community-onset CAP with respiratory failure/MV: IV beta-lactam + macrolide for typical + atypical bacterial coverage in first 24h.
- No MRSA or MDR risk factors (no prior MRSA/ESBL, no recent hospitalization/antibiotics), so avoid routine VAN/linezolid and antipseudomonal escalation.
- eGFR 66: no renal dose adjustment needed for ceftriaxone/azithromycin.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
153,OK,1,274e2ca6277815999f00a0981e4a391c7677f86f75f4754377bdcaf45f8ffcd9,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_05f025b0487d78450169877fcf429881a2bd229e96549f2fb2,1770487759,1976,214,fa2aa19eee0439afaa7d8f4819f1ef88eb92b551237b646ad3cfbc74a24095e7,1,output[0].content[0].text,,"DRUG_1_NAME: MEM_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q8h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Severe community-onset pneumonia with septic shock/MV/vasopressors → IV broad-spectrum empiric coverage for Gram-negatives (incl. Pseudomonas) and typical CAP pathogens while cultures pending.
- Recent hospitalization and antibiotics within 90 days increase risk of resistant Gram-negative pathogens; meropenem provides robust early coverage; renal function normal (eGFR 114), so standard dosing.",MEM_IV,NA,NA,2026-02-08T05:01:07Z
154,OK,1,308e0077c925442ad235710ed07b450718a99b79d2ea48bff729efe286cad1a3,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_01dd1bd863d5bf5a0169877fd068b4819391294ce10dbddc7d,1770487760,2005,213,4069c63f9f04a1de581f1915464daeb962d0c086bae5fd9300e98ba3cecba286,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q6h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Severe community-onset pneumonia with septic shock/MV/vasopressors → broad IV empiric coverage including Pseudomonas/Gram-negatives (TZP_IV).
- Add atypical coverage for severe CAP (AZM_IV).
- No MRSA history/exposure provided → avoid routine MRSA agent in first 24h.",TZP_IV,AZM_IV,NA,2026-02-08T05:01:07Z
155,OK,1,2a283eef015867bba99d641f3e99bcca75a8f7d4bb018cfa8edcd74bd357ff2e,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_003331ace40256120169877fd28d4c8193a5fb32ce3245c32f,1770487762,1999,224,a6db46ed6d7d9cc09cf66bbbdb16b37f9e24fe59ca80171425d0df0d971dbe27,1,output[0].content[0].text,,"DRUG_1_NAME: MEM_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h (renal-adjusted for eGFR 13)
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset pneumonia with septic shock/MV/vasopressors → requires IV broad empiric coverage in first 24h.
- No MRSA history or recent healthcare/MDR exposures → avoid routine MRSA add-on.
- Severe AKI (eGFR 13) → choose a single broad agent and renal-adjust dose to limit toxicity while covering Gram-negatives and typical CAP pathogens.",MEM_IV,NA,NA,2026-02-08T05:01:07Z
156,OK,1,7915c3046cff664c15169ac266187ed4dcfd65cb7fe66f0573654271d51285a1,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_072acb62f92fc1a20169877fd30480819ea8e21a6e9e8ef4db,1770487763,2041,236,45877c3fd003d9d59e3bd3599da029fa1e7818e55dd9ea31b5f48a945b078545,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q6h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset pneumonia with respiratory failure and immunosuppression plus recent hospitalization/antibiotics and failure/pre-treatment with AMC1G_PO → broaden to antipseudomonal beta-lactam for first 24h.
- No prior MRSA history and no shock/ICU/vasopressors → avoid routine MRSA/add-on combination therapy.
- eGFR 73 mL/min/1.73m2 → no renal dose adjustment needed for initial dosing.",TZP_IV,NA,NA,2026-02-08T05:01:07Z
157,OK,1,b184c023395ccaffd82461623f5ebf4a5dee8fe6b48d4839aeb202f3f45661ca,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_078cec1fe92bdee80169877fd474608192a6e106565ddef994,1770487764,1986,249,d9143ca3c9b5d22a062e6d44d43aa41c67d02ff538dc3d2bf69fb6bbd3d9e1c8,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h (renal function unknown adjustment not required; eGFR 17)
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Severe community-acquired pneumonia with respiratory failure requiring MV/NIV → IV beta-lactam + macrolide for typical + atypical coverage in first 24h.
- No MRSA or ESBL/CRE risk factors in structured history → avoid routine VAN/linezolid and carbapenem.
- eGFR 17: ceftriaxone and azithromycin generally do not require renal dose adjustment, minimizing nephrotoxicity in CKD.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
158,OK,1,035d6b1f8fd2d1e00de39829694a80235ea31d79fcb727ccfdd49f6fe0b3e41e,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_09f8418eca4980ae0169877fd6fca8819fa45d62df11fcc55e,1770487767,1968,256,41819fb466c69dd7896f48f567147e56cffe902bbaf4931b8021ca466f54b43f,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h (renal function eGFR 46)
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with respiratory failure and marked inflammation (WBC 18.4, CRP 201): empiric beta-lactam + macrolide for typical + atypical coverage.
- No MDR/MRSA risk factors (no recent abx/hospitalization/LTC; no prior MRSA/ESBL): avoid broader anti-pseudomonal or MRSA agents in first 24h.
- IV route appropriate given respiratory failure; ceftriaxone dosing compatible with eGFR 46.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
159,OK,1,6c9527d8bd4ca86e282855b517c32075f8e176b13c0b39801a9cea2ee532ba5f,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_03a7533f30bbe0060169877fd719a08192861d50c33ea792e7,1770487767,1967,231,4f3f949aea9d41ef2e849d20b372ba33c063e0e54e3b115e8dea8a8eab67c94a,1,output[0].content[0].text,,"DRUG_1_NAME: AMC1G_PO
DRUG_1_DOSE: 875/125 mg
DRUG_1_INTERVAL: q12h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset COPD infectious exacerbation with low severity and no sepsis/respiratory failure: oral amoxicillin-clavulanate provides typical COPD pathogens coverage.
- No MRSA or MDR risk factors and no ICU-level illness, so avoid broader antipseudomonal or MRSA therapy.
- eGFR 61 mL/min/1.73m2: no renal dose adjustment needed for this regimen in the first 24h.",AMC1G_PO,NA,NA,2026-02-08T05:01:07Z
160,OK,1,0e130aceedb94f03ab2954bacbb8af284ab0ecbf831cfd853fc08f0063f576d9,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0c78a2a167e83b750169877fd863648190ba58b628b8f4ff08,1770487768,1968,236,463c47090848df9326fcb8b3dfea01324c932903eef96b735d4128a7a7753546,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with respiratory failure and leukocytosis: empiric beta-lactam + macrolide for typical + atypical coverage.
- No MDR/MRSA risk factors (no recent antibiotics, hospitalization, LTC, or prior MRSA/ESBL): avoid broader anti-pseudomonal/MRSA agents.
- eGFR 31: ceftriaxone and azithromycin do not require renal dose adjustment at this level for first 24h.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
161,OK,1,9ca9cf3328a8f9951a88a0649c0091a0e1bc43cb6e5d7e87c51944e16771e8c9,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0fae254aec473b100169877fdaf404819ebd0c92a2eb24f2bd,1770487770,2077,231,2998070d320ac16526146d2b1a72a025a3d1eaa1182b6e82f852769afbad5db8,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset pneumonia with respiratory failure and very high CRP despite pre-treatment with azithromycin PO → give empiric IV beta-lactam coverage for typical bacterial CAP pathogens.
- No septic shock/ICU/MV and no MDR/MRSA history or exposures → avoid routine MRSA or antipseudomonal combination therapy in first 24h.
- Renal function normal (eGFR 93) → no renal dose adjustment needed for ceftriaxone.",CRO_IV,NA,NA,2026-02-08T05:01:07Z
162,OK,1,ee2bc318bc8652e1513f44800bffa055544fe687ab716b2c06a0aac53cc00e7b,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_085ca00174b5e1120169877fdafc0c819f86716784dc20c5a2,1770487771,2000,253,b48c3e541bc3d1a155051de7243eb8ce2314344ba9fb201a45521c71ef5741aa,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q8h (extended infusion; renal-adjusted for eGFR 34)
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Septic shock with MV/vasopressors/ICU: needs immediate broad IV empiric coverage for community-onset sepsis.
- No MRSA/ESBL/CRE/VRE history and no recent healthcare/LTC exposure: avoid routine MRSA coverage; TZP provides broad Gram-negative (incl. Pseudomonas) and anaerobe coverage pending cultures.
- Viral screen positive does not exclude bacterial sepsis given very high lactate and inflammatory markers; treat as possible bacterial bloodstream infection initially.",TZP_IV,NA,NA,2026-02-08T05:01:07Z
163,OK,1,1168bd14d944db23de688a9c00fc3d3b756f93f648e26fe25f2e35ff9e601461,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0791ded290d6a7020169877fdc220081968156c02c03157f03,1770487772,1982,256,988426297e999560586c4a5d4ec0d665be07f3acb415c5e4f690855fc181a8ac,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h (renal function unknown adjustment not required; eGFR 15)
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset septic shock with very high WBC: prompt broad empiric IV coverage for common bloodstream pathogens (Enterobacterales/streptococci) with ceftriaxone.
- No structured MDR risk factors and no prior MRSA/ESBL history, so avoid routine MRSA coverage/overly broad anti-pseudomonal therapy in first 24h.
- Severe renal impairment (eGFR 15) favors ceftriaxone as it generally does not require renal dose adjustment and avoids nephrotoxic agents.",CRO_IV,NA,NA,2026-02-08T05:01:07Z
164,OK,1,339e845065d405af799562d8bdcbd1b114fd101b7140fcd81b58bcdbaba11152,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_09d79e51efecc9d50169877fde76088197aa6bc885858e151b,1770487774,1979,251,fc47fe0bc411f9e9c8416a06f0f13c997c03e162c005c1d271201163f6f9fd0d,1,output[0].content[0].text,,"DRUG_1_NAME: MEM_IV
DRUG_1_DOSE: 500 mg
DRUG_1_INTERVAL: q24h (renal-adjusted for eGFR ~4)
DRUG_2_NAME: VAN_IV
DRUG_2_DOSE: 15 mg/kg
DRUG_2_INTERVAL: once, then dose by levels (severe renal failure)
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Septic shock with MV/vasopressors: start broad IV empiric coverage for community-onset sepsis pending cultures.
- MEM_IV provides broad Gram-negative (including potential ESBL) and anaerobe coverage appropriate for undifferentiated severe sepsis.
- VAN_IV adds Gram-positive/MRSA coverage given high local Staphylococcus prevalence in bloodstream infections and critical illness severity; renal dosing/monitoring required at eGFR 4.",MEM_IV,VAN_IV,NA,2026-02-08T05:01:07Z
165,OK,1,113afe0157dc33ef79d5050a6974d429a93578f7de365bfc83260c3d54b31afd,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0e6d851bc003deff0169877fdf19c0819c8358e98697b23ac7,1770487775,2069,223,efcbc2d53c4c39621e339684f2b4944e9d061907306a0bbb5873514f848885a1,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with low severity and no MDR/MRSA risk; ceftriaxone provides empiric pneumococcal/H. influenzae coverage.
- Viral screen positive and already pre-treated with azithromycin at home; avoid additional macrolide/combination therapy in first 24h.
- eGFR 68 mL/min/1.73m2: no renal dose adjustment needed for ceftriaxone.",CRO_IV,NA,NA,2026-02-08T05:01:07Z
166,OK,1,d85d22f720f906dee443723d36524dddcc55dbac0368825639095c05c6a6ed56,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_095fc9b8deadd0aa0169877fe03a9481959f0a658368cd1c09,1770487776,1984,272,fcc8b5dcf0cb496711a17b9f9398790ec4fcd465accc590177b4ff63b57cba5e,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h (no renal adjustment needed at eGFR 33)
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Severe community-onset pneumonia with respiratory failure/MV and very high CRP/WBC → empiric CAP coverage with IV beta-lactam + macrolide for typical + atypical pathogens.
- No MDR/MRSA risk factors (no prior MRSA/ESBL, no recent hospitalization/LTC/antibiotics) → avoid routine VAN/anti-pseudomonal escalation in first 24h.
- Viral screen positive lowers bacterial probability but does not exclude coinfection in this high-severity presentation; ceftriaxone does not require renal adjustment at eGFR 33.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
167,OK,1,ae59ebab736d3fd43ae67279f6e41f0e7a8bf85423c05ab8dd7648601ccb52ab,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0faef478cbdb54080169877fe26cc8819fb44f71f25c6919bf,1770487778,1976,222,192eca7eccc13eade809203a2e8210e4b26c1acad743f5db28103315f9187e4b,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset suspected bloodstream infection with low severity and no MDR risk factors: ceftriaxone provides broad empiric coverage for common Gram-negative and streptococcal causes.
- Avoids unnecessary MRSA/anti-pseudomonal combination therapy given no shock/ICU needs and no MRSA/ESBL history.
- No renal adjustment needed (eGFR 113 mL/min/1.73m2).",CRO_IV,NA,NA,2026-02-08T05:01:07Z
168,OK,1,cedc66d9343917fb40ba4d3ae199c2cbf7a458bea4eb4c10c9ba350e9afd6a2e,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_088b3b43b073b3740169877fe2b91c819f884230d3d5adc8fb,1770487778,1979,238,910b72c8de22685bfe7916fd0bef89324f5dba6a3c33de4f338aa75d17e23559,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h (renal function eGFR 31)
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Severe community-onset pneumonia with respiratory failure/MV and markedly elevated CRP → empiric CAP coverage warranted despite positive viral screen.
- Ceftriaxone + azithromycin provides typical + atypical CAP coverage; no structured MDR/MRSA risk factors to justify broader or anti-MRSA therapy.
- Dosed with CKD (eGFR 31); avoids nephrotoxic add-ons in an elderly patient with CKD.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
169,OK,1,262825584f8577ba630beac8c98a97e2ba2dfc894f498aede28f0ae6e9088afe,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_01a46119a2b568970169877fe4b7cc81a2818c647a85222fec,1770487780,1980,231,e4ce86414c62ea66e34c3d965e5463028a51ee65edf65efffe2aca274665b77b,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with marked inflammatory response (WBC 15.9, CRP 208) despite positive viral screen → cover typical bacterial pathogens with ceftriaxone.
- Add azithromycin for atypical CAP coverage; no MDR/MRSA risk factors to justify broader or anti-MRSA therapy.
- Normal renal function (eGFR 116) → standard dosing; IV acceptable for initial 24h admission therapy.
",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
170,OK,1,0d744601cd479285a44a11068b10748fa9697048df0d8b4343a20ed60db79332,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_04cbe08614aa75f70169877fe5bb588196ae441d72395ca577,1770487781,1994,241,572cb9d6db64dfae9d06b6c52d581ace77625254e5dd3025ca3268e341ed1cab,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q8h (extended infusion; renal-adjusted for eGFR 23)
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset septic shock with respiratory failure: needs immediate broad IV bactericidal coverage for likely Gram-negatives and streptococci/anaerobes.
- No MRSA/ESBL/CRE risk factors provided, so avoid routine anti-MRSA or carbapenem empiric therapy in first 24h.
- Dose interval adjusted for severe CKD (eGFR 23 mL/min/1.73m2).",TZP_IV,NA,NA,2026-02-08T05:01:07Z
171,OK,1,d680ef316914a03b949cdadd180c47e2cdabbb53202ba439b861d06b3021dc1b,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_09e6151fa288e6e80169877fe6b8e481a2a53c61b470819edc,1770487782,2040,261,1ef5d9c568fa493fe680b5eda4ec6d0f5312804e3ebdb41e57d94ea679c55143,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset pyelonephritis with marked inflammation (WBC 19.1, CRP 352) warrants parenteral empiric therapy; ceftriaxone provides broad Enterobacterales coverage typical for this syndrome.
- Recent outpatient ciprofloxacin exposure (home CIP_PO) increases likelihood of fluoroquinolone-resistant uropathogens; avoid repeating a fluoroquinolone empirically.
- Low severity and no MDR history/healthcare exposure: no routine need for antipseudomonal or MRSA coverage in first 24h; renal function normal (eGFR 92), no dose adjustment needed.",CRO_IV,NA,NA,2026-02-08T05:01:07Z
172,OK,1,ceeef71f91785643447cf1aff8e8318c03ffa5bdad16a5729a243772f5feda3b,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_007de330d1254e370169877fe86a28819f968464c4dc777d5e,1770487784,1957,222,2d12acfd93584d819a6152422fe7cb270d6d24eacfc93a78151af6afb2652394,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q6h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset COPD infectious exacerbation with high severity (respiratory failure requiring MV/NIV) warrants IV broad empiric coverage.
- Recent antibiotics and hospitalization increase risk for Gram-negative pathogens including Pseudomonas; piperacillin-tazobactam provides antipseudomonal and typical respiratory bacterial coverage.
- No prior MRSA history provided; avoid routine MRSA coverage in absence of supporting risk factors.",TZP_IV,NA,NA,2026-02-08T05:01:07Z
173,OK,1,e34ca7ae68d47eaba78bc4f7154b86878fb29b0f598068c392cac107144eb2c0,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0788cb1e5ad8aa480169877fe96bac81938dd9897cfc2ba2da,1770487785,1963,229,62d5e22e2ec34065aa9ef82606931bdf7b1fcc1df20405806180e850ea037d47,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with very high WBC/CRP → empiric typical + atypical coverage; low severity and no MDR/MRSA risk factors.
- Ceftriaxone covers common CAP bacteria; azithromycin adds atypical coverage (e.g., Mycoplasma/Chlamydophila/Legionella).
- Normal renal function (eGFR 98) → standard dosing; no renal adjustment needed.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
174,OK,1,0914e7c8c5d1412b4356719d9bb23f3b7c19fb108211a069ce7713abc8cdecec,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_03af1943b27b52f90169877fead58c8192a59a702acdf8d292,1770487786,1994,237,5a6b37deec22e2ecd9f83018312cf9421dff77a138891a7d675d08bb4cdbb8ff,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h (renal function eGFR 33)
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset sepsis/bloodstream infection without MDR risk factors: ceftriaxone provides broad empiric coverage for common Gram-negative and streptococcal pathogens.
- Avoids routine MRSA coverage given no prior MRSA/MDR history and no recent healthcare/LTC exposure.
- Single-agent therapy limits nephrotoxicity in CKD (eGFR 33) and avoids unnecessary combination therapy in moderate severity without shock/vasopressors.",CRO_IV,NA,NA,2026-02-08T05:01:07Z
175,OK,1,34c7d05168d8d59a6cd273e34861e9421f93827b8569932c54348e412556a08a,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0329540918a6a04e0169877febbbe8819093273ad30675395d,1770487787,1967,220,0f91570981123fc95c861aca963937968534bdad041e616dc7f30d92cdbe5123,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h (renal function unknown adjustment not required)
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset UTI with marked leukocytosis/CRP but low severity and no MDR risk factors: ceftriaxone provides appropriate empiric Gram-negative coverage (E. coli/Klebsiella/Proteus).
- Avoid aminoglycosides given severe CKD (eGFR 18) and avoid unnecessary broad antipseudomonal/MRSA coverage without risk factors.",CRO_IV,NA,NA,2026-02-08T05:01:07Z
176,OK,1,6d6a619cb6051f1befdefb65690a314a8c387e879bf8feb382d7a189591f6efb,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0b49b24218384c290169877fed1d5c8195b67670f3c5a55f2a,1770487789,1985,240,de71159e8c407de483ea9defba5f81db81fcfeea75cd7bfa10a57c30d5cfd1c3,1,output[0].content[0].text,,"DRUG_1_NAME: FEP_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q8h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- High-severity pneumonia with ICU transfer and marked leukocytosis plus HCA/MDR exposure (recent abx, recent hospitalization, LTC) → need broad IV antipseudomonal Gram-negative coverage.
- Cefepime provides single-agent coverage for Pseudomonas and many Enterobacterales; no MRSA history/risk provided, so avoid empiric MRSA agent.
- Renal function preserved (eGFR 166), so standard high-dose cefepime q8h is appropriate for severe infection.",FEP_IV,NA,NA,2026-02-08T05:01:07Z
177,OK,1,99127fa9fd3d6513c98b364bb6bfae233cd901ec4dbf44ed4cefb1bc6bbd8983,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_03b650bea334dd940169877fef071481a0a176212cacc7bba6,1770487791,1991,201,e8668db6ff5aeb2b00d6018b866e6eb313535c08914250573eff06fea4aa2ec6,1,output[0].content[0].text,,"DRUG_1_NAME: ETP_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset pyelonephritis with very high CRP and documented prior ESBL history/colonization → empiric carbapenem to cover ESBL Enterobacterales.
- Low severity/no shock and eGFR 92: ertapenem provides ESBL coverage without unnecessary anti-Pseudomonas/MRSA therapy.",ETP_IV,NA,NA,2026-02-08T05:01:07Z
178,OK,1,99fae251a72f642e67c7c8997a9d13963c7b9631bff497ad6e3ddb8ec2650ff5,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0a08a12af446aa380169877fef4b8081939f6e923b6fa17472,1770487791,1973,212,f5644937ebcf3f0b0136a3e80aa10cffb14847e1b2b051d6fe30f48b9e2344cb,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q6h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Healthcare-associated pneumonia with respiratory failure and recent hospitalization → broaden to cover Gram-negatives including Pseudomonas.
- No MRSA history/risk provided and no shock/ICU → avoid routine MRSA/add-on combination therapy in first 24h.
- Renal function normal (eGFR 103) → standard dosing; monitor given elevated transaminases.",TZP_IV,NA,NA,2026-02-08T05:01:07Z
179,OK,1,30fabee09d1acf8081216ae1b9f56f42b50fe191db9b2469dc35838a3602d609,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_07725e04e1eed1340169877ff175a081a18870c3c168355820,1770487793,1967,233,f5be8db75de1c68debd4288b9813ee4c87b2ea486edd17c4999facc78a08a82a,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with respiratory failure and leukocytosis: ceftriaxone + azithromycin provides standard empiric coverage for typical + atypical pathogens.
- No MDR/MRSA risk factors and no septic shock/ICU needs: avoid broader antipseudomonal or MRSA agents.
- eGFR 34: ceftriaxone and azithromycin do not require renal dose adjustment at these doses for the first 24h.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
180,OK,1,074a06f9d1dc66e210aa6fca2c9d942e89c2561d2cf9409339a2389a658c072e,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0f03de3e094c89940169877ff21c4c819f86a9e9f1dc2beb63,1770487794,1990,221,c3aa82b2ddc2a1d9e9935c0ed481f88e321b7d3d5a1700dbb5480409c159cdc5,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 2.25 g
DRUG_1_INTERVAL: q8h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset pyelonephritis with septic shock/ICU-level severity: broad IV Gram-negative (incl. Pseudomonas) coverage appropriate while cultures pending.
- No major MDR/MRSA history or recent healthcare exposure, so avoid routine MRSA or carbapenem empirically.
- Severe renal failure (eGFR 4): use renal-adjusted TZP dosing for first 24h.",TZP_IV,NA,NA,2026-02-08T05:01:07Z
181,OK,1,c465e126d7b2b03f7758e7604fbb69b7c3e2170034930cc3d98f2e554b615969,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_06f75ace6478da830169877ff308f8819ebe325e8a6144cfb9,1770487795,1988,262,657637a79491bd8c749befbd9b74ecd1c61cead003bf4977b5bbebc0eea289dd,1,output[0].content[0].text,,"DRUG_1_NAME: MEM_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q12h (renal-adjusted for eGFR 25)
DRUG_2_NAME: VAN_IV
DRUG_2_DOSE: 15 mg/kg
DRUG_2_INTERVAL: q24h (renal-adjusted for eGFR 25; level-guided)
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Septic shock with healthcare-associated sepsis and recent antibiotics/LTC: broad IV Gram-negative (incl. Pseudomonas) and ESBL-risk coverage with meropenem.
- Add vancomycin for empiric Gram-positive coverage in HCA bloodstream infection/sepsis (notably staphylococcal prevalence in local data) pending cultures.
- Renal dysfunction (eGFR 25) favors avoiding aminoglycosides and requires dose-interval adjustment.",MEM_IV,VAN_IV,NA,2026-02-08T05:01:07Z
182,OK,1,3d7b55db5d245929bf24bea2257b96bd4232213f019d557d530089b239bb7470,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0f9e2b90ab7784930169877ff505ec81908ede664ded0c3904,1770487797,1979,232,03141756e96ff91d6b8d50245165057aa94f9f95260d4d4b17b2c711eb8d092f,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Severe community-onset pneumonia with respiratory failure requiring MV/NIV and ICU transfer → IV CAP regimen covering typical pathogens plus atypicals.
- No MDR/MRSA history or recent healthcare/antibiotic exposure → avoid routine anti-MRSA or antipseudomonal therapy in first 24h.
- eGFR 89 mL/min/1.73m2 → no renal dose adjustment needed for ceftriaxone/azithromycin.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
183,OK,1,f18b2f6c23c7d14d8973446e13b3048aefbae024ee4a97438588dfe8ea38a35d,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_01189837015c59640169877ff5d6c481959a4604681c1bff17,1770487797,2077,222,560ae96868323e22bc4b09498666b7fb9a37b447596d22a9e51c4b97dbd20658,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset sepsis/bloodstream infection with marked leukocytosis/CRP; escalate from pre-admission oral cefuroxime to parenteral broad Gram-negative and streptococcal coverage.
- No septic shock/ICU needs and no MDR history/exposure; avoid unnecessary combination therapy.
- No MRSA history or clear risk factors provided; defer empiric anti-MRSA agent in first 24h.",CRO_IV,NA,NA,2026-02-08T05:01:07Z
184,OK,1,b1af2547bdaf7375933a520df5211be61446f54e9fd4319192012faf39dfbc31,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_084e08ccb8187f3d0169877ff75be4819498d2cabb19ae021a,1770487799,2002,245,82252a0dc51a48680be16bd489dd7aee84fd0e88110a00c25da3e399b1ddb74b,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q12h (renal-adjusted for eGFR 13)
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Severe community-onset pneumonia with septic shock/MV/vasopressors → IV broad empiric coverage appropriate in first 24h.
- Recent hospitalization and local ward ecology with notable non-fermenters (incl. Pseudomonas/Acinetobacter) support an antipseudomonal beta-lactam.
- No documented MRSA history/risk factors provided → avoid routine MRSA agent initially; dose adjusted for advanced CKD (eGFR 13).",TZP_IV,NA,NA,2026-02-08T05:01:07Z
185,OK,1,55ebf0002b049781a12212633e642a1710e25069265e5cddf897ecc7456b9abb,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0d7a34eecc066d5d0169877ff89fe881949c889f022471d347,1770487800,1992,236,285c88880a7c1f7f4614345487b8b4ff7c54f1cb420f9b827a676fd4c7f6278c,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q6h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Severe community-onset pneumonia with septic shock/MV/vasopressors → broad IV empiric coverage including Pseudomonas/Gram-negatives (TZP_IV).
- Add atypical coverage for CAP (AZM_IV) in the first 24h.
- No MRSA history or recent healthcare/antibiotic exposure → avoid routine MRSA agent despite viral test positivity (coinfection still possible given shock/CRP 199).",TZP_IV,AZM_IV,NA,2026-02-08T05:01:07Z
186,OK,1,7d703c75a6fe03a528b6b2c5ed2296e2e6da371b7d73176f1f5142781bf375ff,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_031bdcf88e0ac3d10169877ff96e108193a42447619704672b,1770487801,2041,224,55498c7f1c69f059ae0fa6dcf94f0d1a35781a40f31a0e2193bab6a751afd664,1,output[0].content[0].text,,"DRUG_1_NAME: SAM_IV
DRUG_1_DOSE: 3 g
DRUG_1_INTERVAL: q6h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset SSTI with sepsis and leukocytosis; escalate from pre-admission AMC1G_PO to IV beta-lactam/beta-lactamase inhibitor for broader streptococcal/MSSA and polymicrobial coverage.
- No documented MRSA history and no shock/ICU needs, so avoid routine MRSA add-on in first 24h.
- Normal renal function (eGFR 114) supports standard dosing.",SAM_IV,NA,NA,2026-02-08T05:01:07Z
187,OK,1,421a81ee3bd50c14d1002e15bc71629f670b21031d944b3d20307df76916f111,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0acacc1f752b31970169877ffb3a6c819e9912b90432ab8862,1770487803,2051,232,a00a00658fee82a54fef71c7467dd58449140fd896f051ffb6ba1e73b876f4d3,1,output[0].content[0].text,,"DRUG_1_NAME: FEP_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q8h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset pneumonia with respiratory failure and immunosuppression plus recent outpatient AMC exposure → broaden initial Gram-negative coverage (including Pseudomonas) with cefepime.
- Add azithromycin for atypical coverage in CAP; no MRSA history/risk provided, so avoid routine MRSA therapy.
- eGFR 106 mL/min/1.73m2 → no renal dose adjustment needed for first 24h.",FEP_IV,AZM_IV,NA,2026-02-08T05:01:07Z
188,OK,1,9776d8da144fffeb4cdccf495e7d4ae6272193bc5d107e3d3f5fdaf29f38d493,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_02b7422ec16162c90169877ffc874c8194886d3e7f505f9fec,1770487804,1978,231,90899d8ec222850fee3e5a28d5a50e36da1329e0a3805426d0ba2150335f8fbc,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q8h (extended infusion; renal-adjusted for eGFR 43)
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Septic shock with respiratory failure and LTC residence → high risk for severe healthcare-associated pneumonia; needs broad IV antipseudomonal Gram-negative + anaerobe coverage.
- No prior MRSA history and no structured MRSA risk factors provided → avoid empiric MRSA agent in first 24h.
- eGFR 43 supports renal-adjusted TZP dosing for initial empiric therapy.",TZP_IV,NA,NA,2026-02-08T05:01:07Z
189,OK,1,2f145ab08ce6e6610e4e182dea538e7c1edb37826a5f708b69da2f0397b316fa,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0214f6877d7dde2d0169877ffcdc5881a2a87731676ae3ac21,1770487804,1981,252,e40c2daa253eb0621463037cbae557396963cbfdc7510823174e1f3046f3d926,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h (renal function eGFR 44: no adjustment)
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with sepsis/respiratory failure: ceftriaxone + azithromycin provides standard empiric coverage for typical + atypical pathogens.
- No structured MDR/MRSA risk factors (no prior MRSA/ESBL, no recent hospitalization/LTC, no recent antibiotics), so avoid broader anti-pseudomonal or MRSA agents.
- IV route appropriate given sepsis and respiratory failure; avoid hepatically intensive agents beyond necessary given markedly elevated AST/ALT.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
190,OK,1,83ba0752c511e14018bce70d8eb046348a9e92a59aa82d84fe15945460868677,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_003d725c665d2b3c0169877fff3c44819f8ea4b2bcd103bd9f,1770487807,2001,237,1cf9c947414efb0144adcc1efc768cbcce732a51feca62767b56589a3cb8b29b,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q6h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Severe community-onset pneumonia with septic shock/MV/vasopressors → broad IV empiric coverage including Gram-negatives (incl. Pseudomonas) and anaerobes with TZP.
- Add azithromycin for atypical CAP pathogens and potential immunomodulatory benefit in severe pneumonia.
- No MRSA risk factors (no prior MRSA, no recent healthcare/LTC exposure) → avoid routine MRSA coverage in first 24h.",TZP_IV,AZM_IV,NA,2026-02-08T05:01:07Z
191,OK,1,94e9cca2e54054a9a0ea7e38e277b56c17c683af89f7aeea0fbe6000a47c254d,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0582ef364a305c6f0169878000d0d081a080f8fc2d7e9bc314,1770487808,1987,251,b9ac4aaf38cc75643db4d7d689ead1d05dc8997b4956fd00f6575cf27e472f3d,1,output[0].content[0].text,,"DRUG_1_NAME: MEM_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h (renal-adjusted for eGFR ~3 mL/min)
DRUG_2_NAME: VAN_IV
DRUG_2_DOSE: 15 mg/kg
DRUG_2_INTERVAL: once, then dose by levels (severe renal failure)
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Septic shock with community-onset sepsis: broad IV empiric coverage for Gram-negatives/anaerobes with meropenem while cultures pending.
- Add vancomycin for early MRSA/CoNS coverage given high local staphylococcal prevalence in bloodstream infection context and severity.
- Avoid aminoglycosides due to profound renal failure (eGFR 3 mL/min) and toxicity risk.",MEM_IV,VAN_IV,NA,2026-02-08T05:01:07Z
192,OK,1,0ed0c13fc777e4f26b151a50227ffa8313a44678a05e0453d8250278a35070bd,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0729fe673676ccd60169878001247081958c1c1728fb8b91f2,1770487809,1989,229,5c9b20fd4d1afbddb077541843456ae47de9d31f93be003b2ea7606a444480be,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with respiratory failure and elevated CRP warrants empiric bacterial coverage despite positive viral screen.
- Ceftriaxone + azithromycin provides standard inpatient CAP coverage including typical pathogens and atypicals; no MDR/MRSA risk factors to justify broader or anti-MRSA therapy.
- eGFR 86 mL/min/1.73m2: no renal dose adjustment needed for either agent in first 24h.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
193,OK,1,d8bbf2532dfd99ce5804bb420ad91af39325e7fe6c67e232d357d250fd6eba14,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_05c182069b074726016987800323c48192aca8c28a2a7fda55,1770487811,1975,247,f3757f6dfc5d3e69210449de8f2dccb5a98e17b59d93b7446de53d7eee42ff2d,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with respiratory failure and markedly elevated CRP/WBC → empiric inpatient CAP coverage with IV beta-lactam + macrolide.
- No MRSA or MDR risk factors (no prior MRSA/ESBL, no recent hospitalization/antibiotics, no LTC) → avoid routine VAN/LZD and antipseudomonal agents.
- Viral screen positive lowers bacterial probability but does not exclude coinfection given severity/inflammation; eGFR 98 → standard dosing (no renal adjustment).",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
194,OK,1,14519a963bcbdd77c883fbd89de6a25d00df9d4478b66573275d1377e8f0a759,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0f116a2d1927e2fb01698780047d4c8190b584ae28eea69769,1770487812,1980,209,f8763af635669c4a13d25f5345b8a3595ee1785acd88ac744003d56c25033df5,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset suspected bloodstream infection with marked leukocytosis/CRP: ceftriaxone provides broad empiric coverage for common Gram-negative and streptococcal pathogens.
- Low severity and no MDR/MRSA risk factors: avoid routine MRSA coverage and unnecessary combination therapy.
- Renal function normal (eGFR 93): no renal dose adjustment needed.",CRO_IV,NA,NA,2026-02-08T05:01:07Z
195,OK,1,2018666651c289f2fdbdaa220728be786241ac76f48ee20ec06406c918411c6a,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0530b9afc792d96c0169878004ffd48195a765778caffe6dbe,1770487813,2078,237,d8fe636f1f7745ec9c2553ab1fb9b2c5ef407b5e7a562af94ab19936e249ed21,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset pneumonia with respiratory failure and elevated CRP/lactate warrants empiric CAP coverage despite positive viral screen (possible bacterial coinfection).
- Ceftriaxone + azithromycin provides typical + atypical CAP coverage; no MRSA/MDR risk factors to justify VAN/anti-pseudomonal therapy.
- eGFR 91: no renal dose adjustment needed; prior cefuroxime exposure for current episode supports switching to broader standard inpatient CAP regimen.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
196,OK,1,99929e81e6addf38b36fcddff5c95073ff526088f82b19b8316a0b3517c39f1a,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0224ee750587fdb301698780075cd481a28f3513cd154ffeba,1770487815,1989,232,b547e6a0d2af166695f46727b2c4c246cf8c76921a2a7a997f83dd342274f0ae,1,output[0].content[0].text,,"DRUG_1_NAME: MEM_IV
DRUG_1_DOSE: 500 mg
DRUG_1_INTERVAL: q24h (renal-adjusted for eGFR 3)
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset pneumonia with septic shock/respiratory failure (MV, vasopressors, ICU): requires broad IV empiric coverage in first 24h.
- Meropenem provides broad Gram-negative (including Pseudomonas) and anaerobic coverage; local ward-year data show relatively higher predicted activity among available IV options.
- No MRSA history or MDR risk factors provided; avoid routine MRSA add-on empirically.",MEM_IV,NA,NA,2026-02-08T05:01:07Z
197,OK,1,bbde5d319ed657448eb00cf8993661ac9381b19d8c38cbd01f5f01074140da40,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0be611244fd6657f016987800806dc819c85005e23bc0d00ee,1770487816,2077,229,3924a6da3378a780bf3518fa11d18da0402eb3f77efd85ecc9ff97a51d79ed15,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q8h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset pneumonia with respiratory failure and marked inflammation (WBC 21.7, CRP 243) plus LTC residence and local prior showing substantial Gram-negative/Pseudomonas signal → broad IV beta-lactam appropriate for first 24h.
- Continue same agent as pre-admission therapy (home TZP_IV) to avoid unnecessary early switching while cultures pending.
- No MRSA history/risk provided → avoid empiric MRSA agent.",TZP_IV,NA,NA,2026-02-08T05:01:07Z
198,OK,1,4ba50dfb8c564f51438a275495a6a81186335fc47be3afbcc90a04f61b392280,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_06f5908a8257a1200169878008a5f881908fe7972896b84ad5,1770487816,2096,234,e52dc9f0a8865cb9cd1812d042f553501a0ce119eb0182262ec73acc47d3f992,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q6h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Severe community-onset pneumonia with septic shock/MV/vasopressors → broad IV beta-lactam for typical pathogens and Gram-negative coverage.
- Add IV azithromycin for atypical coverage in severe CAP; no structured MRSA risk/history to justify routine MRSA agent.
- Renal function normal (eGFR 105) → standard dosing; home TZP_IV indicates pre-treatment, so continue broad IV coverage pending cultures.",TZP_IV,AZM_IV,NA,2026-02-08T05:01:07Z
199,OK,1,27ba147043e43b2db4d1be7397a1b2998a63a5ce72a71964ae9ce25fbb3553c6,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_093d96917cbf8ce4016987800bc77481949bb3be001b0e963b,1770487819,1992,242,9904a43be55c9b740d46438e1ea14499f3013a9e9ce58a9e9b886d2a5dc0abd8,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q8h (renal-adjusted for eGFR 30)
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Septic shock from community-onset pyelonephritis: broad IV Gram-negative coverage including Pseudomonas with a single agent.
- No MRSA/ESBL/CRE/VRE history or recent healthcare/antibiotic exposure to justify routine MRSA or carbapenem empirically.
- Avoid aminoglycoside add-on given CKD (eGFR 30) and nephrotoxicity risk; TZP provides adequate initial coverage pending cultures.",TZP_IV,NA,NA,2026-02-08T05:01:07Z
200,OK,1,593db0740e6ed4627250f81786ec375a8a9dc91856a136ce0ca7884f5f485b77,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_09a88d96f3391015016987800c3244819c889d4630719acc41,1770487820,1973,261,173c7640c411d177df53f3e1c7091c08211c581f7776b9ddf4a489547c9a08cc,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Moderate community-onset CAP with respiratory failure: IV beta-lactam + macrolide for typical + atypical bacterial coverage in first 24h.
- No MRSA or MDR risk factors (no prior MRSA/ESBL, no recent antibiotics/hospitalization/LTC), so no empiric MRSA/antipseudomonal escalation.
- eGFR 89 mL/min/1.73m2: no renal dose adjustment needed for ceftriaxone/azithromycin; viral screen positive lowers bacterial probability but severity/WBC support empiric coverage pending cultures.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
201,OK,1,ce55e0da2dfa6667dd75ce3e66fdf58a66d7b7d72b2d135e29018d179dfc494d,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0267fc229b38650e016987800cc0a08190b8f09c94b5c9a1a0,1770487820,1974,243,4c55f6a9bb489c95660424edc7472e159f137f5bea414386ae948d852fb89cde,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q8h (renal-adjusted for eGFR ~30)
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Healthcare-associated UTI with high severity (vasopressors) and marked inflammation (WBC 16.6, CRP 167) warrants broad IV Gram-negative coverage including Pseudomonas.
- No major MDR history/exposure; TZP provides appropriate empiric coverage for common ward-year pathogens (E. coli, Klebsiella) while avoiding unnecessary MRSA/VRE agents.
- Dose interval adjusted for CKD (eGFR 30).",TZP_IV,NA,NA,2026-02-08T05:01:07Z
202,OK,1,319133336b013a39b5f11206ce9e313f16e257b9d22cbe847653627e767b6239,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_094023a634cfa987016987800f60448195a393616496cdbd6d,1770487823,1985,198,9adc426f2099f961e52767f59894eca43a90cbf99d87f56a43e815be11f556f0,1,output[0].content[0].text,,"DRUG_1_NAME: MEM_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q8h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Healthcare-associated UTI with sepsis and prior ESBL history/LTC residence → empiric carbapenem to cover ESBL Enterobacterales.
- eGFR 78 mL/min/1.73m2: no renal dose adjustment needed for first 24h; monotherapy avoids unnecessary additional agents/MRSA coverage.",MEM_IV,NA,NA,2026-02-08T05:01:07Z
203,OK,1,9b828c5b5e34b5ae4dacfbadb7c9b2ffd9e2a8c7c1f176dfa8fb35ac434093ae,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0e6b5d9e1a2d0837016987801028c4819198daf93b945bb5ea,1770487824,1993,231,c755f35f330ac50737d1ce435f77d5d9ca8079bc2ee71d93ec5ebf746e35d07e,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q6h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Severe community-onset COPD infectious exacerbation with respiratory failure requiring MV/NIV and ICU transfer → IV broad-spectrum coverage appropriate for first 24h.
- TZP provides single-agent coverage for common COPD pathogens including Gram-negatives (incl. Pseudomonas) and anaerobes; no structured MRSA/MDR risk to justify added MRSA or double Gram-negative therapy.
- Renal function normal (eGFR 111), so standard dosing used.",TZP_IV,NA,NA,2026-02-08T05:01:07Z
204,OK,1,9af329c1ce1641549cb83533f3472793c6c65b2df9a4560e511bf20b7704c6bf,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_015b6fb3588ff0fe01698780109608819793e52b93a1f08a53,1770487824,1971,252,9cd2584f0f86f5d8bb11856e6865c0477e00b33c59d6dcdaba3bcc5ef53ad081,1,output[0].content[0].text,,"DRUG_1_NAME: MEM_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h (renal-adjusted for eGFR 14)
DRUG_2_NAME: VAN_IV
DRUG_2_DOSE: 15 mg/kg
DRUG_2_INTERVAL: once, then dose by levels (renal failure)
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Septic shock with MV/vasopressors/ICU: broad IV empiric coverage for community-onset sepsis pending cultures.
- MEM_IV for broad Gram-negative (including resistant Enterobacterales) and anaerobe coverage given recent antibiotic exposure and high severity.
- VAN_IV added for Gram-positive coverage (including MRSA/CoNS) in bloodstream infection/sepsis with high local staphylococcal prevalence; renal failure requires level-guided dosing.",MEM_IV,VAN_IV,NA,2026-02-08T05:01:07Z
205,OK,1,f8d62a85de2b2b1949b52bc36fc2993f66f930d4354ef4ab943ef08df08aa1ce,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0ebe20ad99a531750169878012b3988193a344a43a472c1866,1770487826,1978,245,2a3bb26bb7823dfdd9526416dbe4e1c6363d8f8c582bbcf3c07a27e90526c3a5,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset sepsis/bloodstream infection with very high WBC/CRP/PCT and elevated lactate; needs prompt broad empiric coverage for common Gram-negative and streptococcal pathogens.
- No major MDR risk factors and no septic shock/ICU needs; ceftriaxone IV provides appropriate first-24h coverage while avoiding unnecessary MRSA/anti-pseudomonal combination therapy.
- eGFR 71 mL/min/1.73m2: no renal dose adjustment needed for ceftriaxone.",CRO_IV,NA,NA,2026-02-08T05:01:07Z
206,OK,1,1c6d47437377d7ec388a635e7a334398849c0f04c1a1883d2504980e09984bc5,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0f798296f5acd0370169878014d7488193b3ef2a8f4165642c,1770487828,1991,246,b05b4c90d86f8bc8f97a74fc1586edb689cbad287a02055dbfe0de29cb6223de,1,output[0].content[0].text,,"DRUG_1_NAME: MEM_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q12h (renal-adjusted for eGFR ~20)
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Septic shock with MV/vasopressors/ICU: needs immediate broad IV bactericidal coverage for community-onset sepsis.
- Meropenem provides broad Gram-negative (incl. severe sepsis pathogens) and anaerobic coverage; renal dose adjusted to eGFR 20.
- No structured MRSA/MDR risk factors (no prior MRSA/ESBL/CRE/VRE; no recent healthcare/LTC), so avoid routine anti-MRSA add-on in first 24h.",MEM_IV,NA,NA,2026-02-08T05:01:07Z
207,OK,1,071b873754d9a9a5a2522abc2b04857a9938bce20fafa2517923b57ecb48f029,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0c13bae218fe1c840169878015ec8481a29015c8d122f0b900,1770487829,2013,247,8c95ae20a80ac584abca4af125cba918543d3180ae651e208d5089457bd7af53,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Severe community-onset pneumonia with septic shock/MV/vasopressors → IV empiric CAP coverage despite positive viral screen (high CRP, shock).
- Ceftriaxone + azithromycin provides typical + atypical respiratory pathogen coverage; no structured MDR/MRSA risk factors to justify broader or MRSA therapy.
- Renal adjustment: ceftriaxone and azithromycin generally do not require dose adjustment at eGFR 18 mL/min/1.73m2 for first 24h.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
208,OK,1,e82da91adee1a8d7ab8eb37b1d8e3fc19bb2d1b45165d1fe03f834f2c13f58dd,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_074efe74d82a1f34016987801672a48192a358803ea51d843d,1770487830,1984,250,a345e6f65cf0945f50252d81f8886d2e38f30622e64563bb8ca96bf90e2a3728,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 2.25 g
DRUG_1_INTERVAL: q8h
DRUG_2_NAME: VAN_IV
DRUG_2_DOSE: 15 mg/kg
DRUG_2_INTERVAL: once (loading dose)
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Septic shock with MV/NIV and healthcare-associated sepsis: broad IV empiric coverage for Gram-negatives (incl. Pseudomonas) and anaerobes with TZP.
- Add vancomycin for likely Gram-positive bloodstream pathogens in this setting (high local staphylococcal burden); avoid aminoglycosides given eGFR 5.
- Severe renal failure: use renal-adjusted TZP dosing; give single vancomycin loading dose pending levels/renal replacement status.",TZP_IV,VAN_IV,NA,2026-02-08T05:01:07Z
209,OK,1,5bbc0e781dede568f79dd2787db2112da4a9855015e700aa3761f46a153bd4af,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0c7434fc0db4ddac0169878018b4cc819583423249a26023e3,1770487832,1978,221,f12d09a69a36bd3686c39cee0fa495c4eb237fc8bcfe1bc12aba100f5080022a,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with respiratory failure and very high CRP/WBC: empiric inpatient CAP coverage with beta-lactam + macrolide.
- No MDR/MRSA risk factors provided; avoid routine anti-MRSA/anti-pseudomonal escalation in first 24h.
- eGFR 74: no renal dose adjustment needed for ceftriaxone or azithromycin.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
210,OK,1,8224309972b40f4b10665cc743bd26f0b524bc294ad08423a92ebf9a08ca1d9f,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_05a9f3f8ef95755601698780198980819d93325beb9e8a7c72,1770487833,2029,237,75548dd275bb293fb3ff38e3fbdc102b8b311b8e5fa7e25f83f8788a16c9dc7f,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q8h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset intra-abdominal infection with high severity/ICU transfer → broad IV empiric coverage for Enterobacterales, anaerobes, and Pseudomonas.
- Recent home amoxicillin-clavulanate exposure (and abx≤90d) supports escalation beyond AMC; no specific MRSA/VRE history to justify VAN/LZD.
- eGFR 67 mL/min/1.73m2: no renal dose adjustment needed for initial 24h.",TZP_IV,NA,NA,2026-02-08T05:01:07Z
211,OK,1,2dfc1c09f3276d3841a504d7e2819ad233971fd3ac4db26e34286b00bdc35968,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_02bb6a57d4bdc41b016987801b0c58819cba94d12a05f8286f,1770487835,2005,238,6ce698a31ed10f67c1e5900c948c735831f15fb832b87ac175f6b8e93a10daee,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q6h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Septic shock with MV/vasopressors/ICU: broad IV empiric coverage for severe community-onset pneumonia; TZP provides Gram-negative (incl. Pseudomonas) and anaerobe coverage.
- Add azithromycin for atypical CAP pathogens and potential immunomodulatory benefit in severe pneumonia.
- No MRSA history or recent healthcare/antibiotic exposure documented, so avoid routine MRSA agent in first 24h.
",TZP_IV,AZM_IV,NA,2026-02-08T05:01:07Z
212,OK,1,7beee977d115ad41f5dd86b7112362955b9d54235aae72fc99e1c698732205de,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_046d3e9c453aa688016987801cf8b881a29bfc444505002a39,1770487836,1980,227,d2b93a4fac36c6f4fe6bac2e23c43d1991b6a9aae98cdc481763115428b6dd74,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q6h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Healthcare-associated pneumonia with sepsis and high inflammatory markers; recent hospitalization/antibiotics increases risk for Gram-negative (incl. Pseudomonas) pathogens.
- TZP provides broad empiric coverage for common HAP/CAP pathogens including Pseudomonas and anaerobes; no MRSA history/risk provided, so avoid routine MRSA agent.
- Renal function preserved (eGFR 89), so standard dosing used.",TZP_IV,NA,NA,2026-02-08T05:01:07Z
213,OK,1,b37424c30d4500e3956290f32d0ebfbd73b2923b5b36d79ab2bf8a71befa25da,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_091b4b2cd75594e0016987801d599c8193b26b8281031bb830,1770487837,1989,224,ce82ad95d972846992ac86a441bdb8b643d627601e061ba2143b6c96bc1d8858,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset pyelonephritis with marked inflammation (WBC 18.5, CRP 163) but low severity and no MDR risk factors → ceftriaxone provides appropriate empiric Gram-negative coverage.
- No MRSA/ESBL history or recent healthcare/antibiotic exposure → avoid broader agents and unnecessary combination therapy.
- Renal function normal (eGFR 111) → no renal dose adjustment needed.",CRO_IV,NA,NA,2026-02-08T05:01:07Z
214,OK,1,6e3bcb5cf4ee7d611fae243a9eea8f40660b254b22f4b823f8fb46333c7c21bb,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0689cf109f8e5aa6016987801f077881a2a8180d9b6bba1d57,1770487839,1984,226,2a3e939de294f50377843bf9c6fd109d83f052dd500d886bd7dc8eb53f0485de,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Moderate community-onset CAP with respiratory failure and very high CRP → empiric bacterial coverage warranted despite positive viral screen.
- CRO_IV + AZM_IV provides typical + atypical CAP coverage; no MRSA/MDR risk factors to justify VAN/anti-pseudomonal therapy.
- eGFR 89: no renal dose adjustment needed for ceftriaxone/azithromycin in first 24h.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
215,OK,1,b0840e55d962b5d024d8b54f32d39d5c086453ae5557c01edadf2d0891f798b5,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_05ba03e55a47517d0169878021470481a1995cacc60ee64a60,1770487841,1982,231,96dd807879a84fbe164c058cbc919f18191b75b6a24552f6f669be971a5f3768,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with documented respiratory failure (moderate severity): ceftriaxone + azithromycin provides empiric coverage for typical pathogens and atypicals.
- No MDR/MRSA history or recent healthcare/antibiotic exposure: avoid routine anti-MRSA or antipseudomonal therapy.
- eGFR 82 mL/min/1.73m2: no renal dose adjustment needed for this first-24h regimen.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
216,OK,1,7c722ef403514a1ecc11b120a8e8b8693bdc9e88c4a902d20487cf45e03113af,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0acf0b671c506aae0169878021685081978eda875364f80682,1770487841,1996,220,5e8dd1ecad73c56481889e5730eaf7ab5b24ccbcf5863127847593a1b1fadce3,1,output[0].content[0].text,,"DRUG_1_NAME: FEP_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q8h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Severe community-onset pneumonia with respiratory failure and ICU transfer → IV broad CAP coverage; cefepime provides Gram-negative (incl. Pseudomonas) coverage given recent hospitalization/antibiotics.
- Azithromycin adds atypical coverage for CAP in the first 24h.
- No MRSA agent: no prior MRSA history provided and no structured MRSA risk flag.",FEP_IV,AZM_IV,NA,2026-02-08T05:01:07Z
217,OK,1,b2e8f05d1a203f3d675228a45d87768e8fe13bddd899727f231334488364033b,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_02a5ab9c33d857ff0169878022df6081a0a0440b31d89a7d5b,1770487842,1995,254,96c024bf28cce690819faae20b4a6f1e51abad28c5a86913bbe81cea978b309a,1,output[0].content[0].text,,"DRUG_1_NAME: MEM_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h (renal-adjusted for eGFR ~15)
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset pyelonephritis with septic shock (lactate 6, vasopressors/ICU): needs immediate broad IV Gram-negative coverage.
- Meropenem provides reliable coverage for Enterobacterales (E. coli/Klebsiella) and Pseudomonas in severe sepsis; no MRSA risk factors to justify VAN.
- Avoid aminoglycoside add-on given severe AKI (Cr 3.75, eGFR 15) and thrombocytopenia (Plt 46).",MEM_IV,NA,NA,2026-02-08T05:01:07Z
218,OK,1,5ca30b72153e0e6de3b6f7f1d5a0f6c019b38c9e5fcd52697ded9011498a250f,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0df36c82291d14680169878024cf2c8194a27ad64c671e945b,1770487844,1998,211,c8bd2962b96d8b2145b857c5ba936677c117623e93ede7479c038091258e3f5f,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset pyelonephritis without sepsis/shock or MDR risk factors: ceftriaxone provides appropriate broad Gram-negative coverage for likely Enterobacterales.
- Very elevated WBC/CRP supports bacterial infection; single-agent therapy avoids unnecessary combination coverage.
- Renal function normal (eGFR 88): no dose adjustment needed for ceftriaxone.",CRO_IV,NA,NA,2026-02-08T05:01:07Z
219,OK,1,aae1e54fd235e81a62462a325bc2f889865f2f7e6b6454a95c00fe1923bc08ff,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0e82f9820b3e7a660169878024df6c8195a79c138937fe5cd3,1770487844,1992,226,7cfec83a7cdc30edc918fa352ae56d01f8c53fde17d44c0150ec6e88a22c06b6,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q8h
DRUG_2_NAME: VAN_IV
DRUG_2_DOSE: 1 g
DRUG_2_INTERVAL: q12h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Healthcare-associated pneumonia with respiratory failure and LTC residence: broaden empiric Gram-negative (incl. Pseudomonas) coverage with TZP.
- Prior MRSA colonization/history supports adding empiric MRSA coverage with IV vancomycin for first 24h.
- eGFR ~59: standard TZP dosing; conservative vancomycin q12h initial dosing pending levels/renal trend.",TZP_IV,VAN_IV,NA,2026-02-08T05:01:07Z
220,OK,1,37dc902bf2ce80cc219cd279e9d8937ac0367aa3ed83ae907d3ba9310afa135e,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0e40090459fbb65e016987802686f481a39586855a27565889,1770487846,1969,214,c58cbf4eaf2216a624968370f4e18cdd038bcb92eddebbcd46529dac2346d79d,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with respiratory failure and high CRP: empiric beta-lactam + macrolide for typical + atypical coverage.
- No MDR/MRSA risk factors documented, so avoid routine anti-MRSA or antipseudomonal therapy.
- Normal renal function (eGFR 106): standard dosing appropriate for first 24h.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
221,OK,1,20d89838fa87d9c6083099062813833bf37fccb5e46d1ddade330407d4bce216,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_01f1a1f994b00dad0169878028b87c81a0a988604ff1775b18,1770487848,1968,229,478f73eb63cda48ce945b1da1063ad58cb4b135d6d219371532c57d565eb57f9,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q8h (renal-adjusted for eGFR 25)
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Severe community-onset pneumonia with sepsis and MV/NIV + ICU transfer → IV broad empiric coverage appropriate for first 24h.
- Recent hospitalization and antibiotics within 90d increases risk of resistant Gram-negatives (including Pseudomonas); TZP provides antipseudomonal and anaerobe coverage.
- No prior MRSA history provided → avoid routine MRSA agent at admission.",TZP_IV,NA,NA,2026-02-08T05:01:07Z
222,OK,1,e5edb27e9c8ddf6582e47fb79a347da4cdda23cbdf163222c6918481cfa313c6,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_06cf318ef3e9c0ae0169878028c774819e9131e93646dd765b,1770487848,1977,227,468bdf8c51af2b00069c55ee66244e379bbf4984fa9cb4caa464d7b0b9c2d013,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset sepsis/bloodstream infection with low severity and no MRSA/ESBL history: ceftriaxone provides broad empiric coverage for common Gram-negative and streptococcal causes.
- Recent hospitalization increases MDR risk somewhat, but without prior ESBL/CRE/MRSA and with stable renal function (eGFR 78), initial 3rd-gen cephalosporin monotherapy avoids unnecessary broadening in first 24h.",CRO_IV,NA,NA,2026-02-08T05:01:07Z
223,OK,1,befe924b93a9c5cd708edc7b465e1737729f6174d3597fc61e06a875ec69f853,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0e18cd6172bcdf810169878029c438819cbe806947470c2860,1770487849,1981,225,4b120d8d7469add8d4eb4608f087c0a0b1459c1fa3f3dcb6667d96b8e618b584,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with respiratory failure (moderate severity): IV beta-lactam + macrolide for typical + atypical coverage.
- No MDR/MRSA history or recent healthcare/antibiotic exposure; avoid routine anti-MRSA/anti-pseudomonal escalation.
- eGFR 92: no renal dose adjustment needed for ceftriaxone/azithromycin in first 24h.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
224,OK,1,438498df16f24e6b78d17df1ac2d778a33fa4dbd5f22b78b902dfac3af02205f,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_089a2f9140bdd736016987802c4bf8819d8d0fb9d4e43e0ab5,1770487852,1993,229,b8f85961e26ea342e208caf8d8c4beab05e4d8c4b8fd0af8e2f301e044c5d3cd,1,output[0].content[0].text,,"DRUG_1_NAME: VAN_IV
DRUG_1_DOSE: 1000 mg
DRUG_1_INTERVAL: q24h (renal-adjusted for eGFR 38)
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset SSTI with sepsis and documented prior MRSA colonization → empiric MRSA-active therapy warranted.
- No shock/ICU/respiratory failure and no MDR Gram-negative risk factors → avoid unnecessary broad Gram-negative combination therapy in first 24h.
- CKD (eGFR 38) → use extended interval vancomycin dosing to reduce nephrotoxicity risk.",VAN_IV,NA,NA,2026-02-08T05:01:07Z
225,OK,1,8860ffb11e16d5c431f26660efbfa0f66c1de0aedaf0777988d7167bca239641,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0c659f6a2349aa75016987802c4bc081a09916444152213311,1770487852,2058,239,2aa473e72581cd1f6b1fc67d0ae38e3e206943518604529c727094f56022d365,1,output[0].content[0].text,,"DRUG_1_NAME: MEM_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q12h (renal-adjusted for eGFR ~25)
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Healthcare-associated sepsis/bacteremia with high WBC and significant MDR risk (LTC, recent hospitalization/antibiotics) plus prior ESBL history → empiric carbapenem coverage.
- Recent ceftriaxone exposure before admission increases concern for resistant Gram-negative pathogens; meropenem provides broad early coverage while cultures pending.
- No documented MRSA history and low shock/ICU severity → avoid routine empiric anti-MRSA agent in first 24h.",MEM_IV,NA,NA,2026-02-08T05:01:07Z
226,OK,1,b67ca897d553ecfd6d0285537c1b104f6abfccb1484c3d5c850032e718d27052,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_035ce1ee3ad28aa5016987802d4314819eae2177a170d62804,1770487853,1981,252,13f36ccab39d4f282835438e7bad05b3681a6dee11ac8c1f1ae7ed6fb3533a6c,1,output[0].content[0].text,,"DRUG_1_NAME: MEM_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q12h (renal-adjusted for eGFR 32)
DRUG_2_NAME: VAN_IV
DRUG_2_DOSE: 15 mg/kg
DRUG_2_INTERVAL: q24h (renal-adjusted; target AUC-based monitoring)
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Septic shock with MV/vasopressors: immediate broad IV empiric coverage for community-onset sepsis pending cultures.
- MEM_IV for broad Gram-negative (incl. severe sepsis pathogens) and anaerobic coverage; renal-adjusted for eGFR 32.
- VAN_IV added for Gram-positive coverage in high-severity bloodstream infection where staphylococci are common in local prior; renal-adjusted dosing/monitoring.",MEM_IV,VAN_IV,NA,2026-02-08T05:01:07Z
227,OK,1,82743fdf7ea7b73ecb230e88d6bf23e09fbcd86ab22fa0fb961613afe4a7527e,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0659c1591d0126d3016987802f94848195b347f194129a1829,1770487855,2087,241,9bea1a3976c841001362b2afb9089fd8d891818701b40a4a14eb6f32ec5a3365,1,output[0].content[0].text,,"DRUG_1_NAME: MEM_IV
DRUG_1_DOSE: 500 mg
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Septic shock with MV/vasopressors/ICU transfer → immediate broad IV empiric coverage for community-onset sepsis; prior home AMC1G_PO suggests possible beta-lactam pre-treatment/failure.
- Meropenem provides broad Gram-negative (including ESBL risk despite low formal MDR history) and anaerobic coverage appropriate for undifferentiated bloodstream infection.
- Severe CKD (eGFR 11) → renal-adjusted dosing (500 mg IV q24h) for first 24h.",MEM_IV,NA,NA,2026-02-08T05:01:07Z
228,OK,1,6e4b28ac0b1073334157fbfafe8d20844fd9e28825d6cba97e200ec63cbbc737,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_08ab8b95dec9dc0e016987803052ac8196b39c2ecf471c24c6,1770487856,2006,234,5be8444f516a155271a997d92bb986fccf11eadfe59714f22d79c69d9f29bf21,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 2.25 g
DRUG_1_INTERVAL: q8h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset pyelonephritis with high severity (MV/NIV, ICU transfer) warrants broad IV Gram-negative coverage including Pseudomonas.
- No major MDR/MRSA history or recent healthcare exposure, so avoid routine MRSA/CRE agents; TZP provides Enterococcus faecalis and anaerobe coverage if complicated UTI.
- Renal adjustment for severe CKD (eGFR 9): reduced TZP dose/interval for first 24h.",TZP_IV,NA,NA,2026-02-08T05:01:07Z
229,OK,1,7c577ad6e57d924729b1bce762201ed590f35f6a4ca3c7c9215663a804123b49,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0b19022e0ab078f701698780314f2c8197867339118ee87105,1770487857,1998,244,5359687cdae17acca30a164195d69aec8a162076be33314189057e84a22f1d03,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Moderate community-onset pneumonia with respiratory failure and marked inflammation (WBC 15.3, CRP 311.5) warrants empiric antibacterial coverage despite positive viral screen.
- Ceftriaxone + azithromycin provides standard CAP coverage (S. pneumoniae, H. influenzae, atypicals) without unnecessary MRSA/ESBL/Pseudomonas coverage given no MDR risk factors.
- eGFR 78: no renal dose adjustment needed for this 24h empiric regimen.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
230,OK,1,7e6aee4cb961f7a3e3b084750714e5884fc20d4d99c34c0e62c6c1b7fbd116c4,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_079e8ce72e5547200169878033350c81a29b22a4ab1ca64ec2,1770487859,1971,224,0d14e767c26a8dc92aea11aa64bd5d7fdc9ceac8828f1c110428b523e7cd9541,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset moderate CAP with respiratory failure: ceftriaxone + azithromycin provides standard empiric coverage for typical and atypical pathogens.
- No MDR/MRSA risk factors and no shock/ICU/vasopressors: avoid broader antipseudomonal or anti-MRSA therapy in first 24h.
- eGFR 95: no renal dose adjustment needed for this regimen.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
231,OK,1,2adccf7252827c1b0ec3f544ce174c4e0f864769ffb5b6d1e6ded5a77dc12057,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0011a2f49c6de968016987803468a481958e80c8835ce5b1bb,1770487860,1975,217,f41e9c0926d5872102c6f9f213c031971ef3208dc713b6dcabc4474a66a9f331,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q8h (extended infusion; renal-adjusted for eGFR 46)
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Severe COPD infectious exacerbation with respiratory failure requiring MV/NIV and elevated CRP → empiric IV therapy warranted.
- TZP provides broad community-onset coverage including Pseudomonas (notable local prior) and typical Gram-negatives/anaerobes without routine MRSA coverage (no MRSA history/risk).",TZP_IV,NA,NA,2026-02-08T05:01:07Z
232,OK,1,3df7c4c01ac099729c355a4aa98d856a5f29e96671ef1ca7355fa757112b3fa2,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_060d5d402c90ba160169878035032c81a0adfd3665edaf7278,1770487861,1995,244,10d98df15217d2bf5f776c902b61e620632d7b6e6076fb8475c5bd2d467ae7f0,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h (renal function unknown)
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset pyelonephritis with marked leukocytosis/CRP; ceftriaxone provides appropriate empiric Gram-negative coverage (E. coli/Klebsiella) without unnecessary antipseudomonal breadth.
- No MDR risk factors or prior ESBL/CRE history; avoid carbapenem/anti-MRSA therapy.
- CKD (eGFR 25): ceftriaxone generally does not require renal dose adjustment, avoiding nephrotoxic aminoglycosides in advanced CKD.",CRO_IV,NA,NA,2026-02-08T05:01:07Z
233,OK,1,25599a5bb00048041275c6d121c892678cd3d44da45e4cd995ec21f56f07cb8c,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_082d590d01a4b3bd0169878036706c8194b216a7d437593bb1,1770487862,1996,228,a043f6139804ecb6c2a487afcbb69349cdded9f17440e4a75a4c9c3354b8c7cf,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with respiratory failure and marked inflammation (WBC 16.8, CRP 318.6) warrants empiric inpatient IV CAP coverage.
- Ceftriaxone + azithromycin covers typical and atypical CAP pathogens; no structured MDR/MRSA risk factors to justify broader or MRSA therapy.
- eGFR ~60: no renal dose adjustment needed for this regimen in first 24h.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
234,OK,1,17fff45dfd8e293b6eaf83e8c0ed76008984a356710882516167746e2491d6b9,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0b162c1d3436bcad0169878037bea4819dafa8402f9b04af05,1770487863,1976,235,8a81e351d1528b7a3904426c0610271f6067d9d7a80ac4c0be97c35e3530ae31,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with respiratory failure (moderate severity): ceftriaxone + azithromycin provides standard empiric coverage for typical and atypical pathogens.
- No MDR/MRSA history or recent healthcare/antibiotic exposure; WBC/CRP low and no shock, so avoid broader antipseudomonal or MRSA therapy in first 24h.
- Renal function normal (eGFR 117); no renal dose adjustment needed.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
235,OK,1,5c5d5739d1e2c89359c700b4af4e2baa00837188d7b92a62b4d38caae8401a61,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_05592c2314c3072001698780389f7c819cab9c74f4a520da16,1770487864,2029,231,0de7996afda32cc0a48877a5445c8ddb3e1010d1e634bb84e171ba5d9f78511f,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset UTI with sepsis and marked inflammation; IV therapy appropriate for first 24h.
- Ceftriaxone provides broad Enterobacterales coverage typical for UTI; no MRSA/ESBL history and no shock/ICU features to justify broader empiric therapy.
- eGFR 27 mL/min/1.73m2: ceftriaxone generally does not require renal dose adjustment; avoids additional nephrotoxicity in CKD.",CRO_IV,NA,NA,2026-02-08T05:01:07Z
236,OK,1,ab3fd98fa76a515ad44f6c1fc3130b5a10f854821313df5404eb3b40644d3865,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0c1c169938b968530169878039c6a88192aba8d297927e490d,1770487865,1990,245,d7aa3a7c4c22d73a44eeb4f94aebbd46c5a59fd0efa501afafd22d5b54f25027,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset UTI with high severity (ICU transfer, lactate 6.6, CRP 141) warrants IV empiric therapy targeting Enterobacterales (local prior: E. coli, Klebsiella).
- No major MDR risk factors (no recent abx/hospital/LTC; no ESBL/CRE history), so ceftriaxone provides appropriate broad Gram-negative coverage without unnecessary antipseudomonal or MRSA therapy.
- Renal function preserved (eGFR 98), so standard dosing used.",CRO_IV,NA,NA,2026-02-08T05:01:07Z
237,OK,1,b04b22657fbdc7ad218f3ae0c6e45439449c6c389949bfd31703733306d71c9d,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0c27e647d36c00dd016987803b18cc81a38bd74e97e0426fa2,1770487867,2045,235,a990c413eabc0b128be879eeb2d3355cb492eba783b947b009e51817cb9ab3f5,1,output[0].content[0].text,,"DRUG_1_NAME: MEM_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q8h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Healthcare-associated sepsis with prior ESBL history and multiple MDR risk factors (LTC, recent hospitalization, antibiotics) → empiric carbapenem for ESBL-active broad Gram-negative coverage.
- Recent ceftriaxone (CRO_IV) exposure before admission increases risk of resistant Enterobacterales; meropenem provides reliable escalation while cultures pending.
- No specific MRSA history and low severity without shock/ICU → avoid routine empiric anti-MRSA add-on in first 24h.
",MEM_IV,NA,NA,2026-02-08T05:01:07Z
238,OK,1,da9bdc7685084caf922ee18f8fb95067134be204fd14de8ef869b2be635c1a57,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0be66a92d6b09f83016987803c27f081a2893bade0039c8016,1770487868,1979,214,319697a0e48e9f34ebc6fc3a10f31652e13be0816eb015bebeb7b55813867e15,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset sepsis/bloodstream infection without shock or MDR risk: ceftriaxone provides broad empiric coverage for common community Gram-negative and streptococcal pathogens.
- Avoids routine MRSA coverage given no prior MRSA/MDR history and low severity; minimizes unnecessary combination therapy.
- Renal function normal (eGFR 98); no renal dose adjustment needed.",CRO_IV,NA,NA,2026-02-08T05:01:07Z
239,OK,1,02302d5247c5bc0c228cc4c7e0df6a86fc8fadd746435daee4fdcf2e22916d7b,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_040fb9bb69afa7f4016987803d87c0819698a6d067dc5a6b0f,1770487869,1982,222,c4840120dc3ea7fe7d8b4a54082ff6e2aefff02e84ce9e06718539a306d84419,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q6h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Septic shock with community-onset COPD infectious exacerbation: broad IV empiric coverage warranted for first 24h.
- TZP provides antipseudomonal and broad Gram-negative/anaerobe coverage; local prior shows substantial Pseudomonas probability.
- No MRSA/MDR history or recent healthcare exposure, so avoid routine MRSA add-on; eGFR 71 → no renal dose reduction needed.",TZP_IV,NA,NA,2026-02-08T05:01:07Z
240,OK,1,625556a105ef5cd5d6e85931374ede4100350650ee5618073d77363bf2bcc2d8,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_099cf49933544b25016987803f117c8192b8abb2411320c614,1770487871,1988,233,283d89655b81d3b33cdb97bc5a02d218d9488094267ac67e71263d9dc0e4bba5,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q6h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Healthcare-associated pneumonia with respiratory failure and high inflammatory markers (WBC 12.9, CRP 176) despite viral screen positive → empiric bacterial coverage warranted.
- Significant MDR risk context (LTC resident, hospitalized and antibiotics within 90d) and local prior shows notable Pseudomonas prevalence → antipseudomonal beta-lactam monotherapy.
- No prior MRSA history provided → avoid routine MRSA coverage in first 24h.
",TZP_IV,NA,NA,2026-02-08T05:01:07Z
241,OK,1,b749e7fac4add823084613f04bb9b6ef8c3f2a21aa38eb09a007313f81765576,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_011d150b72251bf7016987803f964481978fbfd854a85a8cff,1770487871,1980,244,cf6fd563f09b68a541e7dda59e53a035508df43a86b25d56a783217a9d5b7f04,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q6h
DRUG_2_NAME: VAN_IV
DRUG_2_DOSE: 15 mg/kg
DRUG_2_INTERVAL: q12h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Septic shock with healthcare-associated sepsis: broad IV empiric coverage for Gram-negatives (including Pseudomonas) and anaerobes with TZP.
- LTC resident and bloodstream infection context with substantial staphylococcal prior: add empiric MRSA-active coverage with vancomycin.
- eGFR 74 mL/min/1.73m2: no renal dose reduction needed initially; weight-based vancomycin with early level-guided adjustment.",TZP_IV,VAN_IV,NA,2026-02-08T05:01:07Z
242,OK,1,c77f8c245afaf07697d4aab131b8e508531bb1a8fc255b7811e55b5a835b64d0,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_018cc1be0c18a12d01698780412b6c81919d5bf73842e458da,1770487873,1991,225,ed874b99831b97e27ecb3d6cdf111c78916a395b0410b243419a4bfd99c091da,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset pyelonephritis with leukocytosis/CRP elevation but low severity and no MDR risk factors: ceftriaxone provides appropriate empiric Gram-negative coverage (incl. E. coli/Klebsiella).
- eGFR 66 mL/min/1.73m2: no renal dose adjustment needed for ceftriaxone in the first 24h; avoids unnecessary broad antipseudomonal/MRSA therapy.",CRO_IV,NA,NA,2026-02-08T05:01:07Z
243,OK,1,21b9217ff8dab7f170d427cd576fe170e5eed9364b992df5a43f9ecad2383631,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_047ac28081b397f90169878042ec20819fa1c7eccdb13f58b8,1770487874,1973,253,f686ca6fa62be3b6f27df2b585e4e39d18eb9a15c2ea6b3b254f915301310e44,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q12h (renal-adjusted for eGFR ~19 mL/min/1.73m2)
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset pneumonia with septic shock/vasopressors and respiratory failure → broad IV empiric coverage appropriate for first 24h.
- TZP provides coverage for common severe CAP pathogens plus gram-negative rods including Pseudomonas suggested by local ward epidemiology; no structured MRSA risk/history to justify routine anti-MRSA agent.
- Renal dysfunction (eGFR 19) → extended-interval renal-adjusted dosing to reduce toxicity while maintaining early broad coverage.",TZP_IV,NA,NA,2026-02-08T05:01:07Z
244,OK,1,d0c619e86c6df8206d2dff1c0251abaa4362ae979adbbb75fed7ce0d266151a6,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0eb7dc7ef425ab790169878043978c81a1a6dde8c756ecbdee,1770487875,1967,219,3590045e37d0b0d0fdc38caa535cb8a41c04dec9420bf3ef46f408bfb400fc2e,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with elevated CRP but low severity: ceftriaxone + azithromycin provides typical + atypical coverage.
- No MDR/MRSA risk factors and no shock/ICU needs, so avoid broader antipseudomonal or MRSA agents.
- eGFR 119: no renal dose adjustment needed for this regimen in the first 24h.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
245,OK,1,1effb435d4bd9a0c6f13fc9c0576a9c72bb74baac2d139ca00d32f891df8ba49,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0fa797dd13d7478401698780449e2881978318351c9e8a00f1,1770487876,1996,221,543805c4cb24172cc792247f21f5af7c79fe829d78bc1fa433d6b9442ca42a1a,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q12h (renal-adjusted for eGFR 21)
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset pneumonia with septic shock/MV/vasopressors → broad IV empiric coverage appropriate for first 24h.
- Recent antibiotics increases risk for resistant Gram-negatives; TZP provides broad Gram-negative (incl. Pseudomonas) and anaerobe coverage.
- No structured MRSA risk/history provided → avoid routine MRSA agent.",TZP_IV,NA,NA,2026-02-08T05:01:07Z
246,OK,1,279ef2b2d102d85fc2a6df21a980bca7e97f5484f0233e8ae65272da4dfbbd1e,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0efcfd59a73c079b0169878046aad08197906626fbe9c6ecbe,1770487878,1974,211,12f8baa039b90e1672754bf4b1b66432ce05cd2913ca0dede8dd883eb6a5e145,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h (renal function unknown)
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset suspected bloodstream infection with moderate severity and no MDR risk factors: ceftriaxone provides broad empiric coverage for common Gram-negative and streptococcal pathogens.
- Avoids unnecessary MRSA or antipseudomonal coverage given no prior MRSA/ESBL history, no recent healthcare exposure, and no shock/ICU-level instability.",CRO_IV,NA,NA,2026-02-08T05:01:07Z
247,OK,1,0bc21e2aa1509f1fbe6f74275e265799d2c571b5a3cb3ba4cea43b83fc6fc66a,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_063a5e4cfae27e3101698780471618819da30ce64f294febf7,1770487879,2002,215,682bbab0c64ca00dcc37aec98504ae456ecc01f5b633b0960c65808ec42ed58b,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h (renal function unknown)
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset pyelonephritis with sepsis: ceftriaxone provides appropriate empiric Gram-negative coverage (E. coli/Klebsiella predominant) without unnecessary antipseudomonal breadth.
- No MDR risk factors or prior ESBL history; avoid carbapenem/anti-MRSA therapy.
- IV route appropriate given sepsis with respiratory failure flag.",CRO_IV,NA,NA,2026-02-08T05:01:07Z
248,OK,1,020156df46929848aa7f200b8c103b93842b0e4532b9e2be8f6a49216fcb3ccd,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_082b123583c72fa201698780480960819c93892664038fc592,1770487880,1989,246,6671f0230bb925fe0bde071ded4635dfad105e475bebdb56def9a29849bdd213,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with moderate severity/respiratory failure: ceftriaxone + azithromycin provides standard empiric coverage for typical + atypical pathogens.
- No MRSA or ESBL/CRE risk factors and no recent antibiotics/LTC exposure, so avoid routine VAN/linezolid and antipseudomonal escalation.
- eGFR 62 mL/min/1.73m2: no renal dose adjustment needed for ceftriaxone or azithromycin in first 24h.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
249,OK,1,c60349fc6aca01937fe67c411f8d805dfefe66f4cfc77b70cb0ee0a91f894571,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_00b472c3bf845990016987804a3dec819395bc94ae914286c5,1770487882,1975,226,f4e20eaae5f397408757603e66d3e2ae858b884129acceab71fd51e436f82f3e,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with respiratory failure (moderate severity): ceftriaxone + azithromycin provides standard empiric coverage for typical and atypical pathogens.
- No MDR/MRSA risk factors and low inflammatory markers: avoid broader antipseudomonal or anti-MRSA therapy in first 24h.
- eGFR 54: no renal dose adjustment needed for ceftriaxone or azithromycin.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
250,OK,1,75f75d14502c7fd265d807292d5a0d4b9b61bac02df81a22da4c39cd09d5cf9d,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0b09e9300bf39dfb016987804a9550819dafb799d42be2b40c,1770487882,2058,235,dfc9bbbee957a2d523c61e7edf9d5f54c1dea027737461ee28557462a3500448,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with low severity but elevated lactate; provide standard inpatient CAP coverage for typical + atypical bacteria.
- Viral screen positive and low inflammatory markers lower bacterial probability, but age/comorbidities and prior outpatient levofloxacin exposure support continuing empiric non-fluoroquinolone coverage pending cultures.
- No MRSA/ESBL history and no recent hospitalization/LTC, so avoid routine MRSA or broad antipseudomonal therapy.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
251,OK,1,486659f999b2b8443dc32b40b42a410e7fc8d8cf876bcb6a44d90734df524ead,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0441fee3149101da016987804bb18c81938093f98faf026aa2,1770487883,1970,223,78c985d73d60ae2c23793743f5e618d80053cb4e36692dbe770c57973e173f66,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset COPD infectious exacerbation with moderate severity (respiratory failure) and mild leukocytosis/CRP: cover typical + atypical respiratory pathogens.
- No MDR/MRSA history or recent healthcare/antibiotic exposure: avoid routine anti-MRSA and antipseudomonal therapy in first 24h.
- Normal renal function (eGFR 101): standard dosing appropriate.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
252,OK,1,518bb2a4774fbe76f296a9065b3b2cd45e9192f626ac646b65b8a3a342041e3b,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_004fe1a3527eb993016987804d7b0c81938b05368f1b90c8a9,1770487885,1973,229,12f5c82c61ce565ea2ab5a43e1b3e469d7b136c4ae0d467bd89f5679268fe6cc,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset UTI with marked leukocytosis but low severity and no MDR risk factors; ceftriaxone provides appropriate empiric Gram-negative coverage for typical uropathogens (E. coli/Klebsiella/Proteus).
- Avoids unnecessary broad antipseudomonal or MRSA therapy given no shock/ICU needs and no prior ESBL/MRSA history.
- Renal function normal (eGFR 112); no renal dose adjustment needed.",CRO_IV,NA,NA,2026-02-08T05:01:07Z
253,OK,1,840074f9bb6af0dd00bca118257e1e4c9c31b1d8e2f8f474a8509cc4ae2fdd66,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0a873a8d09b3fa60016987804e23d4819ea19ca7d92f38a4a9,1770487886,1976,250,dfdb309a41d302e1e94cd9a467cc62e413346b33695ae117b0f3760cf30fc6a7,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q8h (extended infusion; renal-adjusted for eGFR 46)
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- High-severity community-onset COPD infectious exacerbation with MV/NIV + ICU transfer and elevated WBC/CRP → start IV broad-spectrum therapy.
- Recent hospitalization and local prior with notable Pseudomonas probability support antipseudomonal beta-lactam; TZP provides Pseudomonas and typical respiratory Gram-negative/anaerobe coverage.
- No prior MRSA history and no structured MRSA risk flags → avoid empiric MRSA agent in first 24h.",TZP_IV,NA,NA,2026-02-08T05:01:07Z
254,OK,1,d19e1848e18fc398b1f0375bda8a8982338509ff0b806269e4b42dcecf528032,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_06ce7778c06a97cb016987804eda08819e9d8de5a5668bd898,1770487886,1975,229,ddc0b4587b1fda9f2cd504c15f016fb9fcb6795f0537ca02848159bdba789ddd,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h (renal function unknown adjustment not required; eGFR 19)
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset sepsis/bacteremia without MDR risk factors: ceftriaxone provides broad empiric coverage for common Gram-negative and streptococcal causes.
- Avoids nephrotoxic combination therapy (eGFR 19) and no structured MRSA risk/history to justify routine glycopeptide/linezolid.
- IV-only regimen selected due to respiratory failure severity flag.",CRO_IV,NA,NA,2026-02-08T05:01:07Z
255,OK,1,bf9ef53afc540c708040beeaed83ae34e0fbf7a4b4bf8cb3bb865ea5443a1052,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_09e999b036316a650169878050f930819fb480d40367ade178,1770487888,1988,224,b1eba85f279e400f5b9c1e510e5802140cdb4b3a2bdebd284f999d4abb727adf,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h (renal function unknown)
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with respiratory failure and very high CRP: empiric beta-lactam + macrolide for typical + atypical coverage.
- No MRSA/ESBL/CRE risk factors provided, so avoid routine MRSA or carbapenem therapy.
- Use IV agents given respiratory failure; ceftriaxone dosing acceptable at eGFR ~30 without adjustment.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
256,OK,1,dbdd78bd7d60e165246ea1d3be605b3c8b1a2ea6c60fd7e3f40ec39c6c5c452d,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0c5d9a0e426bd84a0169878052205c81a2ad95350750cf12cc,1770487890,2019,210,d26e68aa624dda58daed86c524701204f5ccc28e8e4db7fdebf08a20371f2fa9,1,output[0].content[0].text,,"DRUG_1_NAME: MEM_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h (renal-adjusted for eGFR 16)
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Septic shock with MV/vasopressors in community-onset pneumonia → immediate broad IV therapy.
- Prior ESBL history + recent hospitalization/antibiotics → carbapenem empiric coverage favored for ESBL Enterobacterales.
- No documented prior MRSA → avoid routine MRSA agent in first 24h.",MEM_IV,NA,NA,2026-02-08T05:01:07Z
257,OK,1,c7be74f5fa65f11272e36cf36ea3e1d11facfc2c98838ab4fa9dbdc94c08202b,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_01de769d16a9514c0169878052858481918d877be9fabac27c,1770487890,1970,255,268e251974786384fff00f52bedc4078d26604adb26a9eebe4ac09965ef139ac,1,output[0].content[0].text,,"DRUG_1_NAME: FEP_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h (renal-adjusted for eGFR 23)
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Severe community-onset pneumonia with respiratory failure/MV → IV empiric therapy covering typical pathogens; cefepime provides broad Gram-negative coverage including Pseudomonas (notable local prior).
- Add azithromycin for atypical coverage in CAP and potential immunomodulatory benefit; no structured MRSA risk factors to justify routine anti-MRSA therapy.
- Avoid aminoglycosides given CKD (eGFR 23) and nephrotoxicity risk; cefepime dose renal-adjusted.",FEP_IV,AZM_IV,NA,2026-02-08T05:01:07Z
258,OK,1,a78350f00a151109bd54250ccf313319bc185b0ad65c7995b33520eea78aeac8,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0bf0f7a26d890b2e0169878054a938819ebf848b935517182a,1770487892,1975,238,9359e13a36bedfac9e9d5f3ee00fad4db1e68683427c3bae461ee47c9f5d70f9,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with respiratory failure and elevated CRP → empiric inpatient CAP coverage with beta-lactam + macrolide.
- No MDR/MRSA risk factors and no septic shock/ICU/vasopressors → avoid routine anti-MRSA or antipseudomonal therapy.
- eGFR 75 mL/min/1.73m2 → no renal dose adjustment needed for ceftriaxone/azithromycin in first 24h.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
259,OK,1,81e2db3ef7c7258b1213d1cf25588586cf4d44e083bd9ac2e4cf0850f5cd5702,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_040be356bca6334a01698780557cb081a282e6eff703b70a29,1770487893,1440,211,38406525f4def660a69fcd64c6cf9048d8219f61fac7fb202a553c7df5abbc08,1,output[0].content[0].text,,"DRUG_1_NAME: VAN_PO
DRUG_1_DOSE: 125 mg
DRUG_1_INTERVAL: q6h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Healthcare-associated acute diarrheal disease with recent antibiotic exposure and hospitalization increases likelihood of C. difficile; oral vancomycin provides targeted empiric therapy.
- No sepsis/shock or ICU-level supports; avoid unnecessary broad systemic antibacterial coverage in first 24h.
- eGFR 64: no renal dose adjustment needed for oral vancomycin (minimal systemic absorption).",VAN_PO,NA,NA,2026-02-08T05:01:07Z
260,OK,1,427cc631ec53e91b80d28300b895e99358cd6f9569d781046031153db5a5a045,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0a18f484013720460169878056b6088194a0a0bc4fe3370958,1770487894,1971,232,5e492cc68c6b1b7e4ca6657bf64d8a8e0300d8188b3bbde1529c1da11d048921,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Severe community-onset CAP with respiratory failure requiring MV/NIV → IV beta-lactam + macrolide for typical + atypical coverage in first 24h.
- No MDR/MRSA history or recent healthcare/antibiotic exposure → avoid routine MRSA or broad antipseudomonal therapy.
- Normal renal function (eGFR 93) → standard dosing; ceftriaxone 2 g daily appropriate for severe CAP.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
261,OK,1,2ff72e909d7118ba681be1c7eaeff73c14dcc8c5aee0e56bbc38185b61bb38e9,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_045cc4cafdeee5170169878058326081908656518d618a9815,1770487896,1977,241,e6371d3ec41ba464535d2b87697fac36af9a62fd96438b748c88178a123231d9,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset UTI with moderate severity and elevated CRP; ceftriaxone provides broad empiric Gram-negative coverage for likely Enterobacterales (local prior: E. coli, Klebsiella) without unnecessary antipseudomonal breadth.
- No MDR risk factors or prior ESBL/CRE/MRSA history, so escalation to carbapenem or MRSA agents not supported.
- eGFR 95 mL/min/1.73m2: no renal dose adjustment needed for ceftriaxone.",CRO_IV,NA,NA,2026-02-08T05:01:07Z
262,OK,1,cb1de4df0e13090c424f1bf7818c8c73577805172cf49bda1efdca75d3a2850b,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_05938fe5f034c1bb0169878058a90c8195857fae37f5fa6387,1770487896,1997,237,338c06f1f77c5a5e97be6503e1cab139d8344c9b27972afc00766b2a2254512c,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with documented respiratory failure (moderate severity): IV beta-lactam + macrolide for typical + atypical bacterial coverage in first 24h.
- No MRSA or ESBL/CRE risk factors and low inflammatory markers with positive viral screen: avoid broader anti-MDR therapy and avoid routine MRSA coverage.
- Renal function preserved (eGFR 83): no renal dose adjustment needed for ceftriaxone/azithromycin.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
263,OK,1,95a050d2389b0007c7fd3a06bf7fd07455f9be0d55189b43df3e8c00f39641e9,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_082f384a25ae2bd5016987805a424881a2b364a4a181824559,1770487898,1997,231,c1b388fe576b659de50ea05e5bb17123c487928ba0c3bfbcccee5338fd292819,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q6h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Severe community-onset pneumonia with septic shock/MV/vasopressors → broad IV empiric coverage including antipseudomonal beta-lactam.
- Add azithromycin for atypical coverage in severe CAP; no structured MRSA risk/history to justify VAN/linezolid.
- eGFR 90 mL/min/1.73m2 → no renal dose adjustment needed for first 24h.",TZP_IV,AZM_IV,NA,2026-02-08T05:01:07Z
264,OK,1,6f77cfc08b66dcacca2f2738e55bd2d7f8ae0c716d49a2679d37cb2b3cd2846d,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_03a5e5968480ae1e016987805bbc3081978b47126019572c62,1770487899,1968,230,2ef4a1f528931a91be11c67a1713ceea9633be8e9f132e5f26b3ff9b6137ea94,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with leukocytosis/CRP elevation; ceftriaxone + azithromycin provides standard empiric coverage for typical + atypical pathogens.
- Low severity and no MDR/MRSA risk factors → no need for antipseudomonal or MRSA agents in first 24h.
- Renal function normal (eGFR 104) → standard dosing; monitor LFTs given mild transaminitis.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
265,OK,1,1f742652dc0a2d6db0ff7beeda9a846cd7be33ce357043b67e2f418b17eb7840,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_06fae11db41c2ffd016987805c3dd0819780ec38790dd60719,1770487900,1973,232,f37206a5e43f10851b2dde89ee7a0cc6a78fa3712b6799d40827d606cc64353e,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with respiratory failure and markedly elevated CRP: empiric inpatient CAP coverage with ceftriaxone + azithromycin.
- No MDR/MRSA risk factors and no septic shock/ICU/vasopressors: avoid routine anti-MRSA or antipseudomonal therapy.
- eGFR 85 mL/min/1.73m2: no renal dose adjustment needed for this first-24h regimen.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
266,OK,1,4c8567ba5297fbc88a61fd79a7ac075df826492c581e966b5f33e1b6295d2014,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_05ca0571eba048b0016987805dc1688197a0e21052a05348d3,1770487901,1981,265,ea9564446398c5a494a5b5a760a809603fa719b1deae8d7ff2213b313e37aadf,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h (renal function unknown adjustment not required; eGFR 14)
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with sepsis/respiratory failure and high WBC/CRP: empiric IV beta-lactam + macrolide for typical + atypical coverage.
- No MRSA or ESBL/CRE history and no recent healthcare/LTC exposure: avoid routine MRSA or carbapenem therapy.
- Severe CKD (eGFR 14): ceftriaxone and azithromycin are suitable without renal dose reduction; avoid nephrotoxic add-ons (e.g., aminoglycosides).",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
267,OK,1,7b090f675f475ab53da48d54ee1808995c47de10773f83b1be678339bebf69cc,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0bdc373724ff654b016987805f6ee081939c2161f0354fd1e5,1770487903,1991,230,596a4c8c2375e0cc841377d469312032c92e6106b63b9b4174c5f2f137fdbd79,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset suspected bloodstream infection with leukocytosis/CRP elevation; ceftriaxone provides broad empiric coverage for common Gram-negative and streptococcal pathogens with low MDR risk.
- No septic shock/ICU needs and no MRSA/ESBL history, so avoid routine MRSA coverage and unnecessary combination therapy.
- eGFR 77 mL/min/1.73m2: no renal dose adjustment needed for ceftriaxone.",CRO_IV,NA,NA,2026-02-08T05:01:07Z
268,OK,1,83de5ad6944407a7230f2f8bb09044dadac5a7180347a8d94ed3b7e014a68e0a,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_09ee6e904720452401698780608aec819fb7dc4dbff4cbdbc7,1770487904,1969,229,149988de47579792b8e6bced8b1853f8e1152566046324b0f81c7d1a29b9c774,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q6h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset pneumonia with septic shock/MV/vasopressors → broad IV empiric coverage including antipseudomonal beta-lactam given high severity and local Pseudomonas prevalence.
- Add azithromycin for atypical coverage and potential benefit in severe CAP.
- No MRSA risk factors documented (no prior MRSA; no recent healthcare/LTC exposure) → avoid routine MRSA agent.",TZP_IV,AZM_IV,NA,2026-02-08T05:01:07Z
269,OK,1,5e4e95b065232e65369257175e2a37300c6a762b03f77a5e2a8f1ff47c935aac,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_076136b644199b840169878061be2c81a2afd3bd1b4f5637f1,1770487905,1982,247,b3713729d0a5516a4e5ac6fc6869dd0a1078751f60f63ccade430ff7b9cdbfaf,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with respiratory failure and markedly elevated CRP/WBC → empiric IV beta-lactam + macrolide for typical + atypical coverage.
- No MRSA or ESBL/CRE risk factors and no septic shock/ICU/vasopressors → avoid routine MRSA or antipseudomonal therapy.
- eGFR 75 mL/min/1.73m2 → no renal dose adjustment needed for ceftriaxone/azithromycin in first 24h.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
270,OK,1,2827aa3799d0c1ae746adf039dda6066c1b13f507f38525e167c366d456620b2,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_05932808accd519b0169878062ccec8190865e392e3356b755,1770487906,2010,227,c05e31617b6a3e073aafc878b2dfbe9059fbfdbbe894fa160526e3c1c6f3b385,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q6h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Severe community-onset pneumonia with septic shock/MV/vasopressors → IV broad-spectrum beta-lactam appropriate for first 24h.
- No documented prior MRSA/ESBL/CRE/VRE history and no recent healthcare/LTC exposure → avoid routine MRSA or carbapenem empiric coverage.
- eGFR 91 mL/min/1.73m2 → no renal dose adjustment needed for initial dosing.",TZP_IV,NA,NA,2026-02-08T05:01:07Z
271,OK,1,3b7556cd988c0195b271d92a505edf78c1180610addff2c4d3a0356a0edada16,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_019f489afc62f4d50169878063cfbc819fbc044554f0134c64,1770487907,1985,254,01d6d8363bb1ad1f118165a7a994bb29192f50a811b9b566d8998e1b4c8a8145,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h (renal function unknown adjustment not required; eGFR 20 noted)
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset pneumonia with moderate severity/respiratory failure: ceftriaxone + azithromycin provides typical + atypical CAP coverage.
- No prior MRSA/ESBL history and no recent hospitalization/antibiotics; LTC alone does not mandate empiric MRSA or carbapenem therapy.
- Avoid nephrotoxic agents (e.g., aminoglycosides) given CKD with eGFR ~20 mL/min/1.73m2.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
272,OK,1,7fa6249341ad8d680ec152cdd32608f08a27be34f027b4a5013a8376a57658af,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0cb2006f9bf2427201698780660c0881a2ae7fac19e9b08ae6,1770487910,1972,225,238a1cd6a1205a51bb26221170402886438a4db1a0d6d29db1679969f3d48454,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset COPD infectious exacerbation with moderate severity/respiratory failure and elevated CRP: cover typical respiratory pathogens plus atypicals.
- No MRSA/ESBL/CRE risk factors and no shock/ICU/MV: avoid routine MRSA or broad antipseudomonal therapy in first 24h.
- eGFR 95: standard adult dosing (no renal adjustment needed).",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
273,OK,1,f50183964fcaa007731b12df9a7cae7ba0e2a2e88be71f453eea81c37da8b0a0,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0d99c8bc02a8322001698780669bfc819dbd5474c5f89bcfee,1770487910,1983,235,87100b77bfbad7d5938f0d9840fbf0eec083d5286c49b1d38fed5f50c26ee687,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with respiratory failure (moderate severity): IV beta-lactam + macrolide for typical + atypical coverage.
- No MDR/MRSA risk factors and no septic shock/ICU needs: avoid routine anti-MRSA or antipseudomonal escalation.
- eGFR 58 mL/min/1.73m2: no renal dose adjustment needed for ceftriaxone or azithromycin in first 24h.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
274,OK,1,be737fe08bf72bfe12a58cb2cb31cbdf1a777f6336ed1901e98c2a5c60ede98d,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0dde4a6e27c906e90169878067dfb0819d801525a05d848625,1770487911,1971,218,8e256cf453b1fffe930ad3cf1c45cd49c3d311fb0584ee1a1bc8d499fbbc6734,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with elevated CRP; ceftriaxone + azithromycin provides empiric coverage for typical pathogens plus atypicals.
- Low severity and no MDR/MRSA risk factors → avoid broader antipseudomonal or anti-MRSA therapy.
- Renal function normal (eGFR 108): no renal dose adjustment needed for this 24h regimen.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
275,OK,1,5f05923bd9937ee72b6066f057606525386cff4d0724146e19827e9b4e3e8c76,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0744b1cfa85e652601698780692a1881a2abded780162b4223,1770487913,1984,234,09a7d1788df92f31e58b0cca95cb5f808aa9e045fbcd1e2c235e0ee670ccab3b,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Moderate community-onset CAP with respiratory failure and very high CRP: empiric inpatient CAP coverage with ceftriaxone + azithromycin for typical + atypical pathogens.
- No MDR/MRSA risk factors and no shock/ICU/ventilation: avoid routine anti-MRSA or antipseudomonal therapy.
- eGFR 86: no renal dose adjustment needed for ceftriaxone or azithromycin in first 24h.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
276,OK,1,01fe61bd77a5bb737d5e4b4bf08f4a292db62ded3982c8bac527971bf4f80553,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0ed41491239df6d9016987806abc88819c9571896930b16c85,1770487914,1489,221,9e369f72f3f6a635e9b9a59ce798e2638fdcdb08ee53a80a9be27c7870d7d17c,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 2.25 g
DRUG_1_INTERVAL: q8h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Septic shock with healthcare-associated intra-abdominal infection: broad empiric IV coverage for enteric Gram-negatives, streptococci, and anaerobes.
- No structured MRSA/ESBL/CRE history; avoid routine MRSA or carbapenem escalation in first 24h.
- Severe renal impairment (eGFR 5): renal-adjusted TZP dosing selected for initial 24h.",TZP_IV,NA,NA,2026-02-08T05:01:07Z
277,OK,1,3c60eac922b0a085e0af79e4389734358656b7ebce219cbbc52be1c08d34e827,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0a314a5f4e7912cc016987806b8df481a1abd496068aa6c4e3,1770487915,1993,239,c7a551e1a71e9b5f7138ca288764bc8a1c1281130866554abf77bd7e0efa8755,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q8h (extended infusion; renal-adjusted for eGFR 43)
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Severe community-onset pneumonia with respiratory failure requiring MV/NIV and very high CRP → empiric IV broad coverage warranted.
- LTC resident with hospitalization in last 90d and local prior showing substantial Pseudomonas probability → antipseudomonal beta-lactam (piperacillin-tazobactam) appropriate.
- No prior MRSA history provided → avoid routine MRSA agent in first 24h.",TZP_IV,NA,NA,2026-02-08T05:01:07Z
278,OK,1,867ffeb9acd499ba6be1dac41468939b2b647175baa58cc150c3d90b0e1e0372,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_00e06726058e85a8016987806ccd608197a4be269fef431128,1770487916,1983,199,07b08588872abc593a84015be5e973a2319c31df8140d396d021aa7fefe216a0,1,output[0].content[0].text,,"DRUG_1_NAME: SAM_IV
DRUG_1_DOSE: 3 g
DRUG_1_INTERVAL: q6h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset SSTI with sepsis and marked leukocytosis/CRP: needs IV empiric coverage for streptococci and MSSA plus some Gram-negative/anaerobe coverage.
- No MRSA/MDR risk factors documented, so avoid routine MRSA agents; eGFR 93 allows standard dosing.",SAM_IV,NA,NA,2026-02-08T05:01:07Z
279,OK,1,7e557354e63feba38483c74713c83a57f5caf4c7912113ff2d11f510b8739825,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0d7c92fe1c64251f016987806e6aec819e9876131e2b702bb4,1770487918,1983,231,1780bb74438a3a225396997de67ad05316cffdc0fec79094303d67f385527b67,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q6h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset COPD infectious exacerbation with respiratory failure and elevated lactate; start IV broad Gram-negative coverage including Pseudomonas (local prior Pseudomonas ~0.23).
- No MRSA history/exposure and no recent healthcare/antibiotic risk factors, so avoid empiric MRSA agent.
- eGFR 72 mL/min/1.73m2: no renal dose adjustment needed for first 24h at standard dosing.",TZP_IV,NA,NA,2026-02-08T05:01:07Z
280,OK,1,02e74e6d16781a3eb0d5cb8bd4b8ee28cf5fb685967f180bbd4fe9eddb2604b4,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_06d3ef40961641f5016987806f32cc8197a7a92aa2319610f9,1770487919,1989,219,06c2a4b897995eb12cc96ef21d8f53dfd4d32290271e77980b4b0aee31e895e3,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q6h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Severe community-onset pneumonia with septic shock/MV/vasopressors → broad IV empiric coverage including antipseudomonal Gram-negative and anaerobe activity (TZP_IV).
- Add atypical coverage for severe CAP (AZM_IV).
- No documented MRSA/MDR risk factors → avoid routine MRSA agent in first 24h.
",TZP_IV,AZM_IV,NA,2026-02-08T05:01:07Z
281,OK,1,6bc3b34adfd146146b3106ba4dd3eb5685b0df508f03cdec84a5b7565ced2b6a,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0eebe1b66a58d530016987806fdfac81958dc7c20c10888b34,1770487919,2005,230,d4e0a97f33834e9527a06d71df1a45daf09293b20e1774c982de80d0ace92e14,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q8h (renal-adjusted for eGFR 31)
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Severe community-onset pneumonia with septic shock/MV/vasopressors → broad IV empiric coverage including antipseudomonal Gram-negatives and anaerobes (TZP).
- Add atypical coverage for CAP in critical illness (azithromycin).
- No MRSA history or recent healthcare/LTC exposure provided → avoid routine empiric MRSA agent.",TZP_IV,AZM_IV,NA,2026-02-08T05:01:07Z
282,OK,1,f5b2fffd42071a839bbe5e784b9705b75adf3a9447e3951efa449cc819696229,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0f8dc67ef1f4f2cc0169878072216c8192b33012dff8e51f4e,1770487922,1990,229,c42379b2e2b3ba8acd2be8f5cf584493aaad7098afa94fc5519b37da20276609,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 2.25 g
DRUG_1_INTERVAL: q8h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Severe community-onset pneumonia with respiratory failure requiring MV/NIV and ICU transfer → IV broad empiric coverage appropriate for first 24h.
- No MRSA history or major MDR risk factors → avoid routine MRSA agents; TZP provides broad Gram-negative (incl. Pseudomonas) and anaerobe coverage.
- Renal adjustment for eGFR 13 mL/min/1.73m2 applied (reduced dose/interval).",TZP_IV,NA,NA,2026-02-08T05:01:07Z
283,OK,1,d30d03499fe4d51d13c0ca5aea7b3cc06dff370c465b0b3140001865ba875960,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0546979aade29793016987807269c4819cb858a8009a13762d,1770487922,1984,236,d42bca201d402ee4af00d59ca769089f34c010152bfad408f8acc97ef6c079c0,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q12h (renal-adjusted for eGFR 26)
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Septic shock with MV/vasopressors from community-onset pneumonia: broad IV beta-lactam with antipseudomonal activity plus atypical coverage for first 24h.
- No MRSA history or recent healthcare/antibiotic exposure documented, so avoid empiric MRSA agent.
- TZP dose interval adjusted for reduced renal function (eGFR 26).",TZP_IV,AZM_IV,NA,2026-02-08T05:01:07Z
284,OK,1,946cece076e90f1f42892b67442cb4d721822cdb2882f4ad03ad2c13104e6724,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0889c70c01d3df3c016987807425ec819db097338968b7a05c,1770487924,2079,229,3a086e073ad90e99357a16c67f159f925c946d6f050742b15d9081eb9d823c39,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q6h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset COPD infectious exacerbation with respiratory failure and prior home amoxicillin/clavulanate exposure → broaden to IV antipseudomonal beta-lactam for first 24h.
- Covers common Gram-negatives including Pseudomonas (notable local prevalence) plus typical respiratory pathogens; no MRSA history/risk so avoid routine MRSA agent.
- Renal function preserved (eGFR 86), so standard dosing.",TZP_IV,NA,NA,2026-02-08T05:01:07Z
285,OK,1,f2c60118c0f9b92b10208c46241b87512bd2121484568a81fa223fa05018242b,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_008310440f0044fd01698780757850819e9555a7dde1e3007d,1770487925,2070,229,b872acf982dad773fc84029923b74d11639a86efc1ce44c6e71ab9a552b976f8,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q12h (renal-adjusted for eGFR 18)
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Septic shock with community-onset sepsis: broad IV empiric coverage for Gram-negatives and streptococci/anaerobes.
- No major MDR/MRSA history or recent healthcare exposure; avoid routine MRSA add-on.
- Prior home cefuroxime (CXM_PO) suggests possible partial pretreatment; escalate to broader IV beta-lactam for first 24h.",TZP_IV,NA,NA,2026-02-08T05:01:07Z
286,OK,1,332302e9e81b60be8db27d63915166ca1b2138481e90a56bc0731a01e9ce391d,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_03ee8058ba4508200169878076469881a3a6a0ccac60ec00c9,1770487926,1988,223,bbaea75e916d6216cb252fe9c9881f3580f7191326cf68f4d9f76af442244f72,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with respiratory failure and elevated PCT supports empiric antibacterial therapy; IV route appropriate.
- Ceftriaxone + azithromycin provides standard CAP coverage (typicals + atypicals) without unnecessary broad antipseudomonal/MRSA therapy given no MDR/MRSA risk factors.
- eGFR 70: no renal dose adjustment needed for this regimen in first 24h.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
287,OK,1,92e32a19540f44da0d9f332e8c75ead40b36d4da668136a940e15b10297c85a4,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0d0ed8d74e3eb1960169878077773081a1b0126efd46af4ad5,1770487927,1976,227,be07e4204bbfd8929bc0d38cfd4319ed198298115495b4efd87128d23eb88648,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h (no renal adjustment needed at eGFR 54)
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset pneumonia with respiratory failure and very high CRP; empiric CAP coverage with ceftriaxone + azithromycin.
- No structured MDR risk factors or prior MRSA/ESBL history to justify routine anti-MRSA or anti-pseudomonal therapy in first 24h.
- eGFR 54 supports standard dosing for both agents.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
288,OK,1,f00f4f84abcf5f86f0fa4d2ddd4e2c11c17444330830d776ce6f4096b5e4012f,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0c52cdf67ef7ca970169878078e12c8195a06dddf0e0dbe117,1770487928,1981,229,dfe775fa1e6f560ae2d80efdbd906aa96a9da7b916ad43378540ea9e12401449,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h (renal function unknown adjustment not needed; eGFR 16)
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset UTI with low severity and no MDR risk factors: ceftriaxone provides appropriate empiric Gram-negative coverage (E. coli/Klebsiella predominant locally).
- Avoids nephrotoxic agents (aminoglycosides) given severe renal impairment (eGFR 16).
- No sepsis/shock or Pseudomonas/MRSA risk to justify broader combination therapy.",CRO_IV,NA,NA,2026-02-08T05:01:07Z
289,OK,1,49bc0f3b3f37a5f93ada104d65bdf22684a432fe645b75e206ed340d614a1f5e,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0c0908ab6347e2ef01698780798f1081a093fe2007be8de5ab,1770487929,2009,214,b2c317401fbd2ceb4b47d096b9166077a3d656037047e8501a9c8091def18c1c,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 2.25 g
DRUG_1_INTERVAL: q8h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Severe community-onset pneumonia with septic shock/MV/vasopressors → IV broad empiric beta-lactam coverage appropriate for first 24h.
- No structured MDR/MRSA history or recent healthcare exposure → avoid routine MRSA/additional combination therapy.
- Dose adjusted for eGFR ~7 mL/min/1.73m2 (advanced CKD).",TZP_IV,NA,NA,2026-02-08T05:01:07Z
290,OK,1,ac07db7bbb994e5d0ac3412cba0fab9a238d28c7356886d15b84f85df583874f,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_04be6cf55565d728016987807b1fdc819486dc62a165969f73,1770487931,2006,237,a44b55558646cb8fa3c06ea47f713c252624b989ba8ed867d2e9f9c36ccc4b0a,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q6h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Severe community-onset pneumonia with septic shock/MV/vasopressors → broad IV empiric coverage including antipseudomonal beta-lactam.
- Add azithromycin for atypical coverage and potential benefit in severe CAP; no MRSA history/risk provided so avoid routine MRSA agent.
- eGFR 58 mL/min/1.73m2: no renal dose adjustment needed for first 24h at standard dosing.",TZP_IV,AZM_IV,NA,2026-02-08T05:01:07Z
291,OK,1,8e21b21cf49a540db9e3aa8ab83163219745f3b5f237e1d475ba045d12221c77,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_02e4d3c9b92de70c016987807cb3dc8191b39a9d1be572603f,1770487932,1974,212,da31e522d8cca0e06368f111a3254aa8a3ad88dbf1238ffde8c5333d70458477,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with respiratory failure and very high CRP; empiric inpatient CAP coverage with beta-lactam + macrolide.
- No MDR/MRSA history or recent healthcare/antibiotic exposure; avoid routine MRSA/antipseudomonal therapy.
- Normal renal function (eGFR 96): standard dosing appropriate.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
292,OK,1,cb478636488af357aaac74252bacdae646123bbeb61ce7d3c013483bde888f9d,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_05b22bbb669e3088016987807d022c8196b6362effdffb4854,1770487933,1976,207,da4bd40ed5475a5b1de455cf65da5aab09975f828717acbb4a5efa3958b2794b,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset UTI without sepsis/shock and no MDR risk/history: ceftriaxone provides appropriate empiric Gram-negative coverage while avoiding unnecessary broad antipseudomonal/MRSA therapy.
- Severe CKD (eGFR 18): ceftriaxone generally does not require renal dose adjustment, simplifying safe first-24h empiric therapy.",CRO_IV,NA,NA,2026-02-08T05:01:07Z
293,OK,1,b1bc3e77028443a605db7a29ffe370676b8d1722cae06c5f53c18b1ea439de15,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0203af8211fee966016987807e9dfc81929c92750cf3dbdb17,1770487934,1973,233,675c4cef13fd39e701ab81a4ae6ea608726888036d3b07fa78f9d46f57a80f92,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with leukocytosis/CRP elevation; low severity but inpatient setting supports standard CAP empiric coverage for typical + atypical pathogens.
- No MRSA or ESBL/CRE risk factors and no shock/ICU needs, so avoid routine VAN/anti-pseudomonal broadening.
- eGFR 86: no renal dose adjustment needed for ceftriaxone/azithromycin in first 24h.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
294,OK,1,a937abd818e8307320c2037f45990166df25766cc40b1b531cdf79be0a814695,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0f430923870923be016987807fbfb481a3bfe67db52831f1d0,1770487935,1990,217,ba5025af96c4c080d73bae4333ad8b1a5351017eb8248324beb5e99c7f36150b,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q6h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Healthcare-associated pneumonia with respiratory failure → start IV broad Gram-negative (incl. Pseudomonas) coverage; local ecology shows substantial Pseudomonas prevalence.
- No MDR history/exposures and no MRSA history → avoid routine MRSA add-on.
- eGFR 69 mL/min/1.73m2 → no renal dose adjustment needed for first 24h.",TZP_IV,NA,NA,2026-02-08T05:01:07Z
295,OK,1,15b78409fe7abd4772a96ce0fe846515f36c522ca013201a19f1b83d8eadcf73,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0c7d30e77656f2050169878080284481929ab6b8426982ebee,1770487936,1998,233,dd5a8f4b9b4e10c7909eaa1297c5f25f1219f8f7c324849c658fe4b5cdcb8503,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q6h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Severe community-onset pneumonia with septic shock/MV/vasopressors → broad IV empiric coverage including antipseudomonal beta-lactam.
- Add azithromycin for atypical coverage and potential benefit in severe CAP; no structured MRSA risk/history to justify routine MRSA agent.
- eGFR 76 mL/min/1.73m2 → no renal dose adjustment needed in first 24h.",TZP_IV,AZM_IV,NA,2026-02-08T05:01:07Z
296,OK,1,ec46d850ead2cc60133cc5e14a382abc912dbd436e8cbe1e9c368e1a826c7a26,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_083815fe8d088f1b016987808277f0819f9cb3f183ab575f18,1770487938,1996,234,846e54a6279eb9c35be9f0f2caff411f7318be9883f797e3e7befd65e3fe05b3,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q6h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Severe community-onset pneumonia with septic shock/MV/vasopressors → broad IV empiric coverage including Pseudomonas and other Gram-negatives plus streptococci.
- Recent hospitalization (hosp<=90d=yes) increases risk for resistant Gram-negative pathogens; no structured MRSA history/exposure to justify routine MRSA coverage.
- eGFR 91 mL/min/1.73m2 → no renal dose adjustment needed in first 24h.",TZP_IV,NA,NA,2026-02-08T05:01:07Z
297,OK,1,951bb13b6d2ad56b33077e315fdf45db889d898dab0c30a145d2c59eea4eeee5,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_06ffb33fb3402d5f0169878083aad081a29470c367f44dc1de,1770487939,1984,251,4c668833fcdeca9198aec3c3153bc87d94e84d61d4064069b76edf4064a8e74c,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q12h (renal-adjusted for eGFR 18)
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset COPD infectious exacerbation with septic shock/MV/vasopressors → broad IV empiric coverage needed in first 24h.
- TZP provides single-agent coverage for common Gram-negatives including Pseudomonas (notable local prior) plus streptococci and anaerobes; no MRSA history/risk to justify VAN/linezolid.
- Avoid aminoglycoside add-on given severe CKD (eGFR 18) and no MDR risk factors.",TZP_IV,NA,NA,2026-02-08T05:01:07Z
298,OK,1,5681896cf40a2fbd5764965d494206752a063601f68728179d6dc5ee93df63cd,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0fcb677e1188d02b0169878083a0b481a0853ac7e4ec02b19d,1770487939,1986,236,a4501cc8c467192308aff4a9646f3fa64f1a1b3db411ba9da325ea2010d4c328,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Moderate community-onset CAP with respiratory failure and elevated WBC/CRP: empiric bacterial coverage warranted despite positive viral screen.
- CRO_IV + AZM_IV provides typical + atypical CAP coverage; no MRSA/MDR risk factors to justify VAN/linezolid or antipseudomonal therapy.
- eGFR 39: ceftriaxone and azithromycin generally do not require renal dose adjustment at these doses for first 24h.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
299,OK,1,6e971c58b901e116e7f8134a51e0bf21a2e69f0a22dd8745b2f3b351b528a951,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0d5ee2fe6a63c2fd0169878085defc819fa3852690603c73cd,1770487941,1997,246,4fbc17f63f491ea976dca304a4876fd055cc4d75a2370ee081cd0906a1b56da2,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h (renal function unknown adjustment not required; eGFR 29)
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset pyelonephritis with sepsis and marked leukocytosis/CRP: needs prompt IV broad Gram-negative coverage.
- Ceftriaxone provides empiric Enterobacterales coverage typical for pyelonephritis; avoids unnecessary MRSA/anaerobe coverage.
- eGFR 29: ceftriaxone generally does not require renal dose adjustment, favorable in CKD compared with nephrotoxic options (e.g., aminoglycosides).",CRO_IV,NA,NA,2026-02-08T05:01:07Z
300,OK,1,1ae4da6237ed73a81066309ca8eb19e521db5bd56605540e2768f523489ccd1b,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0e248cef3434e83201698780879ad0819f962964f2849bfa95,1770487943,1980,246,372deea15d336c36b66c3f48e0a735d47f1b07abccbb6e132440dc8943067741,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Severe community-onset CAP with respiratory failure requiring MV/NIV → IV beta-lactam + macrolide empiric coverage for typical and atypical pathogens.
- No MRSA or ESBL/CRE risk factors and no septic shock → avoid routine VAN/linezolid and avoid carbapenem/antipseudomonal escalation in first 24h.
- eGFR 83 mL/min/1.73m2 → no renal dose adjustment needed for ceftriaxone or azithromycin.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
301,OK,1,0da49ecaab9d887e919fc7b1111413c9466f73f56dfdcb25da0617cdd7447315,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_05c9223b107d969201698780879f0c8194b80f0f996a06e59f,1770487943,1779,236,1d1b1d73707da3cdec35a5d067f5c6e55553a330e4c88e23b4f2a21ea3aad7e0,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Moderate community-onset CAP with respiratory failure and high CRP/WBC: empiric beta-lactam + macrolide for typical + atypical coverage.
- No septic shock/ICU/MV and no prior MRSA/ESBL history: avoid routine MRSA or carbapenem/anti-pseudomonal escalation in first 24h.
- eGFR 138: no renal dose adjustment needed for ceftriaxone/azithromycin.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
302,OK,1,b839f55de6b77b60c2c63ad1850aaeb71815af34fb99c81e46af48fa8824e596,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_02fb331e6ecf32520169878089e76081929409c1b56e034a3a,1770487945,1772,226,4ea9311a084e16d9317200ce4620bb8684805039e8d08fa2ec6b60b875a6c142,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with sepsis and marked leukocytosis: empiric beta-lactam + macrolide for typical + atypical coverage.
- No MRSA or MDR risk factors documented; avoid routine VAN/anti-pseudomonal therapy in first 24h.
- eGFR 22: ceftriaxone does not require renal adjustment; azithromycin generally no renal adjustment at this level.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
303,OK,1,be0e1afcabcd53349a5d22f179ceee91949c5be050e04388a2d58f7c4fdcb088,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0faa56ad13c5ecdb016987808b3e408197b61cff3dd41421d9,1770487947,1966,224,a6dce2e4a87aab588f84b8371817200c83d44ec77c28a3e5e3534fcedf24e6ce,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q6h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset UTI with septic shock/ICU-level severity → broad IV Gram-negative (incl. Pseudomonas) coverage appropriate for first 24h.
- Prior antibiotics in last 90d increases MDR risk; TZP provides broad empiric coverage without routine MRSA therapy (no MRSA history/risk provided).
- Renal function preserved (eGFR 77) → standard high-severity dosing.",TZP_IV,NA,NA,2026-02-08T05:01:07Z
304,OK,1,0c1f089dc0b12e0a97ba6482909953d29382500d16712b5d7a839f2cc1f63ce6,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_057e2afb33b4d8c4016987808b3b50819599b945c583db3354,1770487947,2009,224,5024c1ab4bdb418dce51aa9788face8660bcf531a5a9b75319dc348fd7318d04,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q8h (renal-adjusted for eGFR 22)
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset pyelonephritis with septic shock/ICU-level severity → broad IV Gram-negative coverage including Pseudomonas.
- No major MDR history/exposure and no MRSA risk factors provided → avoid routine MRSA/add-on agents.
- Renal dysfunction (eGFR 22) → use renal-adjusted TZP dosing for first 24h.",TZP_IV,NA,NA,2026-02-08T05:01:07Z
305,OK,1,03a815cf155fcc354bd145b1cbd37f83961755bc8b8670def12fb635c6f4c9ad,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0750ec20acfd57e1016987808edb80819598486ca6d4115542,1770487950,1992,232,7a66e72a0089d030e26d2fbdd3a76bfe56576590f28bc29cdf8aabf6a1e989be,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset pyelonephritis with elevated WBC/CRP but low severity and no MDR risk factors: ceftriaxone provides appropriate empiric Gram-negative coverage (incl. E. coli/Klebsiella/Proteus).
- Avoids unnecessary broad antipseudomonal or MRSA therapy given low shock/ICU risk and no prior ESBL/MRSA history.
- Renal function normal (eGFR 98); no renal dose adjustment needed.",CRO_IV,NA,NA,2026-02-08T05:01:07Z
306,OK,1,bec57fc3f2c1c35c7ca4c80daaffbe907d8c6891995f247ed08b528ae73c5c48,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0693a6f928cda802016987808ed7a481a3b2c855e246c844a7,1770487950,1773,237,42f3e914e5583f7fa56b89583415673eb84592b8257249bc639607f4a55ceaf0,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with respiratory failure and elevated inflammatory markers: empiric beta-lactam + macrolide for typical + atypical coverage.
- No MDR/MRSA risk factors (no prior MRSA/ESBL, no recent antibiotics/hospitalization/LTC), so no empiric MRSA or antipseudomonal escalation.
- eGFR 53: no renal dose adjustment needed for ceftriaxone or azithromycin in first 24h.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
307,OK,1,c92b46bc6dbc84836a3dcb58b42795cfa78f5ee3f88eed1612c2e0d844177168,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_079a085011d5c67f016987808fbf6081a3ac98357748f6a2e6,1770487951,2005,247,5aa62ed1a855da39b86c356d6c6978746941ad2d43a7393576ecb0305179c2d3,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q8h (extended infusion), renal-adjusted for eGFR 39
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset pneumonia with septic shock/MV/vasopressors → IV broad empiric coverage for severe bacterial CAP while cultures pending.
- No MRSA history or major MDR risk factors provided → avoid routine MRSA agent; TZP provides broad Gram-negative (incl. Pseudomonas) and anaerobe coverage appropriate for high-severity presentation.
- Renal dysfunction (eGFR 39) → use renal-adjusted TZP dosing for first 24h.",TZP_IV,NA,NA,2026-02-08T05:01:07Z
308,OK,1,b7e201911ca26a6ac6e990993a4f6f7b3cb87de6554d47986b40d64db3125c04,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0579cec7ca4fb52801698780924f08819197640cfe628c70fa,1770487954,1759,241,343ee903304e5126de60a1855f19b6f5017b695c5f13195b808da10f80b926c7,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with respiratory failure (moderate severity): ceftriaxone + azithromycin provides empiric coverage for typical and atypical CAP pathogens.
- No MDR/MRSA risk factors (no recent antibiotics, no recent hospitalization, no LTC, no prior MRSA/ESBL): avoid broader anti-pseudomonal or MRSA agents.
- eGFR 59: no renal dose adjustment needed for ceftriaxone or azithromycin in the first 24h.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
309,OK,1,0baf35b48d58f10637bf86948a67e3bd8d90fc4e3865673f022e2448ab303e45,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_08760bb1bc49e7420169878092ab4081a3abb9e37e159641ab,1770487954,1981,228,9a649e7cbad599b0ea515489aa4cf138d259b95cd4646ce00fece9a1b0df3a2b,1,output[0].content[0].text,,"DRUG_1_NAME: CZL_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q8h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset skin/soft-tissue infection with low severity and no MRSA/MDR history: cefazolin provides focused MSSA/streptococcal coverage without unnecessary broad Gram-negative/MRSA therapy.
- Immunosuppression and leukocytosis support treating empirically, but stable vitals/lactate and no shock favor a narrow IV beta-lactam.
- Renal function normal (eGFR 112): standard dosing used.",CZL_IV,NA,NA,2026-02-08T05:01:07Z
310,OK,1,43fddf58f0187be5717c5b43282fbdad679a62731352df007e153fcbaf056de0,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_09d038a6dfaebf6d0169878093aee8819694c657cc45ba6830,1770487955,2006,233,64181842b6505fe5119a5a20a8b1596b54f6724e4905db5c1212940d8d621eea,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Severe community-onset pneumonia with respiratory failure requiring MV/NIV and ICU transfer → empiric IV CAP regimen covering typical + atypical pathogens.
- No MDR risk factors or prior MRSA/ESBL history → avoid routine anti-MRSA or antipseudomonal therapy.
- eGFR 69 mL/min/1.73m2: no renal dose adjustment needed for ceftriaxone/azithromycin in first 24h.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
311,OK,1,86c3e1288ddb98ff9342fb2cbf622e421fd79634dbd479ff09c28a6eef714897,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_027156839d4cfdec0169878095c5c48192b818b81463ff60f5,1770487957,1762,233,92fae93dffaba0898ab234c04c238043a3e85dabf867433a43e801960f2a0e46,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with low severity but immunosuppression/malignancy: ceftriaxone + azithromycin provides standard empiric coverage for typical and atypical CAP pathogens.
- No septic shock/ICU/MV and no MDR/MRSA history or recent healthcare exposure: avoid routine anti-MRSA or antipseudomonal therapy.
- Renal function preserved (eGFR 89): no renal dose adjustment needed for this regimen.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
312,OK,1,590bb7b0e8e6cdb14c486a655fd70391e619471df4e62ef641929db770ad9066,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0ee6f9555f52e642016987809639a08191b0916b6f26a0c029,1770487958,1765,255,4085b9752371bc62a3e6dc59aff5563ce1cac3100b7d7ddc168343a2ef9f9b48,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h (renal function eGFR 43: no adjustment)
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with respiratory failure and elevated CRP: empiric inpatient CAP coverage with ceftriaxone + azithromycin for typical + atypical pathogens.
- No MDR/MRSA history or recent healthcare/antibiotic exposure: avoid routine anti-MRSA or anti-pseudomonal broadening in first 24h.
- eGFR 43 mL/min/1.73m2: ceftriaxone and azithromycin do not require renal dose adjustment at these doses.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
313,OK,1,6b0b40c24889919ebf46cd2de1208bc74a9fe79cbd1d08fe0b77e980d9d423bf,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_00ef2b73e6437e6601698780977dd88194b4faecc86e09f3e9,1770487959,1780,253,362aeff8df87624ea7f2731b5cc83b01d3caaccc4570347ffdb62a520773fc7d,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h (renal function unknown)
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset pneumonia with respiratory failure and marked inflammation (WBC 16.2, CRP 200) warrants empiric bacterial coverage despite positive viral screen.
- Ceftriaxone + azithromycin provides standard CAP coverage including typical pathogens and atypicals; no MRSA/ESBL history to justify broader agents.
- Avoid aminoglycosides/fluoroquinolones given CKD (eGFR 24) and toxicity risk; ceftriaxone does not require renal adjustment at this eGFR.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
314,OK,1,8574e152edde921784c862e87ab988f9d16f7052618dbeb27e75988c35d30ec3,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_06334ed703445f56016987809953f48196a7a891bde2dbb0cc,1770487961,1520,221,b8533fc3e7d1f9c54b5e4cdb6c39ce70927822940b00074eabba88db5626683f,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q8h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset intra-abdominal infection with elevated WBC/CRP: broad empiric coverage for enteric Gram-negatives, streptococci, and anaerobes.
- Low severity and no MDR/MRSA history: piperacillin-tazobactam monotherapy avoids unnecessary combination/MRSA coverage.
- Normal renal function (eGFR 117): standard dosing appropriate for first 24h.",TZP_IV,NA,NA,2026-02-08T05:01:07Z
315,OK,1,30dce05c0cb2a0e0418d2de4c08dcf3715b4e775b67b9be4ec4c6899de39ca07,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_066685f7e2b75088016987809a12108196bd536c3fa833bb00,1770487962,1981,249,a7fc4a1588c41db545370692464212acf8a14f2177e386a93b6728ec9c1fcb06,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h (renal function unknown)
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset UTI with marked inflammation (WBC 18.1, CRP 269.6) but no shock/ICU needs: ceftriaxone provides appropriate empiric Gram-negative coverage without unnecessary broad antipseudomonal therapy.
- No major MDR risk factors or prior ESBL history; MRSA coverage not indicated.
- Avoid aminoglycosides given severe CKD (eGFR 17) and nephrotoxicity risk; ceftriaxone does not require renal dose adjustment at this eGFR.",CRO_IV,NA,NA,2026-02-08T05:01:07Z
316,OK,1,80a528a66fe4c50e2f761b952bb2f9607784544dd81ba2889ae17d8e9b183aea,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_08becdc0251b05e0016987809bd038819ca3782591b921f298,1770487963,1761,237,6d563d87e3cc7b03c6773ce1d6e36786026eab063e70007202d876bb5dce2f62,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Severe community-onset CAP with respiratory failure requiring MV/NIV → IV beta-lactam + macrolide empiric coverage for typical and atypical pathogens.
- No MDR risk factors and no prior MRSA/ESBL history → avoid routine anti-MRSA or antipseudomonal therapy in first 24h.
- Normal renal function (eGFR 96) → standard dosing; ceftriaxone 2 g daily appropriate for severe CAP.
",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
317,OK,1,75e21d9ead079614c355e7a0c7f75fb24ac5bdc3a16e1b0ac52aa7969abb3e57,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0a5c0ab837688ac3016987809c8cb08196912872ed71c918af,1770487964,1977,216,f22a9e3ff8c7b26f2527178991c6e46721e82c5319af34ab704b5f49b6989679,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset UTI with elevated WBC/CRP but low severity and no MDR risk factors: ceftriaxone provides appropriate empiric Gram-negative coverage (E. coli/Klebsiella predominant locally).
- Avoids unnecessary broad antipseudomonal and MRSA coverage given low risk and stable presentation.
- Renal function preserved (eGFR 86), so standard dosing appropriate.",CRO_IV,NA,NA,2026-02-08T05:01:07Z
318,OK,1,9bf87501ea8b2e95d607aec238314c85b36fb8e5e6446b7d7c957986361ae42c,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_05b715794ffe099f016987809ee9308194a7e13bc4fd359aac,1770487966,1979,241,aea11c7fd646f7071e943608b7ef09012ab91ac2c62f9187f77e643ed7eda28c,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q6h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset COPD infectious exacerbation with septic shock/respiratory failure (MV, vasopressors, ICU) → IV broad-spectrum empiric coverage including Pseudomonas and other Gram-negatives.
- Recent hospitalization and antibiotics within 90 days increase risk for resistant Gram-negatives; TZP provides broad coverage while avoiding unnecessary MRSA therapy (no prior MRSA history provided).
- Renal function preserved (eGFR 108) → standard high-severity dosing for first 24h.",TZP_IV,NA,NA,2026-02-08T05:01:07Z
319,OK,1,30d07bbb01947961767accd9c40ed8d646a7149d2d73d8c2f75e114d7e92f3b7,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0bdc46ef9d0b9ae8016987809f46888190828e6811a36f7d56,1770487967,1989,207,1c582a76ee4c0f761e6bb6ecd2a30f8ada2812d41fa4668f1e737eb5beb5478c,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with respiratory failure (moderate severity): ceftriaxone + azithromycin provides empiric coverage for typical pathogens and atypicals.
- No MDR/MRSA risk factors and normal renal function (eGFR 82): avoid broader anti-pseudomonal or MRSA agents in first 24h.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
320,OK,1,3e304a5b97a1539e2246a248e15d74ef313d49f80180c3fa48ffb667d742c666,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_04de101fdf6b862301698780a00e4081a1a6dd69beb08b5c20,1770487968,2001,232,face539f725c862216f7b46ce8da5c89957e5cc0154ef3dd1424bff793d59e48,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q12h (renal-adjusted for eGFR ~6 mL/min)
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Severe community-onset pneumonia with septic shock/MV/vasopressors → broad IV empiric coverage including Pseudomonas and other Gram-negatives plus streptococci.
- Recent hospitalization and antibiotics increase risk for resistant Gram-negative pathogens; TZP provides broad single-agent coverage while avoiding unnecessary combination therapy.
- No prior MRSA history provided → avoid routine MRSA agent in empiric regimen.",TZP_IV,NA,NA,2026-02-08T05:01:07Z
321,OK,1,e73b84285b96734069c0d4ffee0d5a5e117401ed17b4838e6febe1ecf7a1be80,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0909a6c2fceb38e301698780a286e88192a47702f7ad6a7a90,1770487970,1747,233,23743a1690ffd0124e29d0d5d18b86fd47e3eab7ac9daa28ce027d1b04a082b5,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q6h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset COPD infectious exacerbation with respiratory failure and elevated CRP; prior outpatient AZM_PO suggests macrolide pre-treatment and supports broader empiric coverage.
- TZP_IV provides broad Gram-negative and antipseudomonal coverage (relevant given COPD and recent antibiotics) while also covering common respiratory pathogens; no MRSA history/risk to justify VAN/linezolid.
- Renal function normal (eGFR 104), so standard dosing used.",TZP_IV,NA,NA,2026-02-08T05:01:07Z
322,OK,1,fb8a4339eedfe6b68a3ecd7c5d67af27d25e72762d7fc844295b889e5d82ec11,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0d1ade0558b445d801698780a2c594819d92035d1d09f474fc,1770487970,1750,219,0fa42d2958bd4b42393d90fafa839933b456d608177688bac0ae218f6b2e0fbe,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q6h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Severe community-onset pneumonia with septic shock/MV/vasopressors → broad IV empiric coverage including antipseudomonal beta-lactam.
- Add azithromycin for atypical CAP pathogens and potential immunomodulatory benefit in severe CAP.
- No MRSA history or MDR risk factors provided → avoid routine MRSA agent in first 24h.",TZP_IV,AZM_IV,NA,2026-02-08T05:01:07Z
323,OK,1,40997f7d34d1edf8b78240666f789cdcba7fa64e64aec0643b1f44473fb1f4b0,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0a9fc655f101355f01698780a3f79c81968823c4a7cc78df03,1770487972,1829,238,7ba59052ccf99ea6d7bb9644929a5717fea6d852acc52e50ac6b083e4f2031dc,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with respiratory failure and immunosuppression: ceftriaxone + azithromycin provides standard empiric coverage for typical and atypical pathogens in the first 24h.
- No septic shock/ICU/vasopressors and no prior MRSA/ESBL history: avoid routine MRSA or carbapenem/antipseudomonal escalation despite prior antibiotics.
- eGFR 70: no renal dose adjustment needed for this regimen.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
324,OK,1,80a5b38788c4e4323f6c87a3fe0fbf0cca22d3422bc9446a95604420b40f2854,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0f0afb3db356d1c901698780a652a0819dba9b76778e6de9ee,1770487974,1765,248,1d18619c9df3e622fa68e9e1e461e4faade06c5c48ee14d8d8bd4787a7aea452,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h (renal function unknown adjustment not needed; eGFR 4)
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset pneumonia with respiratory failure → inpatient CAP coverage with beta-lactam + macrolide for typical + atypical pathogens.
- No MRSA history and no clear MDR risk beyond recent hospitalization → avoid routine VAN/linezolid and avoid broad antipseudomonal therapy in first 24h.
- Severe renal impairment (eGFR 4): ceftriaxone does not require renal adjustment; azithromycin generally no renal adjustment.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
325,OK,1,a9985332cbf796d77152a5f0e645d9c30df7b5047d08b0705a3f71504db3ee9c,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0846ba63420c611001698780a652fc819faef5e1e5de89a285,1770487974,1766,255,2ad65a2261dfbd7be9f31b5a87bc00c64b15ac61ece477ff9fb2d6969ecc07f3,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: VAN_IV
DRUG_3_DOSE: 15 mg/kg
DRUG_3_INTERVAL: once (loading dose; then dose by levels)
RATIONALE:
- Community-onset pneumonia with respiratory failure and very high CRP: empiric CAP coverage with ceftriaxone + azithromycin.
- Prior MRSA colonization/history supports adding vancomycin for early MRSA coverage.
- eGFR 2 mL/min: avoid nephrotoxic add-ons; ceftriaxone/azithromycin need no renal adjustment; vancomycin given as a single loading dose then level-guided due to severe renal failure.",CRO_IV,AZM_IV,VAN_IV,2026-02-08T05:01:07Z
326,OK,1,335a75b731f15b0692b4193dfa7092cb4a57c0519ff87cfb0195e30066a180d8,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_057217cb9f6b5d7401698780a783048192a8b824bb5dd31f7b,1770487975,1742,215,d7730e4157b5a7321deeac43d31ec513627aea4e8eaea415eb327689adcb9aac,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q6h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Septic shock with MV/vasopressors in community-onset pneumonia: broad IV empiric coverage including antipseudomonal beta-lactam.
- Add azithromycin for atypical coverage and potential benefit in severe CAP.
- No MRSA history/risk documented; avoid routine MRSA agent in first 24h.
",TZP_IV,AZM_IV,NA,2026-02-08T05:01:07Z
327,OK,1,bcc7416196a98d1264dc0756c214722e513704ff0fd354e548632aae6d830d27,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_017b45c3912c24fa01698780aa5e0081a0ba24d58f2774280c,1770487978,1776,216,b2a81a8285782562421dbedd1f3ce507135166f667dc4a7ae2a32c5d4718fd58,1,output[0].content[0].text,,"DRUG_1_NAME: MEM_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q8h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset pneumonia with respiratory failure and high inflammatory markers; treat as higher-risk CAP needing broad IV coverage in first 24h.
- Significant MDR risk (LTC resident, recent hospitalization/antibiotics, prior ESBL) supports empiric carbapenem to cover ESBL Enterobacterales and other Gram-negatives.
- No prior MRSA history provided; avoid routine MRSA agent empirically.",MEM_IV,NA,NA,2026-02-08T05:01:07Z
328,OK,1,20ff3c39c59b6b1fc458123289e4bc61b899df55e36cf9dee9210e381f18d5ba,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_092763bbe070374701698780aa9aa881948402c95ef81a1345,1770487978,1756,246,6800c388a15b21a2428700426c3a539e9dd6f8438b2663505cdd0b8638a325d2,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with respiratory failure and elevated inflammatory markers: empiric beta-lactam + macrolide for typical + atypical coverage.
- No MDR/MRSA risk factors (no recent antibiotics, no recent hospitalization/LTC, no prior MRSA/ESBL): avoid routine anti-MRSA or antipseudomonal therapy.
- eGFR 81 mL/min/1.73m2: no renal dose adjustment needed for ceftriaxone or azithromycin in first 24h.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
329,OK,1,8e9948c0ad1d1a20c04ef884213b4371474fcdd44c617ca64a8d05c75442c02b,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0425c3ad1c280e5701698780aabf0c8190a0b45f534fe689a7,1770487978,1821,214,cef2fe878a36d5f3b3a8dd1d3df18d3277e100f3e1ba3aa5e25925efe4c0cc42,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q6h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Severe community-onset pneumonia with respiratory failure requiring MV/NIV and ICU transfer → broad IV empiric coverage appropriate for first 24h.
- Recent outpatient antibiotic exposure (cefixime) increases risk of resistant Gram-negatives; TZP provides broad coverage including Pseudomonas and anaerobes.
- No MRSA history/risk provided → avoid routine MRSA agent.",TZP_IV,NA,NA,2026-02-08T05:01:07Z
330,OK,1,abb454be22469b4a6ff3b4ed8641f3a9506149c4e7a4a879265946f17126821e,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_07c18de867be30c201698780adff608195bf5b55582e1600e1,1770487982,1763,251,64d37f2e59fd95d2b2cfca56467eb949642aa91a5c03b06dbec65648638549ef,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with respiratory failure (moderate severity): ceftriaxone + azithromycin provides standard empiric coverage for typical and atypical pathogens.
- No MDR/MRSA risk factors (no prior MRSA/ESBL, no recent hospitalization/antibiotics, no LTC), so avoid broader anti-pseudomonal or MRSA agents.
- eGFR 66 mL/min/1.73m2: no renal dose adjustment needed for ceftriaxone or azithromycin in the first 24h.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
331,OK,1,07772bb8c8044fef0f62665ef2c96f9bc479826c8b51d765c300e964460e19b6,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_01df6d12d3293fff01698780adfb74819c8b3707b677a8730c,1770487982,2011,248,4307125a386bbdfc91abc5fbbf1a1fbbd4ed4275e5930c98f8ec24ec49ecf42f,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q12h (renal-adjusted for eGFR 16; extended infusion if feasible)
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset pneumonia with septic shock/respiratory failure on MV and vasopressors → requires broad IV empiric coverage for severe bacterial CAP including gram-negatives (incl. Pseudomonas) and anaerobes.
- No MRSA history or major MDR risk factors provided → avoid routine MRSA agent in first 24h.
- Dose/interval adjusted for severe CKD (eGFR 16) to reduce toxicity while maintaining early broad coverage.",TZP_IV,NA,NA,2026-02-08T05:01:07Z
332,OK,1,36dbd43e4cb9bf29730f39ff6ea763d775f9cee99dbbe00d962613630e94ec8f,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0b53642a768d461d01698780aea3648197b9bbd6395785dccd,1770487982,1991,275,5d92e304a8ccf8f7db869c85dba48c7fd0d368f14df3fd07de0e8eddcaa21e72,1,output[0].content[0].text,,"DRUG_1_NAME: VAN_IV
DRUG_1_DOSE: 15 mg/kg
DRUG_1_INTERVAL: IV once (loading dose), then dose by levels; with eGFR 12: re-dose ~15 mg/kg every 48–72 h as guided by trough/AUC
DRUG_2_NAME: TZP_IV
DRUG_2_DOSE: 4.5 g
DRUG_2_INTERVAL: IV q12h (renal-adjusted for eGFR 12)
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Septic shock from community-onset SSTI warrants broad IV empiric coverage for streptococci/MSSA plus Gram-negatives/anaerobes; TZP provides this.
- Add VAN for severe SSTI with shock to cover possible S. aureus (including MRSA) pending cultures.
- Avoid aminoglycosides given severe CKD (eGFR 12) and nephrotoxicity risk.",VAN_IV,TZP_IV,NA,2026-02-08T05:01:07Z
333,OK,1,1c6b2db71252e289bcf2707532cc1c671a808ea88bfeaeb39fee5635a4564acb,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0ccbe79a9aecdfe401698780b23c0c8191aa0900065a8faf4e,1770487986,1989,251,29ff748934d39279056db84e1eec0ba47a8eddd4c9fa3c2417abd6e016eb0f50,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q8h (extended infusion; renal-adjusted for eGFR 30)
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Severe community-onset pneumonia with septic shock/MV/vasopressors → broad IV empiric coverage including Pseudomonas and other Gram-negatives plus streptococci/anaerobes.
- No MRSA history or recent healthcare/antibiotic exposure → avoid routine empiric anti-MRSA agent in first 24h.
- eGFR ~30 mL/min/1.73m2 → use renal-adjusted TZP dosing for initial 24h.",TZP_IV,NA,NA,2026-02-08T05:01:07Z
334,OK,1,74734ef070fee0acb13985244f9fad81613cae94b1eaa08b937ac4ea3e1d6f45,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0d1dfbab08e8feca01698780b274a081949077153682f7c9ea,1770487986,2002,217,323cf76e888c706b219c23eb37d52948ccb916e024004625b92b6ef93690b23c,1,output[0].content[0].text,,"DRUG_1_NAME: MEM_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q8h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset sepsis with marked inflammation (WBC 22, CRP 224) warrants empiric broad IV therapy in first 24h.
- Prior ESBL history plus recent hospitalization/antibiotics increases likelihood of ESBL Gram-negative bacteremia; meropenem provides reliable ESBL coverage.
- MRSA coverage not added: no prior MRSA and no ICU/shock flags in structured data.",MEM_IV,NA,NA,2026-02-08T05:01:07Z
335,OK,1,ae8673123e28a5d5ea7dac5be82d01acbd6e9e178431f04980486829f9435147,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_09406cd23d8e068901698780b3641081a3a3dedfe548a15e51,1770487987,1750,246,c3e8449453f12cab0197d06799150bc420564f5098213c72e0bdf6b9f0d44c03,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with respiratory failure and marked inflammation (WBC 26, CRP 264): empiric beta-lactam + macrolide for typical + atypical coverage.
- No MDR/MRSA risk factors (no prior MRSA/ESBL, no recent abx/hospital/LTC): avoid routine anti-MRSA or antipseudomonal therapy.
- eGFR 90: no renal dose adjustment needed for ceftriaxone/azithromycin in first 24h.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
336,OK,1,17328857f09fac4468e0f24b4b531b75a61aa15ac030e6e2ba7563fd703673cb,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0a242875bedcbbb201698780b607ac8197bcbbe117f5a2fe18,1770487990,2000,240,1e1419a29207c52b05b7b398377e431c38c68c188c2b11981c28fde1f6e61b5d,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q8h (extended infusion preferred); renal-adjust to 3.375 g q8h for eGFR 40
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset pneumonia with septic shock/MV/vasopressors → IV broad-spectrum beta-lactam appropriate for first 24h.
- TZP provides coverage for typical CAP pathogens plus gram-negative/aspiration risk; avoids routine MRSA coverage given no MRSA history/risk factors.
- eGFR 40 mL/min/1.73m2 → renal dose adjustment applied.",TZP_IV,NA,NA,2026-02-08T05:01:07Z
337,OK,1,1fd23350e56f416e14d0576d49ca6be2ec92346b94a269e98ab7040c2832785f,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0368f72e9d8a8efb01698780b64e58819eb1498233320e0351,1770487990,1765,246,279f319d84bee62734ed548d2c2745f6b89b5d4500b51ea78be5a73fcdd1fe24,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with respiratory failure (moderate severity) → IV beta-lactam + macrolide for typical + atypical coverage.
- No MDR/MRSA risk factors (no prior MRSA/ESBL, no recent antibiotics/hospitalization/LTC) → avoid routine anti-MRSA or antipseudomonal therapy.
- eGFR 88 mL/min/1.73m2 → no renal dose adjustment needed for ceftriaxone/azithromycin in first 24h.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
338,OK,1,050e1ebe624427b1d51530bf0442c321bf6cf771bb20f0277722205e0ba03a8b,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0dd93d3f646954f901698780b6f3fc81a2b2c9f144345e553d,1770487990,2036,246,ab11d9fc2e39bfc87f4522cc436a2f29f6af9d438b70020e7376e936549d12b6,1,output[0].content[0].text,,"DRUG_1_NAME: MEM_IV
DRUG_1_DOSE: 500 mg
DRUG_1_INTERVAL: q24h (renal-adjusted for eGFR ~5)
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset UTI with septic shock/MV/vasopressors → broad IV empiric Gram-negative coverage needed in first 24h.
- High MDR risk (LTC resident, antibiotics in last 90d, failed/preceded by AMC1G_PO) → carbapenem chosen to cover potential resistant Enterobacterales.
- Avoid aminoglycosides given severe renal failure (eGFR 5) and avoid routine MRSA coverage (no MRSA history/risk provided).",MEM_IV,NA,NA,2026-02-08T05:01:07Z
339,OK,1,27d0f89412e8210ccdf2b6b11ae65768394aeee14e9eb4bf0ad03da55d304686,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_08dabdc4f6851be101698780b9af88819c9d03e3b824280657,1770487993,1764,245,79173e296735060b512bcaa282c2c4396dea713014f76ed0fe9b3dc5b7acd277,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with respiratory failure and very high CRP: empiric inpatient IV CAP regimen covering typical pathogens plus atypicals.
- No MDR/MRSA risk factors (no prior MRSA/ESBL, no recent hospitalization/antibiotics, no LTC), so no routine anti-MRSA or antipseudomonal escalation.
- eGFR 70 mL/min/1.73m2: no renal dose adjustment needed for ceftriaxone/azithromycin in first 24h.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
340,OK,1,9b591ffad0d4c3ef527e9f57f2b25d899ab61878add5625a025015c4263bd837,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0a4f69468a83954901698780b9bf3c819ea7b6c213b0d8dbd4,1770487993,1773,230,ebc0eee58d6062240171fd659ce6cc5cd354723d3a352c02199d54aa9bc97652,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with respiratory failure and very high CRP supports empiric bacterial coverage despite positive viral screen.
- Ceftriaxone + azithromycin provides standard CAP coverage including typical pathogens and atypicals; no MRSA/MDR risk factors to justify VAN/anti-pseudomonal therapy.
- eGFR 66 mL/min/1.73m2: no renal dose adjustment needed for this 24h regimen.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
341,OK,1,34a5e95aca8bffccd8bc6cddee962c8bd8b3f1bed8a2340eaf34c676795faf9b,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0086ae19afc2fb6e01698780bab57481969b15294d817d9521,1770487994,1760,229,2fb2971d176051bbf52da4c5db6de69627a8fb4976893671efbffbe8f75cd3cf,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with respiratory failure (moderate severity): ceftriaxone + azithromycin provides standard empiric coverage for typical + atypical pathogens.
- No MRSA history and no recent hospitalization/LTC: avoid routine MRSA coverage.
- Severe CKD (eGFR 7): ceftriaxone and azithromycin generally do not require renal dose adjustment; avoids nephrotoxic aminoglycosides.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
342,OK,1,7c22d960b6d6780392cc998aca0429d58cea6928369441b5e9d275352d68c6bb,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0cd5a69299f9cefc01698780bd332481968287057494511143,1770487997,1974,250,47fc6748661423d2b3ff5a3cc42acc2f7b7b21dd59a2878f937b1f3c08fc767e,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q12h (renal-adjusted for eGFR 16)
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset UTI with septic shock/ICU-level severity: broad IV Gram-negative coverage including Pseudomonas appropriate for first 24h.
- No MRSA/ESBL/CRE/VRE history or recent healthcare/antibiotic exposure, so avoid routine MRSA or carbapenem empiric therapy.
- Severe renal impairment (eGFR 16) supports renal-adjusted TZP dosing and avoidance of nephrotoxic add-ons (e.g., aminoglycosides).",TZP_IV,NA,NA,2026-02-08T05:01:07Z
343,OK,1,3c22b5a7dbee84f05ab26099f7ea57f1e180e445ca6f5f2e36bc0b2fa1516e77,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0ce266ead730774601698780bd32a8819698a2d20ec84862f6,1770487997,2003,274,34259fa74b7bba89a7acb76dc647121dac52332be672531e6bed9ded04151d20,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q8h (renal-adjusted for eGFR 29)
DRUG_2_NAME: VAN_IV
DRUG_2_DOSE: 15 mg/kg
DRUG_2_INTERVAL: q24h (renal-adjusted for eGFR 29; target per local protocol)
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Septic shock with vasopressors and very high CRP → broad IV empiric coverage for community-onset sepsis pending cultures.
- TZP provides broad Gram-negative (incl. many Enterobacterales) and anaerobic coverage; vancomycin adds Gram-positive/MRSA coverage given high local Staphylococcus burden in bloodstream isolates.
- Doses/intervals adjusted for CKD (eGFR 29) to reduce toxicity risk in an 88-year-old with thrombocytopenia.",TZP_IV,VAN_IV,NA,2026-02-08T05:01:07Z
344,OK,1,c84cc2b93fb3a96121895c85d1f423734a26b8a9d01832fc94415f80b59fc152,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_066bbc8abb6100be01698780be003c81a086e9d3542b7387fc,1770487998,1764,240,0ed9d2c9d40adb97dd096034861688a97ba0971e73d64a3d42ecca1b7e22cb5b,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with respiratory failure (moderate severity) → IV beta-lactam + macrolide for typical + atypical coverage.
- No MDR/MRSA risk factors (no prior MRSA/ESBL, no recent antibiotics/hospitalization/LTC) → avoid broader anti-pseudomonal or MRSA agents.
- eGFR 90 mL/min/1.73m2 → no renal dose adjustment needed for ceftriaxone/azithromycin.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
345,OK,1,236b97aa4b73e5dd4b897a3cba975716c1c42ea70ffd01487c09b230a35ea387,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_05406154f3d43b0501698780c08a44819fb4724a858de1c5c9,1770488000,1763,237,84b1cc00299fde25ac0339f40a59442e8ac8ca4b45b939c749f33cce489bd831,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q8h (extended infusion; renal-adjusted for eGFR 35)
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Septic shock/vasopressors with community-onset pneumonia: broad IV beta-lactam for severe CAP with Gram-negative coverage plus macrolide for atypicals.
- No MRSA history or recent healthcare/MDR exposure: avoid empiric MRSA agents.
- eGFR 35: use renal-adjusted TZP dosing; azithromycin does not require renal adjustment.",TZP_IV,AZM_IV,NA,2026-02-08T05:01:07Z
346,OK,1,3d8e14f080d34ba45a1520b1a54e3ff407038725814c380220a07f4f210d76f6,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0845fbd1a9f7a1ca01698780c17518819ebfc431dafe94a63a,1770488001,1822,242,244794c5a4ec7ba7fe9bcd8ce7d1a7a4bcd24e4defe2032651d6f0f93ca92c49,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset pneumonia with respiratory failure (moderate severity): IV beta-lactam + macrolide provides empiric coverage for typical pathogens and atypicals.
- Recent outpatient doxycycline exposure suggests need to change class; ceftriaxone + azithromycin avoids repeating tetracycline.
- No MRSA history/risk flags and no septic shock/ICU/vasopressors, so avoid routine MRSA or broad antipseudomonal therapy in first 24h.
",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
347,OK,1,360aa4246b5b21febdd7c9457e92d5e1e7ad0be260a279b2cfd2340444670273,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0ac9eeb4c66ab64001698780c200f88195a3fa51dd44ace92f,1770488002,1752,251,018c5b154294190940db3a0f846e67f1048e69a49dfecc639dad6c96a0fc1b37,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h (renal function eGFR 46: no adjustment)
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with respiratory failure and very high CRP → empiric inpatient CAP coverage with ceftriaxone + azithromycin for typical + atypical pathogens.
- No MDR/MRSA history or recent healthcare exposure → avoid routine anti-MRSA or antipseudomonal therapy in first 24h.
- eGFR 46 mL/min/1.73m2: ceftriaxone and azithromycin do not require renal dose adjustment at these doses.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
348,OK,1,2921e6fe2e07e313e65b96c0d5fd75dddc48a1a74263a9a5147a7b07b1e17c16,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_085c0703087d9c0c01698780c4f5908197a9ae857bba23daeb,1770488004,1997,244,9608ea305f772e1da73ece74e776d0bb72ed702bac3c554a85d7c97582a7faff,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q12h (renal-adjusted for eGFR 17)
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Severe community-onset pneumonia with septic shock/MV/vasopressors → IV broad-spectrum beta-lactam appropriate for first 24h.
- Piperacillin-tazobactam provides coverage for typical CAP pathogens plus gram-negative/aspiration flora including Pseudomonas risk in this high-severity presentation.
- No structured MRSA risk factors (no prior MRSA, no LTC/hospitalization/abx exposure) → avoid empiric MRSA agent.",TZP_IV,NA,NA,2026-02-08T05:01:07Z
349,OK,1,0d903aec6ce7708bc4cdc5528efbd6b94f0c3c18c42a772f058f2360d5557a3e,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0d905d72e09e9dda01698780c5449081a19a0c0522ce748b45,1770488005,1998,202,edf64b26b1974a6ae164232df2308540c6b663caa79ce39de720968823d7ce06,1,output[0].content[0].text,,"DRUG_1_NAME: CZL_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h (renal-adjusted for eGFR 17)
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset low-severity SSTI without MRSA/MDR risk factors: cefazolin provides targeted streptococcal/MSSA coverage.
- Avoids unnecessary broad Gram-negative/antipseudomonal therapy; renal dose adjustment needed given eGFR 17.",CZL_IV,NA,NA,2026-02-08T05:01:07Z
350,OK,1,fd1145ee6484037b5fd86275e5fc5b010b34bc8d2d58d2c530c0df561987735f,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0dd128d25ca7053401698780c5a92081a09ceeff44064c690c,1770488005,1761,231,14584068a2cf76281dd01fa99ecad8ecfee2d4a3cf16c362d617f9ca5c5a52e4,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with respiratory failure and very high CRP: empiric beta-lactam + macrolide for typical + atypical coverage.
- No MDR/MRSA risk factors (no recent abx/hospitalization/LTC; no prior MRSA/ESBL): avoid broader anti-pseudomonal or MRSA agents.
- Renal function preserved (eGFR 86): standard dosing appropriate for first 24h.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
351,OK,1,ace319484ceffbd34a62d4176e5e37a9405157ee8f4a37445b6b01a229f79757,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_03ccc8c3b68eb67601698780c8b500819d85e19de2e22a3ea6,1770488008,1998,222,619273f0890ff178f9a85ea0d64c28e8a33259124deb43a894aa3e8722879707,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q8h (renal-adjusted for eGFR 44)
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset pneumonia with septic shock/MV/vasopressors → needs broad IV empiric coverage in first 24h.
- TZP provides broad Gram-negative (including Pseudomonas) and anaerobic coverage appropriate for severe CAP/aspiration risk in elderly with COPD.
- No structured MRSA risk factors/history provided → avoid routine MRSA agent.",TZP_IV,NA,NA,2026-02-08T05:01:07Z
352,OK,1,1757ff28d01eee91044c4a2e1c1dad3127179fca2d4a12be84645c71ee620eb3,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_085156340baea5d501698780c8fe8881949564e9781721b324,1770488009,1974,222,927b99476583915033df21f1882a997c2ccb16e3d063a4d9768c657f0ac886c9,1,output[0].content[0].text,,"DRUG_1_NAME: FOS_PO
DRUG_1_DOSE: 3 g
DRUG_1_INTERVAL: once (single dose)
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Low-severity community-onset UTI with stable vitals/lactate and no MDR risk factors → narrow oral therapy appropriate for first 24h.
- Local ward-year susceptibility prior supports fosfomycin as high-coverage option for typical uropathogens (E. coli/Klebsiella).
- Renal function preserved (eGFR 89), no dose adjustment needed for single-dose fosfomycin.",FOS_PO,NA,NA,2026-02-08T05:01:07Z
353,OK,1,8257082f3b90f67d3f6d21d35cf13490f69d6ba666726a0ab9a1fc0d1a6460cc,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0207ab544b23bf0101698780c9578c8193bc497a3b02e21863,1770488009,2003,217,00dc167858cbb13dfc634e0366979388b55f655c95ebbc8224483285857bad86,1,output[0].content[0].text,,"DRUG_1_NAME: MEM_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q12h (renal-adjusted for eGFR 32)
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Septic shock with MV/vasopressors/ICU transfer: requires broad IV empiric coverage in first 24h.
- Prior ESBL history + recent hospitalization/antibiotics: meropenem provides reliable ESBL and severe CAP Gram-negative coverage.
- No documented MRSA history/risk in structured data: avoid routine MRSA agent initially.",MEM_IV,NA,NA,2026-02-08T05:01:07Z
354,OK,1,2778a2827ba24262867f98ae607c2373eed85f85f466c4c41a2601dcdb6a1480,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_02439f9fac160ab501698780ccbf84819fafe5774aeba0093d,1770488012,1827,245,31053bb6ae8557c59d5ba85d288696fc90146177e86b99c2749260c4d081730d,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset pneumonia with respiratory failure: empiric CAP coverage with IV beta-lactam + macrolide for typical + atypical pathogens.
- Avoids routine MRSA/ESBL/CRE coverage (no prior MRSA/ESBL/CRE/VRE history; no LTC/hospitalization), and avoids aminoglycosides given severe CKD (eGFR 13).
- Ceftriaxone requires no renal adjustment at this eGFR; azithromycin also does not require renal adjustment.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
355,OK,1,0838808c8278742d8b1f206f3570d0ec911c5b3afbe6fd7a4a773525a38f9726,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_05a578188b462c9101698780cdc9cc8196910821a65cd93b86,1770488013,1976,237,1fb25ca49e099beedac2a87eca7feeba81b85135e114789d470ede53046619a8,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h (renal function unknown adjustment not required; eGFR 20)
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset UTI with sepsis and high inflammatory markers; ceftriaxone provides broad empiric Gram-negative coverage appropriate for typical pathogens (E. coli/Klebsiella/Proteus) without unnecessary anti-MRSA therapy.
- eGFR 20 mL/min: ceftriaxone generally does not require renal dose adjustment, avoiding nephrotoxic options (e.g., aminoglycosides) in acute kidney impairment.",CRO_IV,NA,NA,2026-02-08T05:01:07Z
356,OK,1,ce566337684156951c01a10b8fd019b677b6048a2f7b429ccba66b5b8f020753,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0835c650efa2fb3c01698780cdea9481a09d718c44a25982a4,1770488013,1971,218,9bb97a2289c2fda0b4b7181b9e4f965b8fa0a7c064872f10e8ea22179f80c87e,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h (no renal adjustment)
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset UTI with high severity (MV/NIV) warrants IV empiric therapy; ceftriaxone provides broad Enterobacterales coverage typical for this syndrome.
- Avoid aminoglycosides given severe renal failure (eGFR 6) and avoid unnecessary antipseudomonal/MRSA coverage without ESBL/CRE history or UTI-specific MRSA risk in the structured data.",CRO_IV,NA,NA,2026-02-08T05:01:07Z
357,OK,1,345fd838128e605e16eed521e1fa802bad8b2c21a1a86817728975834ab16543,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_043b27f55642c1f201698780d0859c81968ef178191cb263bf,1770488016,1817,249,bcd55e453350711a0384cdb72328c3171cd3d0d7679cfffca1d1a0a830d71702,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with respiratory failure (moderate severity): ceftriaxone + azithromycin provides standard empiric coverage for typical and atypical pathogens.
- Recent outpatient cefuroxime (CXM_PO) suggests possible beta-lactam pre-treatment; ceftriaxone offers broader pneumococcal/H. influenzae activity than oral cefuroxime.
- No MRSA history and no strong MDR risk factors beyond prior antibiotics; avoid routine MRSA/anti-pseudomonal escalation in first 24h.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
358,OK,1,33fff74f552fbcd0a6aa0712b9ef2e57ca5483b840eb572d9982507cf8feb89c,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0e68450d874708c701698780d170d08191bab195fb7bc926ae,1770488017,1986,232,990e1a1a79de2bf2109ec68947515c0f2a709839502bfc9893504ea2000244cf,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset UTI with sepsis and markedly elevated CRP/WBC: start parenteral broad Gram-negative coverage; ceftriaxone is appropriate empiric monotherapy for most complicated UTIs.
- No prior ESBL/CRE history and no septic shock/ICU/vasopressors: avoid upfront carbapenem or combination therapy.
- eGFR 84 mL/min/1.73m2: no renal dose adjustment needed for ceftriaxone.",CRO_IV,NA,NA,2026-02-08T05:01:07Z
359,OK,1,29e335efffcb657d501caf825abfd5895a97bdc6e3d2e038c6810ed6c502ea71,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0eb6da0434f9b11a01698780d19be4819e8e8977dde4547e2d,1770488017,1972,221,af613a779ef4dd20cfb52edeae64d011408b3db06bacf9c3017f0a0944e2064e,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset UTI with sepsis and very high WBC/CRP warrants initial IV therapy; ceftriaxone provides broad Enterobacterales coverage appropriate for low MDR risk.
- No MRSA/ESBL/CRE history or recent healthcare/antibiotic exposure, so avoid empiric MRSA agents and carbapenems.
- Renal function normal (eGFR 131), so no dose adjustment needed.",CRO_IV,NA,NA,2026-02-08T05:01:07Z
360,OK,1,7de2d4e292c84c657206b9786b46ebf4dbe4d5b3f0936e2173baaf1d6f7d5e06,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0688701b9fa5a45b01698780d49b8c819798d57292c4e0955d,1770488020,1993,229,a17477b6c159873f1819064c8bd4d5e455114032701dfb8f2d6c1e8b609542a7,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset pyelonephritis with sepsis and very high CRP; ceftriaxone provides broad Enterobacterales coverage appropriate for low MDR risk.
- Avoid aminoglycosides given severe CKD (eGFR 15) and nephrotoxicity risk; no clear indication for MRSA/Enterococcus-targeted therapy from structured data.
- Dose selected is renal-safe at eGFR 15 for first 24h while cultures pending.",CRO_IV,NA,NA,2026-02-08T05:01:07Z
361,OK,1,e3cd4c6c260e90e99165e202b62f737a468966699e868bdb1d8f9283d7c58bf6,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0c2bd20ccdd9ea5001698780d4fe188196b915a2b727feeaaf,1770488021,1757,221,eb244f81dbbc72c50f2c1ca37ab4bcec41a970be0b1214a6c04f7fa33fc54de1,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with respiratory failure and marked leukocytosis/CRP: empiric inpatient CAP coverage with beta-lactam + macrolide.
- No MDR risk factors or prior MRSA/ESBL history: avoid routine anti-MRSA or antipseudomonal therapy in first 24h.
- Renal function normal (eGFR 102): standard dosing appropriate.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
362,OK,1,686faba30181dee54130a5a83d8b3a9dd4e03c6f1407c03d930a6ed8d1eecdf4,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_034da3e32dd058ef01698780d4fb88819eab757f08e1ad3069,1770488020,1996,233,a504fbf352907a7961bc57ad371991d448ee97f5ec347969fb927cee8aa67c65,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q6h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Septic shock with MV/vasopressors/ICU transfer → IV broad-spectrum empiric therapy for severe community-onset pneumonia.
- MDR risk factors (LTC resident, hospitalization and antibiotics within 90d) and local ward ecology with notable Gram-negative/Pseudomonas signal support antipseudomonal beta-lactam coverage.
- No structured MRSA history (prior MRSA=no) → avoid routine empiric MRSA agent in first 24h.",TZP_IV,NA,NA,2026-02-08T05:01:07Z
363,OK,1,ccea69a70e7d564fa89e62840b613eabfc49a7ea03744f8ec09338904c7a11a4,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_046e3721c2879cc901698780d857a48193b3eefadef70f51fb,1770488024,1759,232,b624c627cca34b34cfc9bac69358ccb9657605f9235844edf400323e2747d15c,1,output[0].content[0].text,,"DRUG_1_NAME: NO_ANTIBIOTIC
DRUG_1_DOSE: NA
DRUG_1_INTERVAL: NA
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Low severity COPD exacerbation with minimal inflammatory markers (WBC 6.4, CRP 5) and no sepsis/respiratory failure supports non-bacterial etiology.
- Already pre-treated with oral cefixime before admission, further lowering yield/need for additional empiric antibacterial therapy in first 24h.
- No MRSA/ESBL history and no ICU-level illness; avoid unnecessary broad-spectrum exposure given recent antibiotics/hospitalization.",NO_ANTIBIOTIC,NA,NA,2026-02-08T05:01:07Z
364,OK,1,fa1a877e3e6d5ac8f067383db569b08597cfdcfd551dc62632841512362181f4,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0bc87ecbf276305c01698780d8829c8195b037b7c48196f89a,1770488024,1759,226,3a624331d02c8eaa42014a10397913f31348d908b1cf17e73462e037922fed8e,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset pneumonia with respiratory failure and leukocytosis: empiric CAP coverage with ceftriaxone + azithromycin for typical and atypical pathogens.
- No septic shock/ICU/vasopressors and no prior MRSA history: avoid routine MRSA coverage.
- eGFR 109: no renal dose adjustment needed for ceftriaxone or azithromycin in first 24h.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
365,OK,1,27a37ac62df3eb950acdc93fad6a4f815267d18ecf3109081f4e66f56a25a38f,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0d5f7a0886a9237b01698780d8cc64819097692d17a793fd1b,1770488024,1989,246,4e5f1550402ee50fcf3e2f2d024cf0c2daa05d16787aff9e2ed2a02ffc0771c5,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 2.25 g
DRUG_1_INTERVAL: q8h (extended infusion preferred if feasible)
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset pneumonia with septic shock/respiratory failure (MV, vasopressors, ICU): requires broad IV empiric coverage including Gram-negatives (incl. Pseudomonas) and anaerobes.
- No structured MDR/MRSA history or recent healthcare/antibiotic exposure to justify routine MRSA add-on; single-agent TZP limits unnecessary combination therapy.
- Severe renal failure (eGFR 6) → renal-adjusted TZP dosing for first 24h.",TZP_IV,NA,NA,2026-02-08T05:01:07Z
366,OK,1,219ec2e6934ebcf407195bfcf74f8bd20dab3fb6d6da3eab79b3f9ed71fc5f2c,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_02ef1f3d766b04df01698780dbc5a0819c8d41e1b20963295a,1770488027,1764,232,4afb9e1db04b8ac5ae5a61e241c152631975c6e0e0750171b45b257e6fb6cf33,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h (renal adjustment not required at eGFR 30)
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Severe community-onset pneumonia with sepsis and need for MV/NIV → IV CAP regimen covering typical pathogens plus atypicals.
- No MRSA or MDR risk factors provided → avoid routine VAN/LZD and avoid unnecessary broad antipseudomonal therapy in first 24h.
- eGFR 30: ceftriaxone dosing unchanged; azithromycin no renal adjustment needed.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
367,OK,1,bbef5f1df0b7c77406960b131bf4e369f1b016342cf4442346986034c56090d8,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0e9c4aeb7f0d3f8701698780dbf39c8194b0e8887fd07d4497,1770488027,1998,246,4e9252c1176ea8c06874e8b6339d45d6029a98954d74ac00b50e5aa8b59f9325,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q8h (extended infusion; renal-adjusted for eGFR 41)
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- High-severity community-onset COPD infectious exacerbation with septic shock/MV/vasopressors → broad IV empiric coverage including Pseudomonas and other Gram-negatives plus anaerobes.
- No documented MRSA history/exposure or other major MDR risk factors → avoid routine MRSA add-on in first 24h.
- eGFR 41 supports renal-adjusted TZP dosing to balance efficacy and nephrotoxicity risk in CKD.",TZP_IV,NA,NA,2026-02-08T05:01:07Z
368,OK,1,88694f5a4e9ac71174671b27aeda5c59a899b28b00577fcce94813bcbc765129,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_04a3f056b8360e8201698780de19e08190ad1f1f92f23f00ed,1770488030,1980,248,fd207f70f438e6bb651f5212b0c814a3f98e881260ea02b86025f30913bc39c8,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q12h (renal-adjusted for eGFR ~7 mL/min)
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset intra-abdominal infection with septic shock/ICU-level support: broad IV empiric coverage for Enterobacterales, Pseudomonas, and anaerobes.
- No structured MDR/MRSA history or recent healthcare/antibiotic exposure to justify routine MRSA or carbapenem empiric therapy.
- Severe renal failure (eGFR 7) favors avoiding aminoglycoside add-on and using renal-adjusted TZP dosing for first 24h.",TZP_IV,NA,NA,2026-02-08T05:01:07Z
369,OK,1,18fff177e7d0a2bc5c205a8df50f66e58572f43f978c08165cbd9d3e5239b41d,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_032799067dc6a06f01698780df7760819393c1c27cc5531eac,1770488031,1761,218,61d2a0630aa6cf15e24a2d80695247f1b33224e0641a8d17dc33e11259e7ddb9,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with respiratory failure and high CRP/WBC: empiric IV beta-lactam + macrolide for typical + atypical coverage.
- No MDR/MRSA history or recent healthcare/antibiotic exposure: avoid routine anti-MRSA or anti-pseudomonal therapy.
- Renal function normal (eGFR 103): standard dosing appropriate.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
370,OK,1,4adbf014c1842751403a537b8efad506929451ea077a1fcaedbf279c3c6a9ada,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_03a4df2f313c2eee01698780df84e481a3aebbd6a418c583e1,1770488031,1776,258,7589b8ac2f8b86e5289e180a7c56eaddbbb1fe35e44c381bca9f79bd75a72724,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with septic shock/vasopressors → IV empiric therapy covering typical pathogens (ceftriaxone) plus atypicals (azithromycin).
- No structured MDR/MRSA risk factors (no prior MRSA/ESBL, no recent hospitalization/LTC, no recent antibiotics) → avoid routine MRSA or antipseudomonal escalation.
- eGFR 20: ceftriaxone and azithromycin generally do not require renal dose adjustment for the first 24h; avoids nephrotoxic aminoglycosides in CKD.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
371,OK,1,864ff9bbd45d0b9c6449f0d71095c6aff0a2675ecd33066277f07e668b7cde11,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0be4ddc4b1002a6a01698780e1d9b8819daa310877191e19d5,1770488033,1764,221,122ae0aa17284878f86b31bdc5aa66b9781069ff458e131ffc77b0c32292aba9,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with respiratory failure and markedly elevated CRP/PCT supports empiric bacterial coverage.
- Ceftriaxone + azithromycin provides standard CAP coverage (typicals + atypicals) without unnecessary MRSA/ESBL/Pseudomonas coverage given no MDR risk factors.
- eGFR 82: no renal dose adjustment needed for this 24h empiric regimen.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
372,OK,1,9b7974d055174b65df7fcd30b4b8b6210e4f7f1b681cf4a3e8729567e4c78c3b,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_08e2e67a75bb154701698780e30ee88195b7c057063cf56054,1770488035,1777,240,06ef327f8fe7c5559f5bc43ae0f2e24d05fe367d148f5e31756aaa8a8236a4d0,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with respiratory failure and leukocytosis: ceftriaxone + azithromycin provides empiric coverage for typical pathogens plus atypicals.
- No MDR/MRSA risk factors (no recent antibiotics, hospitalization, LTC, or prior MRSA/ESBL): avoid broader anti-pseudomonal or MRSA agents.
- eGFR 43: ceftriaxone and azithromycin do not require renal dose adjustment at this level for the first 24h.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
373,OK,1,ddef9db8e91e3cc9f295be7edc645d428bb7826f6e67cc7c905eb4add5b48118,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0727da2918bdc55501698780e37b7481978133abe08837fac0,1770488035,1762,220,91f0cf2e31aa48fb04c0a2b3386cf685aa63d836f6b65067c50a8c76972b6764,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with low severity and no MDR/MRSA risk factors: ceftriaxone + azithromycin provides standard empiric coverage for typical and atypical pathogens.
- Normal renal function (eGFR 80): no renal dose adjustment needed for this first-24h regimen.
- Avoids unnecessary broad anti-pseudomonal or MRSA therapy given structured risk profile.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
374,OK,1,5b0769010f4066f4fd078eac323b00616abed3fa3600ef4b7363aad59c963f3a,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_072823dcdadd747101698780e5652081a3b5673786b34ae50b,1770488037,1970,234,067ba81e7954cfaafa67af80f9c0f77f0fc54ff21f54a3123894e19250defaa3,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset UTI with marked inflammatory response (WBC 14.7, CRP 272) but no shock/ICU needs → single-agent parenteral therapy appropriate for first 24h.
- Ceftriaxone provides broad Enterobacterales coverage consistent with local organism distribution (E. coli/Klebsiella predominant) and no ESBL/MDR history.
- eGFR 125 mL/min/1.73m2 → no renal dose adjustment needed.",CRO_IV,NA,NA,2026-02-08T05:01:07Z
375,OK,1,219113c802168b4cf468c24be1416e8d021aabe5ea10274c22173d8d8e66cea3,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0aa21df98a95e23101698780e6ab148191bf0423c1cad2b034,1770488038,1972,254,e03f777ded059b05f4add94bd7a7ef0f4b3be65f42d12070ff2a56ba625ab1ca,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h (renal function unknown)
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset UTI with sepsis (WBC 17.6, CRP 55.9) but no shock/ICU needs: ceftriaxone provides broad empiric Gram-negative coverage for typical uropathogens (E. coli/Klebsiella/Proteus).
- No major MDR risk factors and no prior ESBL/CRE/MRSA history, so avoid carbapenem and MRSA agents in first 24h.
- Ceftriaxone does not require renal dose adjustment at eGFR ~37, supporting single-agent therapy initially.",CRO_IV,NA,NA,2026-02-08T05:01:07Z
376,OK,1,7f7d0d3ea1b1c6af923c02663739246acdce708aa4c75b8d8534df012ae675af,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_084a652906b3cd1701698780e74224819cab2e1a37f22bfb0c,1770488039,1786,232,8d063372fecf3b4742e7a075309d5ff84efe60f299481382f5d080541cf036fc,1,output[0].content[0].text,,"DRUG_1_NAME: MEM_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q12h (renal-adjusted for eGFR 33)
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Severe community-onset pneumonia with respiratory failure requiring MV/NIV → IV broad empiric therapy for first 24h.
- Prior ESBL history/colonization increases risk for ESBL Gram-negative pathogens; meropenem provides reliable ESBL and broad respiratory Gram-negative coverage.
- Viral screen positive lowers bacterial probability but does not exclude coinfection in high-severity presentation; avoid routine MRSA coverage given no MRSA history/risk provided.",MEM_IV,NA,NA,2026-02-08T05:01:07Z
377,OK,1,8bfb18dadf0a9c8d4da79930240ce495ad6feae703eb9aab534a0e2a195747c5,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0e1972e2273faf5801698780e8c2c881959f389eae1c501383,1770488040,1690,221,5ae665336516ce9299868a1f5f7dcf028c45d82a0628403166574b30d488f5ff,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset COPD infectious exacerbation with respiratory failure (moderate severity): cover typical respiratory pathogens and atypicals with ceftriaxone + azithromycin.
- No MDR risk factors or prior MRSA/ESBL history; avoid routine MRSA/antipseudomonal therapy in first 24h.
- eGFR 122: no renal dose adjustment needed for this regimen.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
378,OK,1,dc4753d28ae62dce111a2864a4d7f580d6a194272a56de7436b01f3df5b29a09,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0db588e373de9f1b01698780eaaa1881a1aab018c0ba77acd4,1770488042,2091,228,5f2b68360fe4848407d33522f6f99d79b8bf777be3e3517e23daf76a903456b4,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h (renal function severely reduced; eGFR 4)
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset suspected bloodstream infection with low severity and no MDR risk factors: ceftriaxone provides broad empiric Gram-negative and streptococcal coverage.
- Avoid additional MRSA therapy despite prior home vancomycin exposure because no MRSA history/risk is documented and inflammatory markers are low; minimize nephrotoxic/duplicative therapy in severe CKD (eGFR 4).",CRO_IV,NA,NA,2026-02-08T05:01:07Z
379,OK,1,225f41e27986203f14c53833f298a53b3a35c773f81eeb696f83190c7b7dec05,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_04be2962e71b16c001698780eb402c819d9823434d97a6a225,1770488043,1979,240,d498d87f112b1d7cc0a6d1ca1e16b0a900aa36c1811c1682155925a36310a12f,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q12h (renal-adjusted for eGFR 12)
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset UTI with septic shock/ICU-level severity → broad IV Gram-negative (incl. Pseudomonas) and some Enterococcus coverage appropriate.
- No major MDR/MRSA history or recent healthcare/antibiotic exposure → avoid routine MRSA or carbapenem/aminoglycoside combination empirically.
- Severe renal impairment (eGFR 12) → use renal-adjusted TZP dosing for first 24h.",TZP_IV,NA,NA,2026-02-08T05:01:07Z
380,OK,1,569932bedfddc83bb849fb480f787620b297b02cde78b4aa63e041869312053d,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_04a372fdcae6be7001698780ec3288819688adaf1306f20159,1770488044,1765,242,598c57e241e371df0aaeaf4e699c1253c4077d662d25ef19767f8834e4324d6d,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h (no renal adjustment)
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with respiratory failure and very high CRP; empiric IV beta-lactam appropriate for first 24h while cultures pending.
- No structured MDR/MRSA risk factors (no prior MRSA/ESBL, no recent hospitalization/LTC/antibiotics), so avoid routine MRSA or antipseudomonal combination therapy.
- Severe CKD (eGFR 8): ceftriaxone is practical for initial empiric coverage because it does not require renal dose adjustment.",CRO_IV,NA,NA,2026-02-08T05:01:07Z
381,OK,1,21d1ec8ca23e665c64e568e0a66983d896b2056b4b0362679b4ab95ae7a700d3,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_06da16856b58bc7c01698780ee4b7081929a6a11090fec3d1e,1770488046,1981,234,909bab42e4eed943136a26337d3a01d3c8ab08cbf8b8eb8b8744fe6d85aea6d0,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q6h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset pneumonia with septic shock/MV/vasopressors → IV broad empiric coverage; TZP provides antipseudomonal and broad Gram-negative/anaerobe activity.
- Add azithromycin for atypical CAP pathogens and potential immunomodulatory benefit in severe pneumonia.
- No MRSA risk factors documented (no prior MRSA/LTC); avoid routine VAN/linezolid in first 24h.
",TZP_IV,AZM_IV,NA,2026-02-08T05:01:07Z
382,OK,1,92db8d926ba480086b8c2fe42aa174a7e44029a8f8a6d4b47bffd9d8f87792d7,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_097660510a895ddb01698780ef234c81a0be4b89bb183f6266,1770488047,1986,227,f7ff5f4bc404f7b1a41bad7c5ec3b541a6f38ae023e1cb1385b24b6bfb8e1cef,1,output[0].content[0].text,,"DRUG_1_NAME: ETP_IV
DRUG_1_DOSE: 500 mg
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset UTI with prior ESBL history and recent healthcare/antibiotic exposure → empiric carbapenem coverage appropriate.
- Low severity and no ICU/vasopressors; ertapenem provides ESBL Enterobacterales coverage while avoiding unnecessary anti-Pseudomonal/MRSA agents.
- Renal adjustment for eGFR 29 mL/min/1.73m2: ertapenem 500 mg IV q24h.",ETP_IV,NA,NA,2026-02-08T05:01:07Z
383,OK,1,8ed4e180bbf37aee9a0ecd3da3c62bd5537ffef363790cbd02206b29d1369155,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_03ab7ddac19fe9b901698780f01e3881a286460c6f8f060b42,1770488048,1974,230,1a6b8a7d7df2cf48c57f06a81ee0436962787c992d026684750886028f0034f4,1,output[0].content[0].text,,"DRUG_1_NAME: FOS_PO
DRUG_1_DOSE: 3 g
DRUG_1_INTERVAL: once (single dose)
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Low-severity community-onset UTI with no sepsis/shock and no MDR risk factors; oral narrow therapy appropriate for first 24h.
- Local ward-year UTI antibiogram shows high predicted activity for fosfomycin; covers common pathogens (e.g., E. coli, Klebsiella).
- eGFR 63 mL/min/1.73m2: no renal dose adjustment needed for single-dose fosfomycin.",FOS_PO,NA,NA,2026-02-08T05:01:07Z
384,OK,1,37e7a82a3f48f8f2dfa723d30c29ef14eeb4f14a98725b6f705f1499600dc38c,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_048dc24d1ee452a301698780f245ac819db4cde2807792243d,1770488050,1684,235,89201d7e62a6beb18aa0867ad19ec5a6bfb58a13b030988fb5f5b05d55707bd8,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset COPD infectious exacerbation with respiratory failure and elevated CRP: empiric CAP-style coverage for typical + atypical respiratory pathogens.
- No MDR/MRSA history or recent healthcare/antibiotic exposure: avoid routine anti-MRSA or broad antipseudomonal therapy in first 24h.
- eGFR 85 mL/min/1.73m2: no renal dose adjustment needed for ceftriaxone/azithromycin.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
385,OK,1,d27a042e2d0298d073a83f34adc5ef7e217fe0a9d6d27ae502f65196281abe8a,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_032cf544ea4ef97601698780f2c16881a297430f15403cb46a,1770488050,1980,237,3b765fa1377b3fe6162c36fd4901dcd6327528e7681e8645d7f2ba5b91113173,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h (renal function unknown adjustment not needed; eGFR 15)
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset UTI without MDR risk factors; ceftriaxone provides broad Enterobacterales coverage appropriate for initial empiric therapy.
- Avoids unnecessary MRSA/anti-pseudomonal/combination therapy given low documented severity and no prior ESBL/CRE history.
- eGFR 15: ceftriaxone generally does not require renal dose adjustment, suitable in advanced CKD for first 24h pending cultures.",CRO_IV,NA,NA,2026-02-08T05:01:07Z
386,OK,1,adf00e2ef716d5ade623c052068aca46945c9ed58d101328af74e1ff8d42634c,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0723899548545b2401698780f3ac608193933c72898c79728a,1770488051,1682,230,73ba1fbfcafc0d70887d47073e90087f99acfd749a002220b4c5f21c3827ab29,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset COPD infectious exacerbation with moderate severity (respiratory failure) and elevated WBC/CRP: cover typical respiratory pathogens plus atypicals.
- No MDR/MRSA history or recent healthcare/antibiotic exposure: avoid routine anti-MRSA or broad antipseudomonal therapy in first 24h.
- eGFR 71: no renal dose adjustment needed for ceftriaxone or azithromycin.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
387,OK,1,06534ed5360e86e2296dd6d7f430b13edf67d261f5634ca62049e5f46fcbf4a1,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_036f1570935f82d401698780f5d5b081968231a554b98f3f28,1770488053,2001,235,7056cc41b24f834f453915595ee60e9e28e0bb1fb4dcf120e8af28aca280412d,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q8h (extended infusion; renal-adjusted for eGFR 41)
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset pneumonia with septic shock/MV/vasopressors → IV broad-spectrum empiric therapy for first 24h.
- No MRSA history or major MDR risk factors → avoid routine MRSA agent; TZP provides broad Gram-negative (incl. Pseudomonas) and anaerobe coverage.
- Viral screen positive but severity and high inflammatory markers support possible bacterial coinfection warranting empiric antibiotics.",TZP_IV,NA,NA,2026-02-08T05:01:07Z
388,OK,1,353f98781583f62cbd5a15f8f3196b8d163f11d216f0733d3d7c0b87740b8666,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_09a55de43233891201698780f6aee481969a336e15136abd4a,1770488054,1759,249,90eb0d2a10056de5f7a6473954989f541035bfe6086a37bf982c5cea966f3f00,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with respiratory failure and very high CRP: empiric beta-lactam + macrolide for typical + atypical coverage.
- No MDR/MRSA risk factors (no prior MRSA/ESBL, no recent hospitalization/antibiotics, not LTC), so no routine anti-MRSA or antipseudomonal escalation.
- eGFR 79 mL/min/1.73m2: no renal dose adjustment needed for ceftriaxone/azithromycin in first 24h.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
389,OK,1,96ba202802d94f7e29117ad6d3096f27a7d1061dc89e35db1597d36d35c84a3e,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0f3b2a534c73e58301698780f72264819c905e2285789d7438,1770488055,1821,231,5f1658f8569c7277f7053118ca034c7ab5ea1c2e7cf78ab6b11180ed7fe20579,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q8h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset pneumonia with respiratory failure and marked inflammation (WBC 18.4, CRP 200) warrants IV empiric therapy.
- Recent antibiotic exposure and local ward ecology with notable Gram-negative/nonfermenter signal support broader beta-lactam coverage (including Pseudomonas) with piperacillin-tazobactam.
- No MRSA history/risk provided, so avoid routine MRSA coverage in first 24h.
",TZP_IV,NA,NA,2026-02-08T05:01:07Z
390,OK,1,7f695ee51cd0bdbb8883975703782449f54884f59c8822c01cd14225dd052504,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0befe12dbc3c092a01698780f99360819183f2d8e39a52f130,1770488057,1986,219,9e5f1218aeacdfe255d36cfd01a59b32be7d1664155b2d7fb58a441b4b077b5e,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q6h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Severe community-onset pneumonia with septic shock/MV/vasopressors → IV broad empiric coverage including Pseudomonas/Gram-negatives with TZP.
- Add azithromycin for atypical coverage and potential benefit in severe CAP.
- No MRSA history or MDR risk factors provided → avoid routine MRSA agent in first 24h.
",TZP_IV,AZM_IV,NA,2026-02-08T05:01:07Z
391,OK,1,81dee377bdc1216c3b5315525e2b2532bf9502cb977adecdc7a7b96a101e5af8,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_09a376ab8e1d17b901698780fa2f0081969e33b78ae8ff53a2,1770488058,1992,221,f82d1ce2da0719ad6b53914848ac866c46baef2a63b17637f146a5af6f69cca8,1,output[0].content[0].text,,"DRUG_1_NAME: MEM_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q12h (renal-adjusted for eGFR 37)
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset UTI with septic shock/vasopressors → requires IV broad Gram-negative coverage in first 24h.
- Prior ESBL history/colonization → empiric carbapenem to cover ESBL Enterobacterales.
- No MRSA risk factors provided → avoid routine MRSA coverage; meropenem also covers most urinary pathogens including some Pseudomonas.",MEM_IV,NA,NA,2026-02-08T05:01:07Z
392,OK,1,7d68d5def8c8a6fbb40612a5251b2bd4358cba956719d25336913ea36e6ff8bf,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_015559c49e3069d101698780fb206081a3875586d6ff750f9b,1770488059,1992,234,8a15168e0c0f2eadd958fa37413d7dd86cab0d33642c18430ed33807d3768568,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q6h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset pneumonia with septic shock/MV/vasopressors → needs broad IV empiric coverage including Gram-negatives (incl. Pseudomonas) and anaerobes while cultures pending.
- No MRSA history or recent healthcare/LTC exposure → avoid routine MRSA agent in first 24h.
- eGFR 52 mL/min/1.73m2 → standard TZP dosing acceptable for initial 24h in severe sepsis/shock.",TZP_IV,NA,NA,2026-02-08T05:01:07Z
393,OK,1,5a873f462319cd94bd1c4f4098f7864800903ed7eff052a9d481d3979021ccd6,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0d640e39d524ea5001698780fd1b7881938e0f04af3b94c3b9,1770488061,1973,231,68331e811a24fac6cfa3a484a0fdb95d95db47035d29d62e3821678d1543026e,1,output[0].content[0].text,,"DRUG_1_NAME: CZL_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q8h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset, low-severity SSTI with no MRSA/MDR history or recent healthcare/antibiotic exposure: narrow IV anti-staphylococcal/streptococcal coverage appropriate.
- Cefazolin provides strong MSSA and streptococcal activity; broad Gram-negative/antipseudomonal or MRSA coverage not supported by structured risk factors.
- Renal function normal (eGFR 113), so standard dosing used.",CZL_IV,NA,NA,2026-02-08T05:01:07Z
394,OK,1,b8d2546787927d134772010a143cca26ebc58df271e93b7ffc69a161fc971298,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_05f98820498e70b801698780fd99b88194b35700e91930dd8f,1770488061,1760,250,aaa29890504941772973f7dc1fb563b01488c020951c4a38e0c0602c73b9818b,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with respiratory failure (moderate severity): ceftriaxone + azithromycin provides standard empiric coverage for typical + atypical pathogens.
- No MDR/MRSA risk factors (no prior MRSA/ESBL, no recent hospitalization/antibiotics, no LTC), so no empiric anti-MRSA or antipseudomonal escalation.
- eGFR 18: ceftriaxone and azithromycin generally do not require renal dose adjustment, avoiding nephrotoxic agents in advanced CKD.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
395,OK,1,2b0f12af92074c960b02af0981becd1f250a3a52a7e61e16dedb15cd3a8a4931,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0f301133deec2f8701698780fed30081919791d1b60f53d619,1770488062,1983,210,0ce44fd6133a8c495ff28e41f4f056bfb63f04a05e4f48293f2ce28f43affd13,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset UTI with leukocytosis and markedly elevated CRP; ceftriaxone provides broad empiric Gram-negative coverage for typical uropathogens without unnecessary antipseudomonal/MRSA therapy.
- Low severity (no shock/ICU/MV) and no prior ESBL/CRE history; eGFR 61 supports standard dosing for first 24h.",CRO_IV,NA,NA,2026-02-08T05:01:07Z
396,OK,1,27cafa1895379126d41279603ec601a7240c2b6a6503d76a17bea7dfaa4291ae,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0334718addbf83980169878100c62481a190dbb556b885d1ec,1770488064,1981,245,cd8e59e21cf4cad61460039f458c3d5f8ef05874e16e8883d4e2ea0ffee19fdc,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q8h (extended infusion), renal-adjusted for eGFR 30
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset pneumonia with septic shock/MV/vasopressors → IV broad-spectrum empiric therapy for first 24h.
- TZP provides coverage for severe CAP with possible gram-negative pathogens (including Pseudomonas) given high severity and local respiratory ecology; no structured MRSA risk/history to justify routine MRSA agent.
- Renal dysfunction (eGFR 30) supports renal-adjusted dosing to limit toxicity while maintaining exposure (extended infusion).",TZP_IV,NA,NA,2026-02-08T05:01:07Z
397,OK,1,145a29adb7ed296ee95054c6ada0d367a144e31a69dd6ab20651dc177553db96,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_03edab8e07dfd7a60169878101a78881929feeb49486dd6c15,1770488065,1765,249,cd120db6ad095871b2f3a0d26c8f3613bdfe7e323ae34302120c5ecb11784462,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset, low-severity CAP without MDR/MRSA risk: ceftriaxone + azithromycin provides standard empiric coverage for typical and atypical pathogens.
- eGFR 50: no renal dose adjustment needed for ceftriaxone or azithromycin in the first 24h; avoids nephrotoxic aminoglycosides given CKD.
- No shock/ICU/MV: IV regimen acceptable but not escalated to antipseudomonal or MRSA agents based on structured risk profile.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
398,OK,1,12477262be4d669c22bbbee9d2caec73029fc85cad8dbd66411d868cb39e002e,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_096561d620f8b4160169878102123081a0bcf8ff56b3b435ff,1770488066,2013,263,26c045daf10f470869b6fe7e1b71d9eb62047ecf6005921c2677f355faa56ca1,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q12h (renal-adjusted for eGFR ~20 mL/min/1.73m2)
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset COPD infectious exacerbation with septic shock/respiratory failure (MV, vasopressors, ICU) warrants broad IV empiric coverage including Pseudomonas and other Gram-negatives.
- No MRSA history or major MDR risk factors provided, so avoid routine MRSA add-on in first 24h.
- Viral screen positive lowers bacterial probability but does not exclude severe bacterial coinfection given shock, leukocytosis, and elevated lactate; TZP provides single-agent broad coverage with renal adjustment.",TZP_IV,NA,NA,2026-02-08T05:01:07Z
399,OK,1,08c3e441b001ae0cf03b97d8fc7644b85e7e36c00612f4e48129dfd171e45a06,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0adf8c096c44bd1101698781047ab481909e99904545ea6ca0,1770488068,1696,253,32e7f74d9e4a2229f74e5ab119fd9d7a78254f2b0733a412f8f5f19378cfef30,1,output[0].content[0].text,,"DRUG_1_NAME: AMC_IV
DRUG_1_DOSE: 1 g/0.2 g
DRUG_1_INTERVAL: q8h (renal-adjusted for eGFR 49)
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Low-severity community-onset COPD infectious exacerbation with low inflammatory markers; narrow empiric coverage appropriate.
- Amoxicillin-clavulanate provides typical COPD pathogens coverage (H. influenzae, M. catarrhalis, S. pneumoniae) without routine MRSA or broad antipseudomonal therapy.
- Prior antibiotics/LTC increase MDR risk, but no shock/respiratory failure and no prior MRSA/ESBL history; avoid unnecessary broad combination therapy in first 24h.",AMC_IV,NA,NA,2026-02-08T05:01:07Z
400,OK,1,70885cc8e7d3e8ca045464df07b7fa4724b6cbc3f5a4905d59e01e6a9dd89f7b,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_071c12e8248a6c7101698781064604819795be99caf48da620,1770488070,1759,237,ccbf255c5652f2b30503168ae9c19e08e38f9866f05b827a8eaf15983e742c41,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset pneumonia with respiratory failure and very high CRP/WBC supports empiric antibacterial therapy despite positive viral screen.
- Ceftriaxone provides core CAP coverage (incl. pneumococcus and many Enterobacterales) while avoiding unnecessary MRSA/antipseudomonal combination therapy given no MRSA history and no recent hospitalization/LTC.
- Dose/interval selected to accommodate severe renal impairment (eGFR 17 mL/min/1.73m2) for the first 24h.",CRO_IV,NA,NA,2026-02-08T05:01:07Z
401,OK,1,656b03db6480fcfe159dc48d1881b9d5c138d91cf08f83e00b201e14ccd577f3,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_05e719870118130f016987810654d081a2b1a84ac75b91a72d,1770488070,1991,222,ce744664eb410ae3ae228892aab23be0490e09383f3488659b2f3520a780eb7e,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with documented respiratory failure → inpatient IV beta-lactam + macrolide for typical + atypical coverage.
- No MDR/MRSA risk factors and low inflammatory markers → avoid empiric anti-MRSA and antipseudomonal broadening in first 24h.
- Renal function normal (eGFR 110) → standard adult dosing; no renal adjustment needed.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
402,OK,1,8e92d3ff271d8a7eff9bb6054021dd8b226f0186b366fb446cf4094bf7d1ef4c,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0f3d280b811d0472016987810835b88193911cf236e74edfae,1770488072,1986,245,b8df40caa84dd673c291859439f7cabea947971bb21fd35778aa764c56d74b3a,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with respiratory failure and marked leukocytosis → empiric inpatient CAP coverage with beta-lactam + macrolide.
- No MDR/MRSA risk factors (no recent abx/hospitalization/LTC; no prior MRSA/ESBL) → avoid broader anti-pseudomonal or MRSA agents.
- eGFR 74 mL/min/1.73m2 → no renal dose adjustment needed for ceftriaxone/azithromycin in first 24h.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
403,OK,1,c13624344ced021e19fb5753f929eeba858d1aeb7173b0fa7f9825c8e30601c6,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_071db2f9a29a6c0d0169878109c6d48190b7e399edadc6de3f,1770488073,1984,263,97baa8097b643d82fea7a9ffaad337a58c197ce2213c4345d6551a662d79464b,1,output[0].content[0].text,,"DRUG_1_NAME: AMC_IV
DRUG_1_DOSE: 1.2 g
DRUG_1_INTERVAL: q8h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset COPD infective exacerbation with moderate severity/respiratory failure: IV beta-lactam/beta-lactamase inhibitor provides typical COPD pathogens coverage (H. influenzae, M. catarrhalis, S. pneumoniae) and some Enterobacterales.
- No septic shock/ICU/MV and no MDR/MRSA history or recent healthcare/antibiotic exposure → avoid routine MRSA or broad antipseudomonal combination therapy.
- eGFR 61 mL/min/1.73m2: no renal dose adjustment needed for this regimen in the first 24h.",AMC_IV,NA,NA,2026-02-08T05:01:07Z
404,OK,1,d056c7d59c6427efbed3bdaca25ae97d889f0ed4a92c05a41e2a5b1b45554729,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_09d796a86fa05d61016987810a2ba081a3a4dcc17648de6bc2,1770488074,2006,223,16a511af269a19b5287d9088719590887b3c263f7d89009f6705dae23a217318,1,output[0].content[0].text,,"DRUG_1_NAME: MEM_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q8h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset sepsis/bloodstream infection with very high WBC/CRP/PCT and respiratory failure → broad IV empiric therapy appropriate for first 24h.
- Prior ESBL history + recent hospitalization/antibiotics → carbapenem (meropenem) to cover ESBL Enterobacterales pending cultures.
- No prior MRSA history and no shock/line-related context provided → avoid routine MRSA add-on initially.",MEM_IV,NA,NA,2026-02-08T05:01:07Z
405,OK,1,b9a7ef0552e437a009db9db8364f41083534d913b066fe0e766bddbe3c8b7252,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0f3bf58b4959adc3016987810c6a008194b5f866b7246b0d1b,1770488076,2030,228,6645fe79b33db988050b7e0af6f6eb1d8af510c5646a248656667a9027d4f8f6,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with respiratory failure and leukocytosis: empiric beta-lactam + macrolide for typical + atypical coverage.
- Prior outpatient levofloxacin exposure (home antibiotics YES) favors switching class rather than repeating a fluoroquinolone.
- No MRSA history and no recent hospitalization/LTC: avoid routine MRSA coverage; renal function normal (eGFR 92), no adjustment needed.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
406,OK,1,e99dd628d0447d462139ec487d163e37981428e5c746c3097cbdcdb3804ba3f3,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0b6c6ecb1326c11f016987810dbf448190a8d4939b0c511bc9,1770488077,2020,237,97075692e7cbe889fa6f02ea1d1d42b082271558b97d9f93542f61a41f2f98af,1,output[0].content[0].text,,"DRUG_1_NAME: MEM_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q12h (renal-adjusted for eGFR 26)
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset pyelonephritis with septic shock/ICU-level severity → broad IV empiric therapy for first 24h.
- Prior ESBL history + recent antibiotics/hospitalization/LTC → carbapenem (meropenem) to cover ESBL Enterobacterales.
- Avoid added nephrotoxic combination (e.g., aminoglycoside) given CKD (eGFR 26) and severe thrombocytopenia.",MEM_IV,NA,NA,2026-02-08T05:01:07Z
407,OK,1,729444d0c10089ff970b341f9cb9d26f9b00ea00d3486a690dcdd66dca908d54,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0a8682616ae6dce7016987810de5b88191b68b2e7dbc6e5950,1770488077,1972,229,233e475c14b936279b4138a5d980de53ed6c9cb779d13a144f19e615a9314b29,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset, low-severity CAP with marked leukocytosis; ceftriaxone + azithromycin provides standard empiric coverage for typical and atypical pathogens.
- No septic shock/ICU/MV and no MDR/MRSA risk factors, so no need for broader anti-pseudomonal or MRSA therapy in first 24h.
- eGFR 78: no renal dose adjustment needed for either agent.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
408,OK,1,a00afe9c4a16cbe7f42deab488b7aeef21ca562871ca28d820924f70490cd7ac,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_01773d895d02210501698781108a488193a8b93178844b85a2,1770488080,2052,229,af90019654727eb86fe06137a63eb3aa7f4508305f2a9fc9fa1d37de598c49a8,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q6h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset pneumonia with respiratory failure plus recent hospitalization/antibiotics → broaden initial Gram-negative (incl. Pseudomonas) coverage; single-agent antipseudomonal beta-lactam.
- No MRSA history/risk provided and not in shock/ICU → avoid empiric MRSA agent.
- eGFR 96 mL/min/1.73m2 → no renal dose adjustment needed for first 24h.",TZP_IV,NA,NA,2026-02-08T05:01:07Z
409,OK,1,f0eb8f9b8c53141bbdbed231b163dbf48350304995b335fc56d254dcc0c47b18,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0b1d601721a9e06401698781110cd88190b15a0343aa533acd,1770488081,2044,256,1f56203fec17a55985c89ed5b40403ee130805f113c306e2ffc130e3b80996b8,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with sepsis/respiratory failure and elevated WBC/CRP → empiric IV beta-lactam + macrolide for typical + atypical coverage.
- Recent outpatient AMC1G_PO suggests possible beta-lactam pre-treatment; ceftriaxone provides broader pneumococcal/H. influenzae coverage while avoiding unnecessary antipseudomonal/MRSA therapy (no specific risk/history provided).
- Renal function normal (eGFR 117): no renal dose adjustment needed for ceftriaxone/azithromycin.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
410,OK,1,32be6a50926d2f919fad444988c06f862b1852cc1f2ab1b6c1c497141393980c,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_04d086dac8b83c9601698781125614819495cf7cf663d996eb,1770488082,2072,231,abc97f5582d037289dab20d36abdd2e56c74b095d09633cc62e2cbeb4ae288eb,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with respiratory failure (moderate severity) warrants IV therapy; ceftriaxone + azithromycin provides standard empiric coverage for typical and atypical CAP pathogens.
- No MRSA or MDR risk factors and no recent healthcare exposure; avoid routine VAN/anti-pseudomonal therapy.
- eGFR 56: no renal dose adjustment needed for ceftriaxone or azithromycin in first 24h.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
411,OK,1,07701d6bbe52cc0d1cb5a2ad8350234326a69181767dfe91ff0842d62e1b95b3,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0bae3d9215720dc90169878114a5a881a1bbc93725b02a5136,1770488084,2002,229,ce2a316805171dd5ecfbd3702911cd4be0bd01b94c2363b6fb007b8c51223106,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with moderate severity/respiratory failure: ceftriaxone + azithromycin provides typical + atypical coverage for first 24h.
- No MDR/MRSA risk factors and no shock/ICU/vasopressors/MV: avoid broader anti-pseudomonal or MRSA agents.
- Renal function preserved (eGFR 119): no renal dose adjustment needed for this regimen.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
412,OK,1,acf1bef836d854398395581e9fce28a2400fdc085ffa1c0d992585cd15f3e9c4,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_02ce70e956afca5d0169878115e19c8195bc34b5461a517cef,1770488085,2103,232,56ec6a657527a0262f1223dfeef0ba70f3fdf534ce24e8ae44be0d5b3b5a9947,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with low severity and no septic shock/ICU needs; ceftriaxone provides standard empiric bacterial CAP coverage while awaiting cultures.
- Viral screen positive and normal WBC/lactate lower bacterial likelihood; avoid broader therapy and avoid repeating fluoroquinolone after home ciprofloxacin exposure.
- eGFR 25 mL/min/1.73m2: ceftriaxone typically does not require renal dose adjustment for this short empiric course.",CRO_IV,NA,NA,2026-02-08T05:01:07Z
413,OK,1,0431d1c84b3fd457b99885183aa4a56b7ec5a207a777f66c7fdc71b4f82f4e65,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0b440bec24e7909f0169878116c44c8196a809c88675aef40e,1770488086,1986,226,15650502d0eacd963a39a59f9809f91345464eadabc71421cb15cec2f7bed1f2,1,output[0].content[0].text,,"DRUG_1_NAME: FEP_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q12h (renal-adjusted for eGFR 36)
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Severe community-onset pneumonia with respiratory failure requiring MV/NIV → IV therapy and broad Gram-negative coverage including Pseudomonas with cefepime.
- Add azithromycin for atypical pathogen coverage in severe CAP.
- No MRSA risk factors (no prior MRSA, no recent healthcare/LTC exposure) → avoid empiric anti-MRSA agent.",FEP_IV,AZM_IV,NA,2026-02-08T05:01:07Z
414,OK,1,75dc97c1602baa76815ad9b819aae0e60040779cf1602dbeda24bac8c4e6b5ec,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_07b065b6e7d573f701698781181e1c8190979642caeff7a54a,1770488088,1986,249,7057e4332db2006d6ecdf125cbc1c54c3858e3f26c33266c42fde728eb2164b7,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h (renal function unknown)
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset UTI with septic shock/vasopressors → IV broad Gram-negative coverage appropriate; ceftriaxone covers typical Enterobacterales (E. coli/Klebsiella/Proteus) without routine anti-MRSA.
- No major MDR risk factors (no recent abx/hospital/LTC; no ESBL/CRE history) → avoid carbapenem/anti-pseudomonal escalation initially.
- Single-agent regimen to limit toxicity; avoid aminoglycosides given severe renal dysfunction (eGFR 2).",CRO_IV,NA,NA,2026-02-08T05:01:07Z
415,OK,1,de9770292039d6c4dc7406e62e9bb591195ed02d197c08d87814f256057fa3da,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0f725df282fb1fcd0169878119de308195a3b5441668130548,1770488089,2006,223,f1c37417916b597ffe9b0b2791d55f1621ab377acc8efdc57ea0efba761b6d09,1,output[0].content[0].text,,"DRUG_1_NAME: MEM_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q8h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Septic shock with MV/vasopressors/ICU transfer: broad IV empiric coverage for severe community-onset pneumonia.
- Prior ESBL history and recent hospitalization increase risk for ESBL Gram-negative pathogens; meropenem provides ESBL and Pseudomonas coverage.
- Add azithromycin for atypical coverage in severe CAP; no MRSA agent since no prior MRSA history provided.",MEM_IV,AZM_IV,NA,2026-02-08T05:01:07Z
416,OK,1,560d033657342fb692fdf73e7f16fe170e476afe4075e0b463951e71a1fa0dea,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0a2e617174a15195016987811a5b8c81a3b7934aa3da7a53cc,1770488090,1982,233,1d5244723acbb089eafbe4b1c1ce54d97d446146ab6bfed789bdf5c7410c4c6b,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Moderate community-onset CAP with respiratory failure and high inflammatory markers (WBC 16.5, CRP 223.5) → empiric IV beta-lactam + macrolide for typical + atypical coverage.
- No MDR/MRSA history or recent healthcare/antibiotic exposure → avoid routine anti-MRSA or antipseudomonal therapy.
- Renal function normal (eGFR 92) → standard dosing appropriate.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
417,OK,1,c454fed48b8150d04c4a84819a187a90f519b5ecba574bbaa95568a106c0bfa3,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0cc402473e774e8e016987811c9600819ea01a205c65c3f471,1770488092,1981,213,4f3744615abe3ab46118bd8bb5a20025f3f5592af0bfda3ea05da7b726230156,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h (renal function unknown)
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset UTI with low severity and no MDR risk factors: ceftriaxone provides appropriate empiric Enterobacterales coverage without unnecessary broad anti-pseudomonal or MRSA therapy.
- Avoid aminoglycosides given advanced CKD (eGFR 16) and nephrotoxicity risk; ceftriaxone is generally suitable in renal impairment.",CRO_IV,NA,NA,2026-02-08T05:01:07Z
418,OK,1,a5032189b422cea32f65467ddd1a98bf77854d8e4d831b9f89f586d0f6f53e49,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0016a523511412da016987811d3824819fb36b73644dff98c3,1770488093,1981,250,30c3141f320105a78c2b82b17a60f05736d2b26dec6c16cb81ec700006ad9de1,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Moderate community-onset CAP with respiratory failure and elevated WBC/CRP: empiric beta-lactam + macrolide for typical + atypical coverage.
- No MDR/MRSA risk factors (no prior MRSA/ESBL, no recent antibiotics/hospitalization/LTC), so no routine anti-MRSA or antipseudomonal escalation.
- eGFR 74 mL/min/1.73m2: no renal dose adjustment needed for ceftriaxone/azithromycin in first 24h.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
419,OK,1,f3e4981977fd7ebb83ce2ead855847206e2339c8e689b0005ed856c92f640958,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0e7618415f206cef016987811dc24c81a1b776c8afbca197c1,1770488093,2004,244,b9f4b1ef17924e178fb3f180848df95a9a9133a5056951fa938f61a745429c59,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q12h (renal-adjusted for eGFR 13)
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset septic shock with respiratory failure: needs immediate broad IV Gram-negative/anaerobe and streptococcal coverage; TZP provides single-agent broad empiric coverage.
- No structured MDR risk factors and no prior MRSA/ESBL history, so avoid routine MRSA add-on in first 24h.
- Severe CKD (eGFR 13) requires renal dose/interval adjustment; q12h dosing selected for initial 24h.",TZP_IV,NA,NA,2026-02-08T05:01:07Z
420,OK,1,d618a2c26d9ce664bb99180bdc8692527c4a7bf721bc40ce12a6a1fea990d3e9,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_04797d6cce17030e01698781200b8481a0a6622190c57ffbd7,1770488096,2090,243,8ef52b72d9fbb11950313a0f64b4cbef6a29171f149b797146e970a7b9f80b75,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with respiratory failure and elevated CRP; IV beta-lactam + macrolide provides empiric typical + atypical coverage.
- No MRSA/ESBL/CRE risk factors and no septic shock/ICU needs, so avoid broader anti-pseudomonal or MRSA agents.
- eGFR 23: ceftriaxone and azithromycin generally do not require renal dose adjustment; avoids further fluoroquinolone exposure after home LEV_PO.
",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
421,OK,1,46b4fcdb88e27fa71f40b6701eb980c1206d92784b544d4e12bd0846d2e6a534,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0e4f444cc803230a016987812136b881918443ae7026662d1a,1770488097,1980,219,2e262e639f2fabb1ba2217d4e2ab5abde1a51e00400be515383750188817c747,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset UTI with low severity; ceftriaxone provides appropriate empiric Gram-negative coverage for typical uropathogens.
- No septic shock/ICU needs and no prior ESBL/CRE history, so avoid broader antipseudomonal/carbapenem therapy in first 24h.
- eGFR 124 mL/min/1.73m2: no renal dose adjustment needed.",CRO_IV,NA,NA,2026-02-08T05:01:07Z
422,OK,1,dafbf4c163b890cf2d559a1cfb7447b6af8a2997821abc6ff71b3ebc3d1baa85,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_04f462721e2d75240169878121b75c819fbe97b77fb8dd853d,1770488097,1992,250,b39fc807f16fd57eff93d29b4f09265a47654d1e47f6c64e008e9b230587bcef,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset UTI with marked leukocytosis/CRP; ceftriaxone provides appropriate empiric Gram-negative coverage (E. coli/Klebsiella/Proteus) without unnecessary antipseudomonal or MRSA therapy given no MDR risk factors.
- Severe CKD (eGFR 18): ceftriaxone generally does not require renal dose adjustment and avoids aminoglycoside nephrotoxicity in the first 24h.
- Low severity (no sepsis/shock/ICU needs): single-agent IV therapy is sufficient pending cultures.",CRO_IV,NA,NA,2026-02-08T05:01:07Z
423,OK,1,8adb7108c055d6d20adf33e4b5aa42f9019f89cd7e1e48a29db13fec57da2021,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0907f27c3e53563e016987812384cc819599bbff319a363bab,1770488099,1972,228,570cdf40da69eeeb59e398743f64830209e40919ef5c4a23a417b41005f525ca,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Moderate community-onset CAP with respiratory failure: ceftriaxone + azithromycin provides standard empiric coverage for typical and atypical pathogens.
- No septic shock/ICU/MV and no MRSA history: avoid routine MRSA coverage.
- eGFR 69 mL/min/1.73m2: no renal dose adjustment needed for ceftriaxone or azithromycin in first 24h.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
424,OK,1,ddb5621d7f2b0f71c26434c0567976b42140aeb6d339e6debd49c0d446d3ea15,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0d88bbfbd15670eb01698781244670819288ab8cdec500277b,1770488100,1987,244,65fcad0273a4c18d5afb1fb5a39aaf4a3260aeb6dd175e92e9dba4bad43fa5d0,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h (no renal adjustment needed at eGFR 8)
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Low-severity community-onset CAP without sepsis/respiratory failure and low inflammatory markers → narrow single-agent beta-lactam reasonable for first 24h.
- No MRSA or MDR risk factors documented; avoid routine MRSA/antipseudomonal coverage.
- Severe CKD (eGFR 8) favors avoiding nephrotoxic agents (e.g., aminoglycosides) and using ceftriaxone which does not require renal dose adjustment.",CRO_IV,NA,NA,2026-02-08T05:01:07Z
425,OK,1,6c6f0fee055a8f20839ce7b988c46145dee244e2e43939a8473d742526f20e46,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0fd5742036268df20169878125a9d881a2a181989b55b79e99,1770488101,2001,232,42db304eeb49b413bd087b22ed1615b599aa57ad5a9f255d90d884b5e618a903,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q6h (renal-adjusted for eGFR 54)
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Severe community-onset pneumonia with septic shock/MV/vasopressors → broad IV empiric coverage including Pseudomonas/Gram-negatives and anaerobes (TZP_IV).
- Add atypical coverage for CAP in critical illness (AZM_IV).
- No MRSA history or MDR risk factors provided → avoid routine MRSA agent in first 24h.",TZP_IV,AZM_IV,NA,2026-02-08T05:01:07Z
426,OK,1,410786f9c815216e019ce48b645ef87fc1ae36d45dc978527c87734bc0af5e78,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0aaa1be8bde9b77d01698781278a1c8191898ae6881c87a922,1770488103,1989,264,20b0a7e15e5a228602e2be68b0cbc6b3c3912736b933e10b00e98976f205a586,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h (renal function unknown)
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset UTI with sepsis and markedly elevated inflammatory markers (WBC 23.1, CRP 139, PCT 12.27) warrants empiric IV therapy.
- Ceftriaxone provides broad Enterobacterales coverage typical for UTI (E. coli/Klebsiella/Proteus) without routine MRSA/anti-pseudomonal escalation given no prior ESBL/CRE history and no shock/ICU needs.
- Avoids unnecessary combination therapy in an elderly patient with thrombocytopenia (Plt 53) and CKD (eGFR 33).",CRO_IV,NA,NA,2026-02-08T05:01:07Z
427,OK,1,a82ee17087bfe92982b188b53f6f9e62baf5f668b195a312fa05aa3f65e1a2b0,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_025b3d8b778ccb5d0169878127fd5c819fba33cd26e9744b7f,1770488104,1986,223,acf9dc10929a8d8f4cf9a688e651c0341db8da4810046755155b76b06a0bf1eb,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q8h (renal-adjusted for eGFR 27)
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset UTI with septic shock/ICU-level severity → broad IV Gram-negative coverage including Pseudomonas while cultures pending.
- No major MDR/MRSA history or recent healthcare exposure → avoid routine MRSA/dual broad-spectrum therapy.
- Renal impairment (eGFR 27) supports renal-adjusted TZP dosing for first 24h.",TZP_IV,NA,NA,2026-02-08T05:01:07Z
428,OK,1,43a9a729335d67760a29802f55589dd3d0e37da0acf64ed7dbf1d4d20f47a8c1,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0673d4529929623601698781290cc881a3be9913944b2ec460,1770488105,2080,237,ffae3910d5876b6efc063b66bc5f431f38daad9de422d6dc4800fc4901765847,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h (no renal adjustment)
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset UTI with marked leukocytosis/CRP and failure/pre-treatment with SXT_PO → give parenteral empiric therapy.
- No MDR history/exposure and low severity → ceftriaxone provides appropriate broad Enterobacterales coverage without unnecessary anti-MRSA/anti-Pseudomonas therapy.
- Severe renal impairment (eGFR 7) → avoid nephrotoxic aminoglycosides; ceftriaxone does not require renal dose adjustment.",CRO_IV,NA,NA,2026-02-08T05:01:07Z
429,OK,1,3767067ad900e1c8b42c2fcf9b811b07d28a771d11f50bdaa22441c412653ddb,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_05dc2c1e5a4dd533016987812b40f481a39be1e895d423b04e,1770488107,1983,224,de7627f0a6225f1497e2f953bc2b3890f7cf3813e7cec46bae0c53e9b2a70cfa,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with documented respiratory failure (moderate severity): IV beta-lactam + macrolide for typical + atypical coverage.
- No MDR/MRSA risk factors and very low CRP, so avoid broader anti-pseudomonal or MRSA agents in first 24h.
- eGFR 119: no renal dose adjustment needed for ceftriaxone/azithromycin.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
430,OK,1,3d255087d25038f49aa0085403da88d574d44d0cfac0bb02a9237a9c04e1c7ce,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0a66bad6d4a81902016987812ba43c819494ce394dea5d3941,1770488107,1973,244,bee42ed5de227f074af3e5a3bc27cbd3b031fdf0972674457a4b4137f753dce6,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q8h (renal-adjusted for eGFR 29)
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset UTI with septic shock/ICU-level severity → broad IV Gram-negative (incl. Pseudomonas) empiric coverage appropriate.
- No major MDR/MRSA history or recent healthcare/antibiotic exposure → avoid routine MRSA/dual therapy; TZP provides Enterococcus faecalis and anaerobe coverage if complicated UTI source.
- Renal impairment (eGFR 29) → use renal-adjusted interval in first 24h.",TZP_IV,NA,NA,2026-02-08T05:01:07Z
431,OK,1,3c15e9d21df31855e17e229019138db71b3b3b89308cf391266e4fb96a58e153,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0cee18cc4dc10758016987812cb6a0819d90043101e379830a,1770488108,1992,214,503e08533ec2fd12e22c41bcda6154beb67c7013bf56d57613a26bbcda4dc13f,1,output[0].content[0].text,,"DRUG_1_NAME: MEM_IV
DRUG_1_DOSE: 500 mg
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset sepsis/bloodstream infection with very high CRP and history of ESBL colonization → empiric carbapenem for ESBL-risk Gram-negative coverage.
- Severe renal impairment (eGFR 8) → renal-adjusted meropenem dosing.
- No MRSA history or strong MRSA risk factors provided → avoid routine glycopeptide/anti-MRSA add-on.",MEM_IV,NA,NA,2026-02-08T05:01:07Z
432,OK,1,79bc35730198d66a45e065d1a3fe82fded2582f2263d9cf4942a33a4fc03e925,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0cc61dda80d861c1016987812e6e9c81a3a036648ad1ef784b,1770488110,1978,219,94b691206f611cd81be00a952e9122df8f6d902fdf5c754d59a060f7f7aaedad,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset COPD infectious exacerbation with respiratory failure (moderate severity) warrants IV empiric coverage for typical respiratory pathogens plus atypicals.
- No MDR risk factors or prior MRSA/ESBL history, so avoid routine anti-MRSA or broad anti-pseudomonal therapy in first 24h.
- Normal renal function (eGFR 95) supports standard dosing.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
433,OK,1,10baa1ec4a4af3e80ba84fd3bd86bd69cfca94ffae9fad660a7a5d3f231953a0,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_036941a5b52aa469016987812f77108194955533de0465154a,1770488111,1995,246,31be086a337568d8c8f84d21787f8e7435d82fd355dda20c3049680288b14ec1,1,output[0].content[0].text,,"DRUG_1_NAME: FEP_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q12h (renal-adjusted for eGFR ~51)
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset pneumonia with sepsis and respiratory failure plus LTC residence/immunosuppression → broaden initial Gram-negative (incl. Pseudomonas) coverage with cefepime.
- Add azithromycin for atypical CAP pathogens and potential immunomodulatory benefit; no MRSA history/risk provided, so avoid empiric anti-MRSA.
- Doses reflect renal function (eGFR 51) for first 24h empiric therapy.",FEP_IV,AZM_IV,NA,2026-02-08T05:01:07Z
434,OK,1,d7273ac3f5aab916da63a4aba341982fb33eaf5922eada7992f2f36b5270f67c,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0142da286c181f8c016987813013d881a19d0914c3b5dd88aa,1770488112,1994,226,de006d19c9aa5e74e31458a451a44a40e8302a161b7bc5d0ee5f62f5fea6d13a,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset pneumonia with respiratory failure (moderate severity): IV beta-lactam + macrolide for typical + atypical CAP coverage.
- No prior MRSA history and no LTC; avoid empiric MRSA agents.
- eGFR 38: ceftriaxone and azithromycin do not require renal dose adjustment at this level; avoids nephrotoxic aminoglycosides in CKD.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
435,OK,1,cf9530e6d1a4378421d5810d65594af26026b16c9963d4a80200133f06609dbb,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_03f2544067390d7a0169878131d6c481949d796f9555604ddb,1770488113,1991,236,d9d5e3fafd945a9e0722c7c009b84a83595b46c9985416173d75dbd4feedb2f6,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset pneumonia with respiratory failure (moderate severity): IV beta-lactam + macrolide for typical + atypical CAP coverage.
- No MDR/MRSA risk factors (no recent antibiotics, no recent hospitalization, no LTC, no prior MRSA/ESBL): avoid broader agents and MRSA coverage.
- eGFR 42: ceftriaxone and azithromycin do not require renal dose adjustment at this level for first 24h.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
436,OK,1,5c60820cbaa4689630b7f6b50a9d8e6ca8903c32f5a3c0161242d57230832596,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_05db1e35a830f7b10169878133527c8197986115775c01820f,1770488115,2059,254,8c2209032cc5c3938ccacb72eb4a0b4b5e6fa424047609aab8694fb82d7cd415,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset pneumonia with respiratory failure and elevated WBC/CRP → empiric CAP coverage with IV beta-lactam + macrolide.
- Recent outpatient cefuroxime (CXM_PO) suggests possible treatment failure; ceftriaxone broadens typical respiratory pathogen coverage without routine MRSA/ESBL coverage (no prior MRSA/ESBL/CRE/VRE, no LTC/hospitalization).
- eGFR 53: no renal dose adjustment needed for ceftriaxone or azithromycin in first 24h.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
437,OK,1,d7178f9e583903289328a5539905a927ae80a634befc40dfacc9ce96fb44cbde,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_08587e0c0f749a17016987813390d081a0944bcbe1ff324280,1770488115,1988,234,21c470053abf9c0e2299e42c1c90ee3e0a8a8a0acf03855153d6428a5b5804f6,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Severe community-acquired pneumonia with MV/NIV and ICU transfer → IV beta-lactam + macrolide for typical + atypical coverage in first 24h.
- No MDR risk factors or prior MRSA/ESBL history → avoid routine anti-MRSA or antipseudomonal therapy.
- eGFR 72 mL/min/1.73m2 → no renal dose adjustment needed for ceftriaxone/azithromycin.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
438,OK,1,9765df72f5509582b3dab8382fc584192edde1bf97cf9851dd4b8aceef1b886e,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_06b28ad7d29153f001698781354ee48196979be527c6910480,1770488117,2006,231,80183f42be3cfacece87ad4fe84374b9d9f18f006e0137af44b37c5200701011,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h (renal function unknown)
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset pyelonephritis without shock/ICU needs: ceftriaxone provides appropriate empiric Gram-negative coverage for typical uropathogens.
- Avoids unnecessary broad antipseudomonal/MRSA therapy despite recent healthcare/antibiotic exposure, given no prior ESBL/CRE history and low severity.
- Once-daily IV dosing is practical with eGFR ~30; ceftriaxone generally does not require renal adjustment.",CRO_IV,NA,NA,2026-02-08T05:01:07Z
439,OK,1,e593d9a2625a7001a3a23c48503715e89b2a90f3d5852ec68f2153d8930f3ac3,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_09166a2e65c25e4901698781372da0819cb3a03e02aaf3eb0b,1770488119,1990,233,6e4fee2487921a356a581610f3745dff28f68c490bb25249beb1bf5fb472bc21,1,output[0].content[0].text,,"DRUG_1_NAME: FEP_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q12h (renal-adjusted for eGFR 54)
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset COPD infectious exacerbation with respiratory failure and high PCT (7) supports empiric antibacterial therapy.
- Cefepime provides broad Gram-negative (including Pseudomonas) and reasonable pneumococcal coverage; local prior shows notable Pseudomonas/Klebsiella prevalence.
- No MRSA history or major MDR risk factors, so avoid routine MRSA/combination coverage in first 24h.",FEP_IV,NA,NA,2026-02-08T05:01:07Z
440,OK,1,f4402d047b81e0e03d585d835a7dae5737431ce1626ddf22826fc04655d04bf9,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0b757ea28b6f80cf016987813795908194919e790257a237b8,1770488119,1985,233,43a32c017bbd8289663d252495f31018f00e4b4ec748ddf4658c1aa94877e92e,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with respiratory failure (moderate severity): ceftriaxone + azithromycin provides standard empiric coverage for typical + atypical pathogens.
- No MDR/MRSA risk factors and no septic shock/ICU/vasopressors: avoid broader anti-pseudomonal or MRSA agents.
- eGFR 58: no renal dose adjustment needed for ceftriaxone or azithromycin in first 24h.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
441,OK,1,39d456067465215e65d037f3c962ef60b304db99e6a26f347934b6bdfa8563c3,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_073d9841995b7abb016987813941188190abdaa84871479492,1770488121,1987,246,e90d74f4c99e00614896cef776da313478a75771bb00385fe5d76de63b6ca758,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with respiratory failure and very high CRP; IV beta-lactam + macrolide provides typical + atypical coverage for first 24h.
- No MDR/MRSA risk factors (no prior MRSA/ESBL, no recent antibiotics/hospitalization/LTC), so no empiric MRSA or antipseudomonal escalation.
- eGFR 77 mL/min/1.73m2: no renal dose adjustment needed for ceftriaxone or azithromycin.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
442,OK,1,c16b02399908e240a3a16d445bdfb9bc97e41f9f7009e9adb7e66c52b83ef1e6,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_08d8b484bf1b603b016987813ae0b0819eb0fca11e7c1b9f4e,1770488122,1973,233,6846c5976db652f8b928efa605edf7b7e737cd650d7dba9ba1bb2c4468907907,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset UTI with marked leukocytosis/CRP but no shock/ICU needs: ceftriaxone provides appropriate empiric Gram-negative coverage (E. coli/Klebsiella/Proteus predominant) without unnecessary antipseudomonal breadth.
- No MDR risk factors or prior ESBL history; MRSA coverage not indicated.
- eGFR 55 mL/min/1.73m2: no renal dose adjustment needed for ceftriaxone.",CRO_IV,NA,NA,2026-02-08T05:01:07Z
443,OK,1,92cf9d56398c1c2d2d2fe869a31889f290463d21ce830a63c5c73dd79009bf50,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0dced80aaa5a618d016987813ae5b08194af5136957c4680a9,1770488122,1992,245,82c19595c246abb2b5cf9ebd008d9d97f920b9a3d942204e9c314a5afeb475fe,1,output[0].content[0].text,,"DRUG_1_NAME: FEP_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q12h (renal-adjusted for eGFR 52)
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Septic shock with MV/vasopressors in community-onset pneumonia + recent hospitalization: broad IV antipseudomonal beta-lactam (cefepime) for severe CAP with higher Gram-negative/Pseudomonas risk.
- Add azithromycin for atypical coverage and potential benefit in severe CAP.
- No MRSA agent: no prior MRSA history provided and no LTC; avoid routine MRSA coverage absent structured risk factors.",FEP_IV,AZM_IV,NA,2026-02-08T05:01:07Z
444,OK,1,fe022d3c86aec8f6d5c977c2eabc11bbd846479b7dd94c5bf2b0a366ad8119c6,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0ca50991782bd006016987813d457c8195ab068aef704780fc,1770488125,1993,218,5efa76c4c7992ac837143288cc6993cb2eb12f9f3dfd8b5f2d7e4e21b5c0bc77,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with respiratory failure and very high CRP → empiric inpatient IV CAP regimen covering typical pathogens plus atypicals.
- No MDR/MRSA risk factors → avoid broader anti-pseudomonal or MRSA agents in first 24h.
- eGFR 32: ceftriaxone and azithromycin do not require renal dose adjustment at these doses.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
445,OK,1,5fd22b4aaa36a19b9aa4f5e30e1cd1d4fc68630c7351accb7f7a7ad0972558f3,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0b5077f5caa314a3016987813ea31c81a28a6936c6c31c7a37,1770488126,2093,227,e560d2f59f0c84a0b294219454f0d3d70a282308847e67b72033f2ad8b8b41f6,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset pneumonia with respiratory failure and very high CRP/PCT despite pre-treatment with oral cefuroxime → escalate to IV CAP regimen.
- Ceftriaxone provides core pneumococcal/Enterobacterales coverage; azithromycin adds atypical coverage.
- No MRSA or MDR risk factors in structured data → avoid routine VAN/LZD and antipseudomonal therapy in first 24h.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
446,OK,1,b0549e6e0a527c0eaf5791dbeea3f0ae5f8197e68d80f3ab3e6a2beb55a7fcbf,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0a94ef4fc8815fc6016987813eeb888195b43dd56e7e865e96,1770488126,1998,245,0a20b4b3549201a108b18cc1492e401b78970885713ba639f2e48f0a63025919,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset pyelonephritis without sepsis/shock: ceftriaxone provides appropriate empiric Gram-negative coverage (E. coli/Klebsiella/Proteus) with low complexity.
- No MRSA/ESBL history and no LTC; recent hospitalization alone does not mandate broader antipseudomonal or carbapenem therapy in a low-severity presentation.
- eGFR 61 mL/min/1.73m2: no renal dose adjustment needed for ceftriaxone in the first 24h.",CRO_IV,NA,NA,2026-02-08T05:01:07Z
447,OK,1,4cf9ca75b949a1b370d57b320a9f28f526d9130cce2d671303aaf131fd70959b,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_002ee0f3ac2e85b5016987814082a48194a24e278bf8355c62,1770488128,1996,224,04527072c38b3ecd2d59234521ac5d6e75f27abaaf185f2bedb145c5f384af3a,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h (no renal adjustment needed at eGFR 51)
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset pneumonia with respiratory failure and elevated CRP/lactate → empiric inpatient CAP coverage with IV beta-lactam + macrolide.
- No MRSA history and no clear MDR risk beyond recent hospitalization → avoid routine VAN/anti-MRSA; CRO provides pneumococcal/typical coverage, AZM adds atypical coverage.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
448,OK,1,b62bf7fff3dde20a88f8d1d063efb757a87471842dea52ed9fba406994e9933b,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_03c3f67c60621b700169878142269081939b44afee85f398cf,1770488130,1980,232,b79c1310c999beac48d7677456d77d5e561f77eff4a3b038fb21bc75fbd7f0e9,1,output[0].content[0].text,,"DRUG_1_NAME: AMC_IV
DRUG_1_DOSE: 2 g/200 mg
DRUG_1_INTERVAL: q8h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset COPD infectious exacerbation with moderate severity/respiratory failure: cover typical respiratory pathogens and beta-lactamase producers with a single agent.
- No MDR risk factors or prior MRSA/ESBL history; WBC/CRP only mildly elevated, so avoid broader antipseudomonal/MRSA combination therapy in first 24h.
- eGFR 95 mL/min/1.73m2: no renal dose adjustment needed.",AMC_IV,NA,NA,2026-02-08T05:01:07Z
449,OK,1,d1f6ec992d6ecc2a7c693315ac10a155ce40d83944ccad07cfe228a048c49071,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_04bb10d24d3a8b830169878142aa048191914c952680258128,1770488130,1986,257,028066031d00947a8b4a98f72654f8d7fa8a910e69b3b0cb9228691772552d25,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h (renal function unknown not applicable; eGFR 28)
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with respiratory failure (moderate severity): ceftriaxone + azithromycin provides standard empiric coverage for typical + atypical pathogens without routine MRSA/Pseudomonas coverage given no MDR risk factors.
- Avoids nephrotoxic agents (e.g., aminoglycosides) in eGFR 28 and limits unnecessary broad-spectrum therapy.
- Ceftriaxone dosing acceptable at eGFR 28; monitor given marked hepatic injury/cholestasis on admission.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
450,OK,1,db8597ee01a466f325c2a7e42d633eddf1b5d1ed707dbb6cc9213b542353ca98,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0614d478084a58d90169878144ad84819097a9024f70d7eb83,1770488132,1999,236,f8f753aaba2d2a57df424ec17961015ddfb877c787ccf019885b6016312fa35d,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h (no renal adjustment needed at eGFR 3)
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with respiratory failure and leukocytosis: ceftriaxone + azithromycin provides standard empiric coverage for typical and atypical pathogens.
- No structured MDR/MRSA risk factors; avoid broader anti-pseudomonal or MRSA agents in first 24h.
- Severe renal impairment (eGFR 3): selected agents are appropriate without dose reduction for initial dosing.
",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
451,OK,1,c8616e5cd521e25e6750235ea236deafb3a6934e1e8b1cd6c6e515ca35416502,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0579a95a1779e81001698781459cc8819780789c5ca9f735cc,1770488133,1994,226,9000229ed40483327fc6b7b26868aa24c0b28bef83ab1a9e17cf38d6ce013596,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with respiratory failure and elevated WBC/CRP: empiric inpatient CAP coverage with beta-lactam + macrolide.
- No MDR/MRSA history or recent healthcare exposure: avoid routine anti-MRSA or antipseudomonal therapy.
- eGFR 54: ceftriaxone and azithromycin do not require renal dose adjustment at these doses for first 24h.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
452,OK,1,f6fb6b9d09c80996233efb787ca950d9c1d9fdfd280b07f20c839bf8823a1ea9,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0286451b9d1159d50169878146ace081a18da29418b227b05f,1770488134,1975,225,8a150b70741c3e8fc799249ca3ceda1c524c6bb0a7c465963073f4d60ab253e0,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with respiratory failure (moderate severity): ceftriaxone + azithromycin provides standard empiric coverage for typical and atypical pathogens.
- No MRSA or MDR/Pseudomonas risk factors in structured history, so avoid broader anti-MRSA/anti-pseudomonal therapy.
- eGFR 88: no renal dose adjustment needed for either agent in first 24h.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
453,OK,1,6b9c191670871d9edc584b33faf8d2307a05fc765a09e6f6ae63a6907e370078,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_075ff62488d4247a01698781487d248195a41c932fe3fb19f9,1770488136,1985,224,cdf175a98f2057f4be81dc84714540d97c36c7e3db802262026984ff02482e9f,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset COPD infectious exacerbation with respiratory failure → inpatient IV therapy covering typical respiratory pathogens plus atypicals.
- No MDR risk factors and no MRSA history → avoid routine anti-MRSA or antipseudomonal escalation in first 24h.
- eGFR 109 mL/min/1.73m2 → no renal dose adjustment needed for ceftriaxone/azithromycin.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
454,OK,1,2aa8f5cb0d112747562e8654548162ff92e94fe80397dc0d3976bdc45f9ba4da,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_084917c3fb9d475d016987814a0568819fb197a71c39a2becf,1770488138,1988,234,297921d1e3e45a34de5a98b5c1b7104bfe7c59b1242d39c927638510bacfb388,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset UTI with sepsis (but no shock/ICU needs): ceftriaxone provides broad empiric Gram-negative coverage for likely Enterobacterales.
- No major MDR risk factors (no recent antibiotics/hospitalization/LTC; no ESBL history), so carbapenem/anti-pseudomonal therapy not indicated initially.
- eGFR 63 mL/min/1.73m2: no renal dose adjustment needed for ceftriaxone in this range.",CRO_IV,NA,NA,2026-02-08T05:01:07Z
455,OK,1,12a69caa91e2a62f7aaf4b9005412e0391602d3099533c11213308162ab92d75,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0476bdbe68bff806016987814a3368819fa08f79d3f47e996d,1770488138,2111,243,a666e24d0b4182d93160219edbdc0c3a44b57f0fdb2f001927734185de0105d3,1,output[0].content[0].text,,"DRUG_1_NAME: MEM_IV
DRUG_1_DOSE: 500 mg
DRUG_1_INTERVAL: q12h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset pyelonephritis with sepsis and very high CRP; prior ESBL history and failure/pre-treatment with norfloxacin support empiric ESBL-active therapy.
- Meropenem provides broad Gram-negative (including ESBL Enterobacterales) coverage appropriate for severe UTI; no MRSA/Enterococcus-targeted agent added given no supporting risk data.
- Renal adjustment for eGFR 24 mL/min/1.73m2: 500 mg IV q12h for first 24h.",MEM_IV,NA,NA,2026-02-08T05:01:07Z
456,OK,1,0cfebd087a7036327b766e8e59e027a00925f9c06a920b3061adc7f14580cdd8,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_07bbd5a0a8e39767016987814bf3f081908cae0c0a3d352972,1770488139,2013,240,b4b5966407ed7817dc5b9527b5ba5c80c48ee82a4f6156e96f362d3b155572f2,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q6h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Septic shock with MV/vasopressors in community-onset pneumonia: broad IV beta-lactam with antipseudomonal activity plus atypical coverage for first 24h.
- No MRSA history/exposure and no LTC/hospitalization/antibiotics in prior 90d, so avoid empiric MRSA agent.
- eGFR 71 mL/min/1.73m2: no renal dose adjustment needed for initial dosing.",TZP_IV,AZM_IV,NA,2026-02-08T05:01:07Z
457,OK,1,134c5efa163bc67a472bbe1db0bbca88dfab81ce02918a61eb96c417086a2a5b,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_09973e2229f1d68e016987814dab708193896f3584cf70fb25,1770488141,2006,225,7174b30279ceb14c3677c08ec461491ea34c2e25bc74c13824c1969173353e30,1,output[0].content[0].text,,"DRUG_1_NAME: MEM_IV
DRUG_1_DOSE: 500 mg
DRUG_1_INTERVAL: q24h (renal-adjusted for eGFR 14)
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Septic shock with MV/NIV/vasopressors/ICU transfer → IV broad empiric therapy for severe community-onset COPD infectious exacerbation.
- Prior ESBL history and recent hospitalization increase likelihood of ESBL Gram-negative pathogens; meropenem provides reliable ESBL and Pseudomonas coverage.
- No documented MRSA history → avoid routine MRSA agent in first 24h.",MEM_IV,NA,NA,2026-02-08T05:01:07Z
458,OK,1,89e617590360c96caa5be489c2440a1c54678c0fffc19ebeda91f8641fba25a8,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_07df47339b5cdc08016987814e2ed8819e8caf85f45058b8a5,1770488142,2093,221,e4e7cbc0c42c2c2a0ec7b922391f666140403410cbec91d543a493c6c85aa98a,1,output[0].content[0].text,,"DRUG_1_NAME: MEM_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q8h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset pneumonia with respiratory failure plus LTC residence and documented prior ESBL history → empiric carbapenem to cover ESBL Enterobacterales and other Gram-negatives.
- No sepsis/shock and no MRSA history/risk provided → avoid routine MRSA coverage and avoid unnecessary combination therapy.
- eGFR 118 mL/min/1.73m2 → standard meropenem dosing (no renal adjustment).",MEM_IV,NA,NA,2026-02-08T05:01:07Z
459,OK,1,897e75492fbed9b5e2a00d4e7903b1ef5781c92dda9b891a959a4e2da468cbee,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0514f48768c81b0e016987814fa6c4819595b2386481d16ede,1770488143,1995,237,ec9ae5a0d3ed89753f2e9cf55442e9a9da733082bf09a97269fb0efa87657181,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h (no renal adjustment needed at eGFR 34)
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset UTI without shock/ICU needs; ceftriaxone provides appropriate broad Gram-negative coverage for typical pathogens (E. coli/Klebsiella/Proteus) with low MDR risk.
- Avoids unnecessary antipseudomonal and MRSA/Enterococcus-directed therapy given no risk factors in structured data.
- Renal function (eGFR 34) supports standard ceftriaxone dosing for first 24h.",CRO_IV,NA,NA,2026-02-08T05:01:07Z
460,OK,1,621f51c8e18d513c042ca1aedbdf824c5ef0c98fbba4180134ecadf42b52bb43,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0da724e22e7c0e6501698781512548819e80b08b6669325b94,1770488145,2046,248,62b72b9216208ca2766967b52c6eaed28e8dc09d685356d8df76680a8a26fbba,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset UTI with sepsis → parenteral empiric therapy; ceftriaxone provides broad Enterobacterales coverage aligned with local UTI epidemiology (E. coli/Klebsiella predominant).
- No prior ESBL/CRE/MRSA history and no recent hospitalization/LTC; avoid unnecessary broader agents (e.g., carbapenem, anti-MRSA) despite prior antibiotic exposure.
- eGFR 94 mL/min/1.73m2 → no renal dose adjustment needed for ceftriaxone in first 24h.",CRO_IV,NA,NA,2026-02-08T05:01:07Z
461,OK,1,e2009ccbd18d92c8c9d91439630fc23a6c878776531ce1592a9e36bd1b74cdec,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0719ea512648ea1c0169878151935881a197a4ceeae153d219,1770488145,1996,237,14a7db83cfc182713e6ab505806b63c56eb385231cced11690d42b33e1bdc54a,1,output[0].content[0].text,,"DRUG_1_NAME: FEP_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h (renal-adjusted for eGFR 15)
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset COPD infectious exacerbation with respiratory failure and markedly elevated CRP; treat empirically for bacterial lower respiratory infection.
- LTC residence and local syndrome ecology with notable Pseudomonas/Gram-negative prevalence support an antipseudomonal beta-lactam; cefepime provides broad Gram-negative coverage without routine MRSA coverage (no MRSA history).
- Avoid aminoglycosides given severe renal impairment (eGFR 15).",FEP_IV,NA,NA,2026-02-08T05:01:07Z
462,OK,1,64e828e858512faf9cbffc3b3b2f353a6dda54a520bd64191bfb9be769319401,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_083dc3122f9b15c901698781537ffc819dbd9fd73a8fcaa0f2,1770488147,2002,240,e4015c95d561dbd702dd1c06d483f17d6b0e8421210f0ff8bc52fefaf107e958,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with respiratory failure (moderate severity): ceftriaxone + azithromycin provides standard empiric coverage for typical + atypical bacterial pathogens.
- No MDR/MRSA risk factors and no septic shock/ICU/vasopressors, so no empiric anti-MRSA or anti-pseudomonal escalation.
- eGFR 87 mL/min/1.73m2: no renal dose adjustment needed for either agent in first 24h.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
463,OK,1,be27e400bb554fd468b8413d0b0d0476cdc7f29cf95fafaaae81e04a2021f63b,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0629ad98a7ba3f6b016987815532d0819ca663823dc89165a1,1770488149,1972,210,00d38da08e62bff7d9d03c3b34b65ecf3b21501270e9ddffd7dcd23e6926e60b,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset UTI with marked leukocytosis; ceftriaxone provides appropriate empiric Gram-negative coverage (E. coli/Klebsiella/Proteus) without unnecessary antipseudomonal or MRSA therapy.
- Respiratory failure flag → use IV therapy for first 24h; renal function normal (eGFR 90), no dose adjustment needed.",CRO_IV,NA,NA,2026-02-08T05:01:07Z
464,OK,1,6c7cf86dc3744090f9adf6100b23ee018327662399d779f74b7c4ac6d9295fe4,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0aea6c991a6fb316016987815572088190b007236b46453010,1770488149,1983,239,1b4d4d52415d8b937504081f757b0e4ab863fa3c88046d3ecc48316a3536dd16,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with respiratory failure and elevated inflammatory markers (CRP 124, PCT 0.6): empiric beta-lactam + macrolide for typical + atypical coverage.
- No MDR/MRSA risk factors (no recent abx/hospitalization/LTC; no prior MRSA/ESBL): avoid broader anti-pseudomonal or MRSA agents.
- eGFR 94: standard adult dosing appropriate (no renal adjustment needed).",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
465,OK,1,5b13aec1e38227e6e2ab7c9d3c478d6a6592d7cfd3453c79c61e025d2b898d0b,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_095a08142d71da12016987815715f0819da70da083a9f1ebef,1770488151,2007,221,870d183eec6ed7a625638e20624f178aaef9bac20b4cf495d59b13c35f52fb6e,1,output[0].content[0].text,,"DRUG_1_NAME: MEM_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q8h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- High-severity community-onset COPD infectious exacerbation with septic shock/MV/ICU transfer → broad IV empiric therapy appropriate for first 24h.
- Prior ESBL history and recent hospitalization increase likelihood of ESBL Gram-negative pathogens; meropenem provides reliable ESBL and Pseudomonas coverage.
- No structured MRSA risk/history provided (prior MRSA=no) → avoid routine MRSA agent in empiric regimen.",MEM_IV,NA,NA,2026-02-08T05:01:07Z
466,OK,1,ee686d975715e9e891caa9a3d283fe935e9f3385eae6283e17b975e276efee53,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0ef3a5357f9d0e3801698781584a8c819698ec16a180187ba2,1770488152,2080,229,d5405a524fd072d51cdade449a0fa73753e3db594bc862a67f6acba8db9c27cd,1,output[0].content[0].text,,"DRUG_1_NAME: FEP_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q12h (renal-adjusted for eGFR 68)
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Severe community-onset pneumonia with respiratory failure requiring MV/NIV → IV broad-spectrum beta-lactam appropriate for first 24h.
- No MRSA history/risk factors and no septic shock → avoid routine MRSA/combination therapy.
- Ward-year epidemiology shows substantial Gram-negative burden (incl. Pseudomonas) → cefepime provides antipseudomonal coverage while awaiting cultures.",FEP_IV,NA,NA,2026-02-08T05:01:07Z
467,OK,1,a7c7866f79f4f9f97d5f598a4f24ab451c45d091a496fcda71d7a0f5c43dde4a,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0e8c9a60a94c6a5f0169878158fa00819c8ec16c645cbdbcda,1770488153,1979,240,b76d43cf7dff886196e137c4d2ef133a04da418eb6efb5a329ef11d3f38c9973,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with respiratory failure (moderate severity) → IV beta-lactam + macrolide for typical + atypical coverage.
- No MDR/MRSA risk factors (no recent abx/hospitalization/LTC; no prior MRSA/ESBL) → avoid broader anti-pseudomonal or MRSA agents.
- eGFR 52: ceftriaxone and azithromycin do not require renal dose adjustment at this level for first 24h.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
468,OK,1,c12b8cc2d2e89ff27f69c5fc913ac27ed0a6772823a36231c66af9fccb547b51,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0eb48057134e2a20016987815a762081a3b383e79929a57ebc,1770488154,1980,236,570325ad1b34b779ea9e1400d4f01cd8d1d0944ee4c2d7963ecc8c13051550a8,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset COPD infectious exacerbation with respiratory failure (moderate severity) → IV therapy appropriate; ceftriaxone + azithromycin covers typical and atypical respiratory pathogens.
- No MDR risk factors and no prior MRSA/ESBL/CRE/VRE history → avoid routine anti-MRSA or antipseudomonal broadening in first 24h.
- Normal renal function (eGFR 98) → standard dosing; no renal adjustment needed.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
469,OK,1,2e30535652d5d03b8c747d6c93415a5656cc633395dd157fdf9232b515332aee,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0ba148f9f64d832e016987815b9bd481969da632b8c862abc2,1770488155,1980,240,f6919638ed03fe4b3c5372a6fef5ddeee2d49086241e99c059893f30928dd02b,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with respiratory failure and marked inflammation (WBC 17.8, CRP 278.6) warrants empiric IV therapy covering typical pathogens.
- Add azithromycin for atypical coverage; no MRSA or MDR risk factors to justify VAN/linezolid or antipseudomonal beta-lactam up front.
- eGFR 101: no renal dose adjustment needed for ceftriaxone/azithromycin in first 24h.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
470,OK,1,f83b6d04cdb85922c7e23033e00b7b909a35738bf0512f7c419cac3320f0a03d,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0f825c3675a4d7f2016987815c93b481919dee03f4b9da2c13,1770488156,1994,237,bbae92d11dd574a257ec63d7e272479b5dabcfe4b93f262f25ceeda485a679c6,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with respiratory failure and high CRP/PCT supports empiric bacterial coverage; ceftriaxone + azithromycin covers typical + atypical CAP pathogens.
- No MDR/MRSA history or recent healthcare/antibiotic exposure, so no empiric MRSA or antipseudomonal therapy.
- eGFR 35: ceftriaxone and azithromycin generally do not require renal dose adjustment at these doses for first 24h.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
471,OK,1,aeb651d4031b06ca23cbe710751774f64af8538d526a9c9b2fe734f8adbb2a5e,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0da1270e1a9a77ed016987815e1e90819da7e0d76e1a18553a,1770488158,2000,235,e61b58a5861e2d610c1cdc02595040f4058ad2d03f8f1b92525e385aa45368f6,1,output[0].content[0].text,,"DRUG_1_NAME: FEP_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h (renal-adjusted for eGFR 18)
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Severe community-onset pneumonia with septic shock/MV/vasopressors → IV broad empiric coverage including Gram-negatives (incl. Pseudomonas) with cefepime.
- Add azithromycin for atypical CAP pathogens and potential immunomodulatory benefit in severe pneumonia.
- No MRSA history/exposure or LTC/hospitalization risk factors provided → avoid empiric MRSA agent.",FEP_IV,AZM_IV,NA,2026-02-08T05:01:07Z
472,OK,1,b3f5d86fe2519152d15e2a4698dbd2e3f2be473f6918e6a1c1f0cd0fd75e9f32,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0a4c06a541ce2d46016987815f1c6c81978be43a51ebaae145,1770488159,1992,216,89cfb4a878db20ad1631d65ce47a97ed66f1e5dbf9e7fb36f85efe9147f5127e,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset pyelonephritis with low severity and no MDR risk factors: ceftriaxone provides appropriate empiric Gram-negative coverage (E. coli/Klebsiella/Proteus predominant locally).
- Avoids unnecessary broad antipseudomonal or MRSA therapy given low risk and stable presentation.
- Renal function normal (eGFR 91); no renal dose adjustment needed.",CRO_IV,NA,NA,2026-02-08T05:01:07Z
473,OK,1,981702c5cc0e3e88e3bbd90741d60a52b58a13d23de890232ed4c50cd10f67b4,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_06b9804e3f1407d301698781604e308197becacd189e0d9c60,1770488160,1998,228,cdc03c0bfb671600e5927cab247a426fddb1f0d80e7738b15f27ff2d6226b268,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with respiratory failure and elevated PCT/lactate → empiric bacterial coverage warranted.
- CRO_IV covers typical CAP pathogens; AZM_IV adds atypical coverage; no MRSA/MDR risk factors to justify VAN/anti-pseudomonal therapy.
- eGFR 46: ceftriaxone and azithromycin generally do not require renal dose adjustment at these doses for first 24h.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
474,OK,1,9d85b63e13c35b9a4c575a2aeddefc82a86c73f0a7130a67eb3462582757e396,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0c4cb60943a8ee560169878162258081909f7b5b97b11dd3a5,1770488162,2052,255,fba148bf5f16229b38790a616246d06c2dc72b0d8276af11d122d6c0b4435900,1,output[0].content[0].text,,"DRUG_1_NAME: FEP_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q12h (renal-adjusted for eGFR ~61)
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset pneumonia with respiratory failure and high CRP; prior AMC1G_PO exposure + LTC resident increases risk for resistant Gram-negatives → cefepime for broad (incl. Pseudomonas) coverage.
- Add azithromycin for atypical coverage in CAP; no MRSA history/risk provided, so avoid empiric anti-MRSA.
- eGFR 61 supports q12h cefepime dosing for first 24h; no additional agents to limit unnecessary combination therapy.",FEP_IV,AZM_IV,NA,2026-02-08T05:01:07Z
475,OK,1,055403d1e4f9efd0ca62cd0c057fc52d7af7bf019eea07841b0ff350648c1365,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_06b70197d571fa6f0169878162d1dc8196aecf96a219395f8a,1770488162,1981,239,ceedb432426c197222ea7bfdcfd7ad7e924d3435e4cc68f1f5676cd5e715fb07,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h (renal function eGFR 40)
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with respiratory failure and very high CRP → empiric inpatient CAP coverage with beta-lactam + macrolide.
- No MDR/MRSA history or recent healthcare/antibiotic exposure → avoid routine anti-MRSA or anti-pseudomonal broadening in first 24h.
- Ceftriaxone provides pneumococcal/typical Gram-negative coverage; azithromycin adds atypical coverage.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
476,OK,1,35324cc8f611ed93f9c5713c24a92e4fe54c1feda87f36b7869f1e92c0256d30,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0203b1e6e48ca8710169878163dc6481a3991a6d78059eb618,1770488165,1991,243,687f0fa8de173e022946f206e0ce689ec4c832f9daba0f19b0190333bd2707e1,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q12h (renal-adjusted for eGFR 18)
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset UTI with septic shock/vasopressors → requires broad IV Gram-negative coverage; TZP provides Enterobacterales and Pseudomonas coverage.
- No MRSA/ESBL/CRE/VRE history and no recent healthcare/antibiotic exposure → avoid routine MRSA or carbapenem empiric therapy.
- Renal dysfunction (eGFR 18) → extended-interval renal-adjusted dosing to reduce toxicity while maintaining early coverage.",TZP_IV,NA,NA,2026-02-08T05:01:07Z
477,OK,1,02b2bd07629c9ee3124378eb2c5193d26f7ddb53aa33b8337d3d75815e07bd24,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_094631852888e76f0169878166b5a481958b878a0f6b8266ab,1770488166,1987,226,12d83252e4771cc7115e58267473866cb8b70f730bada30ee48cd947c01b7630,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q6h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Septic shock with community-onset pneumonia: broad IV beta-lactam for severe CAP with some Gram-negative/Pseudomonas coverage given local respiratory ecology.
- Add azithromycin for atypical coverage and potential benefit in severe CAP; no MRSA history/risk to justify routine VAN/linezolid.
- eGFR 90: no renal dose adjustment needed for first 24h.",TZP_IV,AZM_IV,NA,2026-02-08T05:01:07Z
478,OK,1,547c0cad9ac1f629330c8f5c7842d0b82ecec353a3157e0af8cbc340d5c26965,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_05ab4b1f7293659b0169878166cf7481a3b620d62142498231,1770488166,1979,228,6a9c52cfe5b152cc0dfa4c123d4f6085c80c090d63ab1cb640d5dfdd16980f1e,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset UTI with low severity and no shock/ICU needs: single-agent IV 3rd-gen cephalosporin provides appropriate empiric Gram-negative coverage.
- CKD with eGFR 22: ceftriaxone generally does not require renal dose adjustment, avoiding nephrotoxic aminoglycosides.
- No MRSA/ESBL history and no recent hospitalization/LTC: no empiric MRSA or carbapenem coverage.",CRO_IV,NA,NA,2026-02-08T05:01:07Z
479,OK,1,077edce2d9a3ec26163e40bdb6c70d4b9f769944e6b3064a9e85060d5701b6a0,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0ef644c0f786a3690169878168c5f4819792decdcca4788be9,1770488168,2002,236,64c7c64ea42bcc20a10871400cd99a5e6f1cc763c0b13770bc8c5ff0b637d509,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q8h (extended infusion; renal-adjusted for eGFR 39)
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Severe community-onset pneumonia with septic shock/MV/vasopressors → broad IV empiric coverage including Pseudomonas and other Gram-negatives plus streptococci (TZP).
- Add atypical coverage for CAP in ICU/septic shock (azithromycin).
- No MRSA history/exposure provided → avoid routine MRSA agent in first 24h.",TZP_IV,AZM_IV,NA,2026-02-08T05:01:07Z
480,OK,1,f5b9c15d30f25d13e552feb3aa67d6270206ea3d8221f8b74e89de4337fb956a,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_07c72d9957c7f82e016987816a99b481a3a7586a0b5c8a61a3,1770488170,1996,253,3038f375f7fc0b434a310d32987c8c939aa59dab61800ca6fd910756427e4615,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h (renal function unknown adjustment not required; eGFR 24)
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset pneumonia with sepsis/respiratory failure and high WBC/CRP: empiric CAP coverage with ceftriaxone + azithromycin.
- No MRSA or ESBL/CRE risk factors in structured history, so avoid routine VAN/linezolid or carbapenem/antipseudomonal escalation.
- eGFR 24: ceftriaxone and azithromycin generally do not require renal dose adjustment for first 24h.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
481,OK,1,616c0193f70ed2c408ae9c5b844e58e53ac96db5ad603787cb7b22cde826ea3b,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_007ea2f23dd93a2b016987816ac948819d99ac5eee377b9318,1770488170,1998,235,04f58282abce72fddf7bc98c8de599ffe13e99744c387522f791c277806f2dca,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q6h (renal-adjusted for eGFR 55)
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Severe community-onset pneumonia with septic shock/MV/vasopressors → broad IV empiric coverage; TZP provides Gram-negative (incl. Pseudomonas) and anaerobe coverage.
- Add AZM for atypical CAP pathogens and as standard severe CAP combination therapy.
- No MRSA history or MDR risk factors provided → avoid routine VAN/LZD in first 24h.",TZP_IV,AZM_IV,NA,2026-02-08T05:01:07Z
482,OK,1,c760a7a328d56c6acf2c7564ede37675792c635e6ae0624d9578113d3ef0d5e9,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_06e90e4a159eb0c1016987816ce9ec81918f05be4fef44c0b3,1770488172,1983,240,06916e14035fd3fb69394503aa9243591b31b52875dff2dcd2bbbdded4a26433,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset UTI with sepsis but no shock/ICU needs; ceftriaxone provides appropriate empiric Gram-negative coverage for typical uropathogens (E. coli/Klebsiella/Proteus) without unnecessary antipseudomonal breadth.
- No MDR risk factors or prior ESBL history; avoid carbapenem/anti-MRSA therapy.
- eGFR 17: ceftriaxone generally does not require renal dose adjustment; use standard once-daily dosing for first 24h.",CRO_IV,NA,NA,2026-02-08T05:01:07Z
483,OK,1,efe2b3f628fd5a9f0e08250553fca29fa43885ac16edbe3301461c950319c273,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_00f81a4865e72a88016987816e8d44819c9b1ad67e4ad47fa7,1770488174,1994,229,0067f777d91931cf5286b29e18e1a63b3b67f1f11ef7e7565ed7091367393f3f,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q8h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Severe community-onset pneumonia with septic shock/MV/vasopressors → broad IV empiric coverage; TZP provides Gram-negative (incl. Pseudomonas) and anaerobe coverage.
- Add azithromycin for atypical CAP pathogens and potential immunomodulatory benefit in severe pneumonia.
- No MRSA history or MDR risk factors provided → avoid routine MRSA agent in first 24h.
",TZP_IV,AZM_IV,NA,2026-02-08T05:01:07Z
484,OK,1,e60ed052f21691f2f3fb5f554970db17ef7c00546b553b8f07dc398dc7c924b4,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_09081670526188c2016987816e8ee081a2980624f8bc45c9dc,1770488174,1984,242,8305b1ab569057ebda94d706d389fa3d4de09751adb8a5b08419b9851a2aeea8,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with respiratory failure and elevated WBC/CRP: empiric beta-lactam + macrolide for typical + atypical coverage.
- No MDR/MRSA risk factors (no recent abx/hospitalization/LTC; no prior MRSA/ESBL): avoid routine anti-MRSA or antipseudomonal therapy.
- eGFR 33: ceftriaxone and azithromycin do not require renal dose adjustment for this short empiric course.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
485,OK,1,760eae2a92eb334f049d8971fe3a9f9a32e329de884987273258ebcd2890f717,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_047d89db12810bd60169878170c0488193abe5d2efd8860c3a,1770488176,2048,240,58c3f12dcaff487b29e919bf5c89ed9ef803c08ea1df4c5f9264b6c01e388e97,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q8h (renal-adjusted for eGFR 55)
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset UTI with leukocytosis and LTC/prior antibiotics (abx<=90d) increases risk for resistant Gram-negative pathogens; TZP provides broad urinary Gram-negative coverage including Pseudomonas.
- Low severity and no MRSA history/risk in structured data → no empiric MRSA agent added.
- Home ceftriaxone exposure suggests possible nonresponse/selection pressure; escalation to broader beta-lactam reasonable pending cultures.",TZP_IV,NA,NA,2026-02-08T05:01:07Z
486,OK,1,abe669b07c368c12dcc6c1e13641ff06b2d98b42b4bdd3f2e267f8cf60d49b06,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0b7a05af24302f0c01698781722f1481a286cddd7f9c2148b4,1770488178,1974,221,507077f0a4fd23e98d1d8b97b414b2e7319aeead33003925ec8db3282336223b,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset UTI with marked leukocytosis; ceftriaxone provides broad empiric Enterobacterales coverage appropriate for non-severe presentation.
- No septic shock/ICU/MV and no prior ESBL/CRE history; avoid unnecessary carbapenem/anti-MRSA therapy.
- eGFR 111 mL/min/1.73m2: no renal dose adjustment needed for ceftriaxone.",CRO_IV,NA,NA,2026-02-08T05:01:07Z
487,OK,1,786d2e27bf0e0e92024bc6de0eb19fa4125f5f33b79f7d6f1b4055102ef0b1a0,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_01fa9d629909853501698781729714819386e5bef7a1cbf361,1770488178,1984,244,569eba6fb4e54a8c4dccd4324ece9606aa844d325cc18b65e644ae20a179a7aa,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset UTI with sepsis but no shock/ICU needs and no MDR risk/history: ceftriaxone provides appropriate empiric Gram-negative coverage for typical uropathogens.
- eGFR 40 mL/min/1.73m2: ceftriaxone generally does not require renal dose adjustment at this level, minimizing nephrotoxicity risk in CKD.
- No MRSA/ESBL/CRE/VRE risk factors: avoid unnecessary broad-spectrum or anti-MRSA combination therapy in first 24h.",CRO_IV,NA,NA,2026-02-08T05:01:07Z
488,OK,1,a9025a7ef846f790cb089f189763739fa43b85222490317c3e0a076856946410,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0b25391043f8558c01698781755090819095152524d125cc51,1770488181,1979,255,11679314747e1d18f785704f0c32eaf18ebcd98c838aefe21530e768a24246f7,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset UTI with sepsis and marked leukocytosis; ceftriaxone provides appropriate empiric Gram-negative coverage for typical uropathogens (E. coli/Klebsiella/Proteus) without unnecessary broad antipseudomonal therapy.
- No prior ESBL/CRE history and no recent hospitalization/antibiotics; LTC residence alone does not mandate carbapenem or MRSA coverage.
- eGFR 23 mL/min/1.73m2: ceftriaxone generally does not require renal dose adjustment, suitable for first 24h pending cultures.",CRO_IV,NA,NA,2026-02-08T05:01:07Z
489,OK,1,a1ebaaa2baa4727abd537e014e1baee3361c14b71f1cce30e84c38185f8d33dd,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_07dd2a451f26d3fa0169878175c1048196ad7caf1172c0f042,1770488181,1977,209,18ae268eec49e561fabdff2d57d03f67def096c2a138edf5843763fb9e19165d,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset UTI with sepsis and very high CRP; ceftriaxone provides appropriate empiric Enterobacterales coverage without unnecessary antipseudomonal/MRSA therapy given no MDR risk factors.
- Severe renal impairment (eGFR 17): ceftriaxone generally does not require renal dose adjustment, making it suitable for first 24h pending cultures.",CRO_IV,NA,NA,2026-02-08T05:01:07Z
490,OK,1,cca60a6b9e446830a88218962b1c84162e656657e9a42a598e2fdd80d7cca383,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0d3a69a40070e1ef01698781769304819fb977dfa31e6d13e3,1770488182,2012,216,ad3be92107a080d90df0137e213343be7318efe58eac98951e2a87dd4b690207,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Moderate community-onset CAP with respiratory failure and elevated CRP: empiric bacterial coverage warranted despite positive viral screen.
- Ceftriaxone + azithromycin provides typical + atypical CAP coverage; no MRSA/ESBL risk factors to justify broader therapy.
- eGFR 74: no renal dose adjustment needed for either agent in first 24h.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
491,OK,1,e46a823b618bf62aef55adda86a70934fdce117fc4f5f0ee721c763ed6041573,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0095a719d7cb52cb01698781791a0881a0bb2d576d516fc9f8,1770488185,1987,234,a03dc5d31a001acfe622cf0dd809d2531f938dc1eb374c80b941f99294a8b2f0,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q8h (renal-adjusted for eGFR 31)
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset UTI with septic shock/ICU-level severity → broad IV Gram-negative coverage including Pseudomonas; local susceptibility for piperacillin-tazobactam is relatively high.
- No major MDR history/exposure and no MRSA risk → avoid routine MRSA/combination therapy in first 24h.
- Renal impairment (eGFR 31) → use renal-adjusted interval.",TZP_IV,NA,NA,2026-02-08T05:01:07Z
492,OK,1,efdfb5ae97103d0cc21eb08d84a94a1cfc8817e5f028e87719a5320fcca667f9,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_06ed715ee602dce7016987817956dc81a0a999919b1f80cf42,1770488185,2057,229,9a7ca9d7da47bfe1ee9f214b58c1436337522545c3d08775330b38230e9ff9c1,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q6h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Severe community-onset pneumonia with septic shock/MV/vasopressors → IV broad empiric coverage; TZP covers pneumococcus and Gram-negatives incl. Pseudomonas risk given recent hospitalization/antibiotics.
- Add azithromycin for atypical coverage in severe CAP and potential immunomodulatory benefit early.
- No MRSA agent: no prior MRSA history or LTC exposure in structured data.",TZP_IV,AZM_IV,NA,2026-02-08T05:01:07Z
493,OK,1,ee7ed9a058ae9b16e9ff76aa26ef986bd84b4bd6fcf616fa69eb1c9acfd4d4c5,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_084d42908c30537e01698781798c18819784a07a53c26241b3,1770488185,1983,248,237f2f0ed45c792d1ed7bf6842430a01b8aada3fed4b99a53061e9eee3b21860,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h (renal adjustment not required at eGFR 37)
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- High-severity community-onset pneumonia with ICU transfer and leukocytosis/CRP elevation → empiric IV beta-lactam + macrolide for typical + atypical CAP pathogens.
- No MDR risk factors and no prior MRSA/ESBL history → avoid routine MRSA or broad antipseudomonal coverage in first 24h.
- eGFR 37: ceftriaxone and azithromycin do not require renal dose adjustment.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
494,OK,1,64b0b4592c98063b117146510c814beec4406baefe0d9f105bacf5dc90850382,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_07f34674d473a27f016987817c557881928e097ae1301a2f4a,1770488188,2049,221,531e56044be382d567e4a47f8dbcbb623a91a29ace583332f97226334b44a3ac,1,output[0].content[0].text,,"DRUG_1_NAME: MEM_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q12h (renal-adjusted for eGFR 43)
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset UTI with septic shock/vasopressors and marked inflammatory response → broad IV Gram-negative coverage needed in first 24h.
- Recent hospitalization and prior antibiotics increase risk of resistant Enterobacterales; meropenem provides reliable ESBL-active coverage and urinary source penetration.
- No MRSA history/context and UTI syndrome → avoid empiric anti-MRSA therapy.",MEM_IV,NA,NA,2026-02-08T05:01:07Z
495,OK,1,9e77e63028e3271298dedb36256cd67cf58f67fab9cbda2e3e0d975c03add514,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_08c6ae61db649d1c016987817cf82c8197a141857394a836a9,1770488188,1991,216,42d471c99cf438a6c5ba90282038ceae527c5a73d0df23dfba2a811041a07903,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with elevated CRP; ceftriaxone + azithromycin provides empiric coverage for typical pathogens plus atypicals.
- No septic shock/ICU/MV and no MRSA history → avoid routine MRSA coverage.
- eGFR 91 mL/min/1.73m2 → no renal dose adjustment needed for this regimen.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
496,OK,1,67dabf5599bd5a74b528c024a83526ea591d6b9df70638a2505a1086325b1a6c,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0063eca0d36b44e0016987817d4f3081a3a2c3930b7b9f347c,1770488189,2064,227,6a27d1c9758e6bc0272d24cfe32bb37f19f2d3af0cb8fe09ea762549d11c1fce,1,output[0].content[0].text,,"DRUG_1_NAME: FEP_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q12h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset pneumonia with respiratory failure plus recent hospitalization and antibiotics → broaden initial Gram-negative coverage (including Pseudomonas) with cefepime.
- Add azithromycin for atypical CAP coverage; no MRSA history/risk provided, so avoid empiric anti-MRSA.
- eGFR 77 mL/min/1.73m2: no renal dose adjustment needed for first 24h.",FEP_IV,AZM_IV,NA,2026-02-08T05:01:07Z
497,OK,1,6ef9005b81f47590e88de1f056e413e888f15ded2597122808ca07d861e43050,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_002f6b14401d349e016987817ffe288191af4e8a1804a76d4b,1770488192,2039,233,05c8bfff4385fc5db74d13d3afcd65071267b46d9890b7aeb1181da930b3d02d,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 1 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset UTI with sepsis and high CRP; needs IV empiric therapy, but no shock/ICU features.
- Recent outpatient ciprofloxacin exposure suggests avoiding fluoroquinolone empiric therapy; ceftriaxone provides broad Enterobacterales coverage typical for UTI.
- Severe renal impairment (eGFR 7) favors ceftriaxone (no renal dose adjustment needed) and avoids nephrotoxic aminoglycosides in the first 24h.",CRO_IV,NA,NA,2026-02-08T05:01:07Z
498,OK,1,3f5058bf823eaeb3056eba51cfe49151e29c7ec573df4fe2fd16dfae4ea0bac1,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_051060b3cc46278901698781801fe48193b5d9113d7606261e,1770488192,2094,255,79c276ea27f0a19cbe93b0d1c98eb2bd9ff61e896594afb57f1d2d35499842be,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset CAP with respiratory failure and elevated CRP/lactate: empiric inpatient IV beta-lactam + macrolide for typical + atypical coverage.
- Recent home AMC1G_PO suggests possible outpatient treatment failure; ceftriaxone provides broader pneumococcal/H. influenzae coverage without routine MRSA/ESBL coverage (no prior MRSA/ESBL/CRE/VRE; no LTC).
- eGFR 58: no renal dose adjustment needed for ceftriaxone or azithromycin in first 24h.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
499,OK,1,d81379fc820ccf5c9a3e0fdba0c138d8041dda2247fa999e064510b806995150,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_0598385bde2395690169878180e53881939fdfd52db6083108,1770488192,1996,230,499e8c5f2a07b0c1fc47f74bdee984dc415dc15644aa99fff539a4226097ee75,1,output[0].content[0].text,,"DRUG_1_NAME: TZP_IV
DRUG_1_DOSE: 4.5 g
DRUG_1_INTERVAL: q8h (renal-adjusted for eGFR 44)
DRUG_2_NAME: NA
DRUG_2_DOSE: NA
DRUG_2_INTERVAL: NA
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset pyelonephritis with septic shock/vasopressors: needs broad IV Gram-negative coverage including possible Pseudomonas.
- No major MDR/MRSA risk factors documented; TZP provides Enterobacterales + some Enterococcus faecalis coverage without routine MRSA therapy.
- Renal impairment (eGFR 44) supports dose-interval adjustment for first 24h.",TZP_IV,NA,NA,2026-02-08T05:01:07Z
500,OK,1,987e5ad1c61fb0922ea2405330dee01fb56b8e466c223b445789037a5d273cf1,gpt-5.2-2025-12-11,gpt-5.2-2025-12-11,resp_03f3083f1e4bc03801698781838e288193984dfd099b11e4c3,1770488195,1975,230,4435abf8732759a8098c875ae6b3f1ce7887a0af5b30832871549a374c463747,1,output[0].content[0].text,,"DRUG_1_NAME: CRO_IV
DRUG_1_DOSE: 2 g
DRUG_1_INTERVAL: q24h
DRUG_2_NAME: AZM_IV
DRUG_2_DOSE: 500 mg
DRUG_2_INTERVAL: q24h
DRUG_3_NAME: NA
DRUG_3_DOSE: NA
DRUG_3_INTERVAL: NA
RATIONALE:
- Community-onset moderate CAP with respiratory failure but no shock/ICU/MV: ceftriaxone + azithromycin provides standard empiric coverage for typical and atypical pathogens.
- No MDR/MRSA risk factors or recent antibiotics/hospitalization: avoid broader antipseudomonal or MRSA agents.
- Normal renal function (eGFR 122): no renal dose adjustment needed for this 24h empiric regimen.",CRO_IV,AZM_IV,NA,2026-02-08T05:01:07Z
